menu
    • menu
    [{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TAT4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Topokine Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TAT4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Topokine Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Topokine Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Topokine Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Vicept Therapeutics, Inc.","sponsor":"Accenture","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"V-101","moa":"Adrenergic receptor alpha-2C (ADRA2C)","graph1":"Dermatology","graph2":"Phase II","graph3":"Vicept Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Vicept Therapeutics, Inc. \/ Accenture","highestDevelopmentStatusID":"8","companyTruncated":"Vicept Therapeutics, Inc. \/ Accenture"},{"orgOrder":0,"company":"DermaGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"DPK-060","moa":"\nCell membrane permeability","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"DermaGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"DermaGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"DermaGen \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"MSRD-100","moa":"\nGR","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"MSRD-100","moa":"\nGR","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mimetica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"MTC896","moa":"\nMC5R","graph1":"Dermatology","graph2":"Phase II","graph3":"Mimetica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mimetica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mimetica \/ Undisclosed"},{"orgOrder":0,"company":"Mimetica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MTC896","moa":"\nMC5R","graph1":"Dermatology","graph2":"Phase II","graph3":"Mimetica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mimetica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mimetica \/ Undisclosed"},{"orgOrder":0,"company":"Mimetica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"MTC896","moa":"\nMC5R","graph1":"Dermatology","graph2":"Phase II","graph3":"Mimetica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mimetica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mimetica \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MingMed Biotechnology","sponsor":"Claruvis Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"MingMed Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MingMed Biotechnology \/ Claruvis Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"MingMed Biotechnology \/ Claruvis Pharmaceutical"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"HTL Biotechnology","sponsor":"Eirion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"HTL Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"HTL Biotechnology \/ Eirion Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"HTL Biotechnology \/ Eirion Therapeutics"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Shanghai Haohai Biological Technology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series A Financing","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Shanghai Haohai Biological Technology"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"AN2898","moa":"3',5'-cyclic-AMP phosphodiesterase 4D; 3',5'-cyclic-AMP phosphodiesterase 4B; 3',5'-cyclic-AMP phosphodiesterase 4A","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Biolexa","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"IDP-126","moa":"50S ribosomal protein L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Retapamulin","moa":"70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Derm Research \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ GSK"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Acetoacetyl-CoA thiolase (ACAT1)","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Corium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Dermatology","graph2":"Phase I","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Corium \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corium \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olumacostat Glasaretil","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olumacostat Glasaretil","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Olumacostat Glasaretil","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Olumacostat Glasaretil","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Olumacostat Glasaretil","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PF-05175157","moa":"Acetyl-CoA carboxylase","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Hugel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Croma-Pharma \/ Hugel","highestDevelopmentStatusID":"8","companyTruncated":"Croma-Pharma \/ Hugel"},{"orgOrder":0,"company":"Azidus","sponsor":"Laborat\u00f3rio Qu\u00edmico Farmac\u00eautico Bergamo Ltda.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Azidus \/ Laborat\u00f3rio Qu\u00edmico Farmac\u00eautico Bergamo Ltda.","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Laborat\u00f3rio Qu\u00edmico Farmac\u00eautico Bergamo Ltda."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":63,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":63,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ AbbVie Inc","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ AbbVie Inc"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Allergan Aesthetics","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"SYMATESE FR 69630 Chaponost","sponsor":"Evolus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Protein","year":"2025","type":"Collaboration","leadProduct":"Botulinum toxin type A","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SYMATESE FR 69630 Chaponost","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SYMATESE FR 69630 Chaponost \/ Evolus","highestDevelopmentStatusID":"15","companyTruncated":"SYMATESE FR 69630 Chaponost \/ Evolus"},{"orgOrder":0,"company":"Temple University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ Allergan","highestDevelopmentStatusID":"7","companyTruncated":"Temple University \/ Allergan"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Clinical Testing of Beverly Hills \/ Allergan"},{"orgOrder":0,"company":"AboutSkin Dermatology and DermSurgery, PC","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"AboutSkin Dermatology and DermSurgery, PC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AboutSkin Dermatology and DermSurgery, PC \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"AboutSkin Dermatology and DermSurgery, PC \/ Allergan"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revision Skincare \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Revision Skincare \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Protox Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Protox Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protox Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Protox Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Medytox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medytox \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medytox \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"The Maas Clinic","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"The Maas Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Maas Clinic \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"The Maas Clinic \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"SUNY Downstate Medical Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"SUNY Downstate Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SUNY Downstate Medical Center \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"SUNY Downstate Medical Center \/ AbbVie Inc"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Allergan | Mattioli","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Wisconsin, Madison \/ Allergan | Mattioli","highestDevelopmentStatusID":"9","companyTruncated":"University of Wisconsin, Madison \/ Allergan | Mattioli"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Nova Scotia Health Authority \/ Allergan"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Merz Aesthetics \/ Merz Pharma"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Dalhousie University","highestDevelopmentStatusID":"8","companyTruncated":"Nova Scotia Health Authority \/ Dalhousie University"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evolus \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ PPD"},{"orgOrder":0,"company":"Evolus","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evolus \/ PPD","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ PPD"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ivo Pitanguy Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Ivo Pitanguy Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ivo Pitanguy Institute \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Ivo Pitanguy Institute \/ Allergan"},{"orgOrder":0,"company":"Espad Pharmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Espad Pharmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Espad Pharmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Espad Pharmed \/ Undisclosed"},{"orgOrder":0,"company":"Vitality Institute Medical Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Vitality Institute Medical Products","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vitality Institute Medical Products \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vitality Institute Medical Products \/ Undisclosed"},{"orgOrder":0,"company":"ATGC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"ATGC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATGC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ATGC \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aquavit Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AqubotulinumtoxinA","moa":"ACh receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Aquavit Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aquavit Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aquavit Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Sihuan Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Letibotulinumtoxina","moa":"ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Sihuan Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Sihuan Pharmaceutical"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"YY003","moa":"ACh receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Viatris","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Viatris"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN59011","moa":"ACh-alpha-1\/beta-1\/delta\/gamma receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Affinium Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AFN-12520000","moa":"Acid-sensing ion channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Affinium Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Affinium Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Affinium Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Ewopharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Ewopharma","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Ewopharma"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Piclidenoson","moa":"Adenosine A3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Caffeine","moa":"Adenosine receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"ProCertus BioPharm","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Norepinephrine","moa":"Adrenergic receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"ProCertus BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ProCertus BioPharm \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"ProCertus BioPharm \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actavis Inc \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Candela","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Candela","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candela \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Candela \/ Undisclosed"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Novan","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Novan"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Actavis Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actavis Inc \/ Actavis Inc","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Actavis Inc"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase III","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"The Hospital for Sick Children \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"The Hospital for Sick Children \/ Galderma"},{"orgOrder":0,"company":"Skin Laser & Surgery Specialists","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Skin Laser & Surgery Specialists","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Skin Laser & Surgery Specialists \/ Galderma","highestDevelopmentStatusID":"1","companyTruncated":"Skin Laser & Surgery Specialists \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Tarian Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Tarian Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tarian Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarian Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Eurotrials Brasil","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Eurotrials Brasil","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Eurotrials Brasil"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Zepeda Dermatologia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Zepeda Dermatologia","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Zepeda Dermatologia"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Double Point Ventures","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Double Point Ventures"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SM-020","moa":"AKT","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Reproxalap","moa":"aldehyde traps","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Aldena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldena Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Aldena Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Tongji Hospital | First Affiliated Hospital of Suzhou Medical College | Wolwo Bio-pharmaceutical Co. LTD. | Huashan Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University Third Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Dermatophagoides Farinae","moa":"Allergen cell","graph1":"Dermatology","graph2":"Phase II","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zhejiang University \/ Tongji Hospital | First Affiliated Hospital of Suzhou Medical College | Wolwo Bio-pharmaceutical Co. LTD. | Huashan Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University Third Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang University \/ Tongji Hospital | First Affiliated Hospital of Suzhou Medical College | Wolwo Bio-pharmaceutical Co. LTD. | Huashan Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University Third Hospital"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TAK-279","moa":"Allosteric TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"NeoStrata Company","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Dermatology","graph2":"Phase III","graph3":"NeoStrata Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"NeoStrata Company \/ Massachusetts General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"NeoStrata Company \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Conmed Pharmaceutical","sponsor":"Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AST-120","moa":"Ammonia","graph1":"Dermatology","graph2":"Phase IV","graph3":"Conmed Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University","highestDevelopmentStatusID":"11","companyTruncated":"Conmed Pharmaceutical \/ Tri-Service General Hospital | Tungs\u2019 Taichung Metroharbour Hospital | Chang Gung Memorial Hospital | Taichung Veterans General Hospital | Kaohsiung Medical University | Taichung Tzu Chi Hospital | Fu Jen Catholic University"},{"orgOrder":0,"company":"Energenesis Biomedical","sponsor":"A2 Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ENERGI-F701","moa":"AMP-activated protein kinase (AMPK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Energenesis Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Energenesis Biomedical \/ A2 Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Energenesis Biomedical \/ A2 Healthcare"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Samsara BioCapital","highestDevelopmentStatusID":"5","companyTruncated":"OrsoBio \/ Samsara BioCapital"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"Essity","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Copper","moa":"Amyloid-beta precursor protein; Adenosylhomocysteinase; Histone H2B type 1-C\/E\/F\/G\/I; Glyceraldehyde-3-phosphate dehydrogenase; Nucleoside diphosphate kinase A; Histone H1.4; Peroxiredoxin-1; Protein S100-A8; Small ribosomal subunit protein uS2; Actin, cytoplasmic 2; Alpha-enolase; Elongation factor 1-alpha 1; Keratin, type II cytoskeletal 8; Protein disulfide-isomerase; Protein disulfide-isomerase A3; 60 kDa heat shock protein, mitochondrial; Heat shock 70 kDa protein 13; Endoplasmic reticulum chaperone BiP; Endoplasmin; Serotransferrin; Cell growth-regulating nucleolar protein; Small ribosomal subunit protein uS5; Serine\/arginine-rich splicing factor 1; Heterogeneous nuclear ribonucleoproteins A2\/B1; Heterogeneous nuclear ribonucleoprotein H; Heterogeneous nuclear ribonucleoprotein H3; Cobalt-precorrin-5B C(1)-methyltransferase; Heterogeneous nuclear ribonucleoprotein L; Splicing factor, proline- and glutamine-rich; Splicing factor 3A subunit 2; Small ribosomal subunit protein RACK1;","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ Essity","highestDevelopmentStatusID":"9","companyTruncated":"Hospital Israelita Albert Einstein \/ Essity"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Intrepid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Intrepid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Intrepid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intrepid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrepid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Intrepid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Intrepid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intrepid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intrepid Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Intrepid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intrepid Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intrepid Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Cassiopea","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Cassiopea"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"3S Bio Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ 3S Bio Inc","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ 3S Bio Inc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyphens Pharma"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Hyundai Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Hyundai Pharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Hyundai Pharm"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23999999999999999,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23999999999999999,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cassiopea \/ Undisclosed"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Ergomed | Pharmapace | Canfield Scientific | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Ergomed | Pharmapace | Canfield Scientific | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Cassiopea \/ Ergomed | Pharmapace | Canfield Scientific | Icon Plc"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cosmo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cosmo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Narrows Institute for Biomedical Research \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"Narrows Institute for Biomedical Research \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Curia","sponsor":"Cassiopea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Curia \/ Cassiopea","highestDevelopmentStatusID":"15","companyTruncated":"Curia \/ Cassiopea"},{"orgOrder":0,"company":"Suzhou Koshine Biomedica, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Koshine Biomedica, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Koshine Biomedica, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Koshine Biomedica, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KX-826","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ IQVIA"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AndroScience","sponsor":"Europharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ASC-J9","moa":"Androgen receptor (AR)","graph1":"Dermatology","graph2":"Phase II","graph3":"AndroScience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AndroScience \/ Europharma","highestDevelopmentStatusID":"8","companyTruncated":"AndroScience \/ Europharma"},{"orgOrder":0,"company":"AnHorn Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AH 001","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AnHorn Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHorn Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AnHorn Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Enalaprilat","moa":"Angiotensin-converting enzyme","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"P005672","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Paratek Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sarecycline","moa":"antibiotics (tetracycline derivatives)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lotilaner","moa":"antiparasitics (isoxazoline compounds)","graph1":"Dermatology","graph2":"Phase II","graph3":"Tarsus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tarsus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tarsus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"Remlarsen","moa":"antisense oligonucleotides","graph1":"Dermatology","graph2":"Phase II","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Miragen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Miragen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"antithrombotics (thromboxane A2 receptor antagonists)","graph1":"Dermatology","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cellceutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Abacavir Hydroxyacetate","moa":"antivirals: carbocyclic nucleosides","graph1":"Dermatology","graph2":"Phase II","graph3":"Cellceutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cellceutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellceutix \/ Undisclosed"},{"orgOrder":0,"company":"Cellceutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abacavir Hydroxyacetate","moa":"antivirals: carbocyclic nucleosides","graph1":"Dermatology","graph2":"Phase II","graph3":"Cellceutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cellceutix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cellceutix \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2021","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Suzhou Koshine Biomedica, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2024","type":"Inapplicable","leadProduct":"GT20029","moa":"AR","graph1":"Dermatology","graph2":"Phase II","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Kintor Pharmaceutical \/ Suzhou Koshine Biomedica, Inc."},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Q301","moa":"Arachidonate 5-lipoxygenase (5-LOX)","graph1":"Dermatology","graph2":"Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Qurient","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Q301","moa":"Arachidonate 5-lipoxygenase (5-LOX)","graph1":"Dermatology","graph2":"Phase II","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Qurient \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Qurient \/ Undisclosed"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"Peking University People's Hospital","sponsor":"Zhonghao Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Peking University People's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Peking University People's Hospital \/ Zhonghao Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Peking University People's Hospital \/ Zhonghao Pharmaceutical"},{"orgOrder":0,"company":"GSK","sponsor":"PPD | ERT: Clinical Trial Technology Solutions | Q2 Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ PPD | ERT: Clinical Trial Technology Solutions | Q2 Solutions","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ PPD | ERT: Clinical Trial Technology Solutions | Q2 Solutions"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"iCardiac Technologies | Innovaderm | PPD | Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ iCardiac Technologies | Innovaderm | PPD | Altasciences Company Inc","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ iCardiac Technologies | Innovaderm | PPD | Altasciences Company Inc"},{"orgOrder":0,"company":"Welichem Biotech Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Welichem Biotech Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Welichem Biotech Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Welichem Biotech Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Welichem Biotech Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Welichem Biotech Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Welichem Biotech Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Welichem Biotech Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Torii Pharmaceutical","amount2":1.05,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Cream","sponsorNew":"Torii Pharmaceutical \/ Shionogi","highestDevelopmentStatusID":"15","companyTruncated":"Torii Pharmaceutical \/ Shionogi"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Indiana University","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana University \/ Dermavant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Dermavant Sciences"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Marathon Asset Management"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"Montes Archimedes Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Merger","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Cream","sponsorNew":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Roivant Sciences \/ Montes Archimedes Acquisition Corporation"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Innovaderm","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Innovaderm"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ IQVIA"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dermavant Sciences","amount2":1.2,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Dermavant Sciences \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Dermavant Sciences \/ Organon"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziritaxestat","moa":"Autotaxin","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LY3361237","moa":"B- and T-lymphocyte attenuator (BTLA)","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Bacteriophage Microcapsule","moa":"Bacteria","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Precisio Biotix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Precisio Biotix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BX005-A","moa":"Bacteria microbiome","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GWT-TUD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GWT-TUD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GWT-TUD \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GWT-TUD \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Akorn Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Akorn Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akorn Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Wake Forest University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Wake Forest University \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Solaris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Solaris Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Solaris Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Solaris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Erythromycin","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Maruho","highestDevelopmentStatusID":"11","companyTruncated":"Centre for Human Drug Research \/ Maruho"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Hovione Scientia Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"Hovione Scientia Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hovione Scientia Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hovione Scientia Limited \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Center of Scientific and Clinical Studies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Center of Scientific and Clinical Studies","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Center of Scientific and Clinical Studies"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Foamix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Foamix Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Foamix Pharmaceuticals \/ Cutia Therapeutics"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Menlo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Divestment","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Journey Medical Corporation"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"University of Florida","sponsor":"Alchem Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase II","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"University of Florida \/ Alchem Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"University of Florida \/ Alchem Laboratories"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FMX101","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"FMX101","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"FMX101","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"FMX103","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FMX103","moa":"Bacterial cell wall","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sonoma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Pharmaceuticals","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Hypochlorous Acid","moa":"Bacterial cell wall synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sonoma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sonoma Pharmaceuticals \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Dermatology","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melinta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"TNP-2092","moa":"Bacterial DNA gyrase | Topoisomerase IV | Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alfasigma \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Alfasigma \/ Biorasi"},{"orgOrder":0,"company":"Biocodex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase IV","graph3":"Biocodex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocodex \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Biocodex \/ Undisclosed"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftriaxone","moa":"Bacterial penicillin-binding protein","graph1":"Dermatology","graph2":"Phase III","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institut Pasteur \/ Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille","highestDevelopmentStatusID":"10","companyTruncated":"Institut Pasteur \/ Centre Hospitalier Universitaire de Caen | H\u00f4pital Necker-Enfants Malades | Ministry of Health, France | Assistance Publique Hopitaux De Marseille"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"TR701 FA","moa":"Bacterial ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Bayer AG"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Rapcabtagene Autoleucel","moa":"BCMA","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN202","moa":"BD2-selective BET","graph1":"Dermatology","graph2":"Phase I","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lemuteporfin","moa":"benzoporphyrin derivatives","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"LifeSci Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ LifeSci Capital LLC","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ LifeSci Capital LLC"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Access Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Access Biotechnology"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VYN201","moa":"BET","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metoprolol Tartrate","moa":"Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Auson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Auson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Auson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Auson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rady Children's Hospital, San Diego","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rady Children's Hospital, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rady Children's Hospital, San Diego \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Rady Children's Hospital, San Diego \/ Bausch Health"},{"orgOrder":0,"company":"Prism Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"C-82","moa":"Beta-catenin","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Prism Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Prism Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prism Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Associazione Infermieristica per lo studio delle Lesioni Cutanee","sponsor":"B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Betaine","moa":"Betaine-homocysteine S-methyltransferase","graph1":"Dermatology","graph2":"Phase III","graph3":"Associazione Infermieristica per lo studio delle Lesioni Cutanee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Associazione Infermieristica per lo studio delle Lesioni Cutanee \/ B. Braun Medical","highestDevelopmentStatusID":"10","companyTruncated":"Associazione Infermieristica per lo studio delle Lesioni Cutanee \/ B. Braun Medical"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obeticholic Acid","moa":"Bile acid receptor FXR","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Ferndale Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CTX-101","moa":"B-lymphocyte surface antigen B4 (CD19)","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescita Therapeutics \/ Ferndale Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Crescita Therapeutics \/ Ferndale Laboratories"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Osiramestrocel","moa":"Bone marrow cell","graph1":"Dermatology","graph2":"Phase III","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Osiramestrocel","moa":"Bone marrow cell","graph1":"Dermatology","graph2":"Phase III","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Osiramestrocel","moa":"Bone marrow cell","graph1":"Dermatology","graph2":"Phase III","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Osiramestrocel","moa":"Bone marrow cell","graph1":"Dermatology","graph2":"Phase III","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"X-pert Med GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Strontium-89 Chloride","moa":"Bone resorption","graph1":"Dermatology","graph2":"Phase I","graph3":"X-pert Med GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"X-pert Med GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"X-pert Med GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BOS-475","moa":"BRD2","graph1":"Dermatology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Boston Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BOS-475","moa":"BRD2","graph1":"Dermatology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Boston Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PRN473","moa":"BTK","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remibrutinib","moa":"BTK","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"ANB032","moa":"BTLA","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ TD Cowen","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ TD Cowen"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DLQ02","moa":"Calcineurin","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Dermaliq Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Weill Medical College of Cornell University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Pfizer Inc"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"Rejuva Medical Aesthetics","sponsor":"HealMD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Rejuva Medical Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Rejuva Medical Aesthetics \/ HealMD","highestDevelopmentStatusID":"6","companyTruncated":"Rejuva Medical Aesthetics \/ HealMD"},{"orgOrder":0,"company":"One World Cannabis Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"One World Cannabis Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"One World Cannabis Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"One World Cannabis Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sera Labs","sponsor":"Cure Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sera Labs","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Sera Labs \/ Cure Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sera Labs \/ Cure Pharmaceutical"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Bio-Gate AG"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"Cr\u00e8me de Canna","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Pressure BioSciences \/ Cr\u00e8me de Canna","highestDevelopmentStatusID":"15","companyTruncated":"Pressure BioSciences \/ Cr\u00e8me de Canna"},{"orgOrder":0,"company":"TO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Dermatology","graph2":"Phase II","graph3":"TO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corbus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MC2-25","moa":"Carbamylation","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"HJ23","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Phenol","moa":"Carbonic anhydrase (CA)","graph1":"Dermatology","graph2":"Phase IV","graph3":"HJ23","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HJ23 \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HJ23 \/ Undisclosed"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bio-Gate AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"||CB1\/2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avicanna \/ Bio-Gate AG","highestDevelopmentStatusID":"6","companyTruncated":"Avicanna \/ Bio-Gate AG"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Safety Shot","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"JW-100","moa":"CB1\/2 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Applied Biology \/ Jupiter Wellness","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Jupiter Wellness"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Financing","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Financing","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ KB investment","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ KB investment"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Alira Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Alira Health","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Alira Health"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"OLX10010","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"PF-06473871","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"PF-06473871","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"PF-06473871","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"RXi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"RXI-109","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase I","graph3":"RXi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RXi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RXi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RXi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"RXI-109","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase I","graph3":"RXi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RXi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"RXi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RXi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"RXI-109","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"RXi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RXi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RXi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RXi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"RXI-109","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"RXi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RXi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RXi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RXi Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"RXI-109","moa":"CCN2 messenger RNA (CCN2 mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"RXi Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RXi Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RXi Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Villaris Therapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Auremolimab","moa":"CD122","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Villaris Therapeutics","amount2":1.4299999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":1.4299999999999999,"dosageForm":"Undisclosed","sponsorNew":"Villaris Therapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Villaris Therapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ET-02","moa":"CD19","graph1":"Dermatology","graph2":"Phase I","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HB0034","moa":"CD200R1","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HB0034","moa":"CD200R1","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HB0034","moa":"CD200R1","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ONO-4685","moa":"CD3","graph1":"Dermatology","graph2":"Phase I","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Philikos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Dafsolimab Setaritox","moa":"||CD3\/CD7","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Philikos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Philikos \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Philikos \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"BT061","moa":"CD4","graph1":"Dermatology","graph2":"Phase II","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA vaccine","moa":"CD4 T-cell","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"MONGOLIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronan Fragment HA35","moa":"CD44 \/ ECM components","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nakhia Impex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Undisclosed"},{"orgOrder":0,"company":"Derming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Carbohydrate","year":"2013","type":"Inapplicable","leadProduct":"Ialuronic Acid","moa":"CD44 \/ ECM components","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derming","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derming \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derming \/ Undisclosed"},{"orgOrder":0,"company":"Pharma Holdings","sponsor":"University Hospital of North Norway","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LTX-109","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Pharma Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pharma Holdings \/ University Hospital of North Norway","highestDevelopmentStatusID":"7","companyTruncated":"Pharma Holdings \/ University Hospital of North Norway"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Daptomycin","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase IV","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Zeltiq Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase IV","graph3":"Zeltiq Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zeltiq Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Zeltiq Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Juva Skin & Laser Center","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase IV","graph3":"Juva Skin & Laser Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juva Skin & Laser Center \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Juva Skin & Laser Center \/ Allergan"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Omiganan","moa":"Cell membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Polymyxin B Sulfate","moa":"Cell outer membrane","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2022","type":"Financing","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Micreos Human Health","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Micreos Human Health \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PCS499","moa":"cGMP\/PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PCS499","moa":"cGMP\/PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PCS499","moa":"cGMP\/PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atacama Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Dexmecamylamine HCl","moa":"CHRNA4\/CHRNB2","graph1":"Dermatology","graph2":"Phase II","graph3":"Atacama Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atacama Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atacama Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Atacama Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Dexmecamylamine HCl","moa":"CHRNA4\/CHRNB2","graph1":"Dermatology","graph2":"Phase II","graph3":"Atacama Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atacama Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atacama Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ASB17061","moa":"Chymase (CYM)","graph1":"Dermatology","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BLU-808","moa":"c-Kit","graph1":"Dermatology","graph2":"Phase II","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CDX-0159","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CDX-0159","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Third Harmonic Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"THB001","moa":"c-KIT receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Third Harmonic Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Third Harmonic Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Third Harmonic Bio \/ Undisclosed"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ALY-301","moa":"c-Kit\/CD-203c","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alys Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Alys Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Jeune Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeune Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jeune Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jeune Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"KB301","moa":"COL3A1","graph1":"Dermatology","graph2":"Phase I","graph3":"Jeune Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeune Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jeune Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"LSU Health Sciences Center Shreveport","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Undisclosed","graph3":"LSU Health Sciences Center Shreveport","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"LSU Health Sciences Center Shreveport \/ Healthpoint","highestDevelopmentStatusID":"1","companyTruncated":"LSU Health Sciences Center Shreveport \/ Healthpoint"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Newco Trials Pesquisa Cient\u00edfica Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Newco Trials Pesquisa Cient\u00edfica Ltda"},{"orgOrder":0,"company":"DMR Research","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"DMR Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DMR Research \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"DMR Research \/ Endo Pharm"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2011","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Endo Pharm"},{"orgOrder":0,"company":"Men's Health Boston","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Men's Health Boston","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Men's Health Boston \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Men's Health Boston \/ Undisclosed"},{"orgOrder":0,"company":"Charitable Union for the Research and Education of Peyronie's Disease","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Charitable Union for the Research and Education of Peyronie's Disease","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm"},{"orgOrder":0,"company":"Charitable Union for the Research and Education of Peyronie's Disease","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Charitable Union for the Research and Education of Peyronie's Disease","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Charitable Union for the Research and Education of Peyronie's Disease \/ Endo Pharm"},{"orgOrder":0,"company":"Manhattan Medical Research Practice, PLLC","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"Manhattan Medical Research Practice, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Manhattan Medical Research Practice, PLLC \/ Endo Pharm","highestDevelopmentStatusID":"11","companyTruncated":"Manhattan Medical Research Practice, PLLC \/ Endo Pharm"},{"orgOrder":0,"company":"BioSpecifics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Acquisition","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Approved FDF","graph3":"BioSpecifics","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.54000000000000004,"dosageForm":"Injection","sponsorNew":"BioSpecifics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"BioSpecifics \/ Endo Pharm"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"SMITH & NEPHEW INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Dermatology","graph2":"Phase IV","graph3":"SMITH & NEPHEW INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SMITH & NEPHEW INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"SMITH & NEPHEW INC \/ Undisclosed"},{"orgOrder":0,"company":"Austin Institute for Clinical Research","sponsor":"SkinCeuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Austin Institute for Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Institute for Clinical Research \/ SkinCeuticals","highestDevelopmentStatusID":"1","companyTruncated":"Austin Institute for Clinical Research \/ SkinCeuticals"},{"orgOrder":0,"company":"Luxurgery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum-Aaes","moa":"Collagen alpha-1(I) chain; Collagen alpha-1(II) chain; Collagen alpha-1(III) chain","graph1":"Dermatology","graph2":"Phase IV","graph3":"Luxurgery","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luxurgery \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Luxurgery \/ Undisclosed"},{"orgOrder":0,"company":"Simply Plus Co., Ltd.","sponsor":"Chia Nan University of Pharmacy and Science","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Simply Plus Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Simply Plus Co., Ltd. \/ Chia Nan University of Pharmacy and Science","highestDevelopmentStatusID":"1","companyTruncated":"Simply Plus Co., Ltd. \/ Chia Nan University of Pharmacy and Science"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Collagen Lifesciences Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Collagen Lifesciences Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Collagen Lifesciences Private Limited"},{"orgOrder":0,"company":"ProofPilot","sponsor":"Noho Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Phase III","graph3":"ProofPilot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProofPilot \/ Noho Health","highestDevelopmentStatusID":"10","companyTruncated":"ProofPilot \/ Noho Health"},{"orgOrder":0,"company":"VIST","sponsor":"Tosla d.o.o. | Slovenian Research Agency","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Collagen","moa":"Collagen hydrolysis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Tosla d.o.o. | Slovenian Research Agency","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Tosla d.o.o. | Slovenian Research Agency"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"China National Biotech Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ China National Biotech Group","highestDevelopmentStatusID":"15","companyTruncated":"Croma-Pharma \/ China National Biotech Group"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Emoled","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Emoled","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Emoled \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Emoled \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"Contipro Pharma a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Contipro Pharma a.s","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Contipro Pharma a.s \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Contipro Pharma a.s \/ Undisclosed"},{"orgOrder":0,"company":"Luminera","sponsor":"Innovative Luminera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Luminera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luminera \/ Innovative Luminera","highestDevelopmentStatusID":"15","companyTruncated":"Luminera \/ Innovative Luminera"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Serum","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Ceapro","sponsor":"Symrise","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Avenanthramides","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ceapro \/ Symrise","highestDevelopmentStatusID":"15","companyTruncated":"Ceapro \/ Symrise"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C.","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ DeNova Research | University of California, San Diego | The Wall Center for Plastic Surgery | Mathew Avram, MD | Laser & Skin Surgery Medical Group, Inc. | Investigate MD, LLC | Biesman, Brian, M.D. | Plastic Surgical Associates of Fort Collins, P.C."},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cch-Aaes","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"EN3835","moa":"Collagenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Quintiles Inc"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Dermatology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diclofenac","moa":"COX||Cyclooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Diclofenac","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Divestment","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Salicylic Acid","moa":"COX-1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2011","type":"Inapplicable","leadProduct":"EXC 001","moa":"CTGF messenger RNA (CTGF mRNA)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"NI-0801","moa":"C-X-C motif chemokine 10","graph1":"Dermatology","graph2":"Phase I","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Light Chain Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"EB06","moa":"CXCL-10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Velan Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"EB06","moa":"CXCL-10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Velan Capital","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Velan Capital"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eltrekibart","moa":"CXCR1","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"C-C chemokine receptor type 4 (CCR4)||CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"C-C chemokine receptor type 4 (CCR4)||CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rapt Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zelnecirnon","moa":"CXCR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Rapt Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapt Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapt Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Diclofenac Sodium","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Ulthera, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ulthera, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ulthera, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ulthera, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sephoris Pharmaceuticals LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Dermatology","graph2":"Phase II","graph3":"Sephoris Pharmaceuticals LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sephoris Pharmaceuticals LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sephoris Pharmaceuticals LLC \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dermatology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University of North Carolina \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Allergan"},{"orgOrder":0,"company":"Spherium Biomed","sponsor":"Germans Trias i Pujol Hospital | Hospital del Mar | Hospital Sant Joan de Deu | Hospital Universitario Virgen Macarena | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica - Hospital Universita","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dermatology","graph2":"Phase II","graph3":"Spherium Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Spherium Biomed \/ Germans Trias i Pujol Hospital | Hospital del Mar | Hospital Sant Joan de Deu | Hospital Universitario Virgen Macarena | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica - Hospital Universita","highestDevelopmentStatusID":"8","companyTruncated":"Spherium Biomed \/ Germans Trias i Pujol Hospital | Hospital del Mar | Hospital Sant Joan de Deu | Hospital Universitario Virgen Macarena | Hospital Universitario La Fe | Hospital General Universitario de Alicante | Fundaci\u00f3n de Investigaci\u00f3n Biom\u00e9dica - Hospital Universita"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Scientis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Scientis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scientis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Scientis \/ Undisclosed"},{"orgOrder":0,"company":"Medivet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oxygen","moa":"Cytochrome c oxidase subunit 1; NADPH oxidase 1","graph1":"Dermatology","graph2":"Phase I","graph3":"Medivet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medivet \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medivet \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clotrimazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ketoconazole","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Spirig Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sertaconazole Nitrate","moa":"Cytochrome P450 51","graph1":"Dermatology","graph2":"Phase II","graph3":"Spirig Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Spirig Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spirig Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Soterios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"STS-01","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Soterios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Zabalafin Hydrogel","moa":"Cytokine","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Spermidine","moa":"Cytoplasmic thioredoxin reductase (TXNRD1)||TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Momenta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Momenta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Momenta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Goldman, Butterwick, Fitzpatrick and Groff","sponsor":"Advanced Dermatology | MediCell Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Defensins","moa":"Defensin","graph1":"Dermatology","graph2":"Phase III","graph3":"Goldman, Butterwick, Fitzpatrick and Groff","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldman, Butterwick, Fitzpatrick and Groff \/ Advanced Dermatology | MediCell Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Goldman, Butterwick, Fitzpatrick and Groff \/ Advanced Dermatology | MediCell Technologies"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BOS-356","moa":"DGAT1","graph1":"Dermatology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Boston Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences"},{"orgOrder":0,"company":"Beverly Hills","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimethyl Sulfone","moa":"||DHT","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Beverly Hills","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beverly Hills \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Beverly Hills \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase III","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"medac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"medac \/ Undisclosed"},{"orgOrder":0,"company":"medac","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase I","graph3":"medac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"medac \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"medac \/ PPD"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Accutest Research Lab I Pvt. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase I","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amneal Pharmaceuticals \/ Accutest Research Lab I Pvt. Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Amneal Pharmaceuticals \/ Accutest Research Lab I Pvt. Ltd"},{"orgOrder":0,"company":"Prof. Kristian Reich","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Dermatology","graph2":"Phase III","graph3":"Prof. Kristian Reich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prof. Kristian Reich \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prof. Kristian Reich \/ Undisclosed"},{"orgOrder":0,"company":"Aco Hud Nordic","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Urea","moa":"Dihydrofolate reductase; Arginase-1; Carbonic anhydrase 2; Catenin beta-1; Sulfoxide reductase catalytic subunit YedY","graph1":"Dermatology","graph2":"Phase II","graph3":"Aco Hud Nordic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Aco Hud Nordic \/ University of Sheffield","highestDevelopmentStatusID":"8","companyTruncated":"Aco Hud Nordic \/ University of Sheffield"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Farudodstat","moa":"Dihydroorotate dehydrogenase","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Provincial Institute of Dermatology and Venereology","sponsor":"Shandong Provincial Hospital | Jinan Central Hospital | Shandong Qianfo Hospital | Jinan Military General Hospital | Qingdao Hiser Medical Group | Liaocheng People's Hospital | Dongyuan People's Hospital | Jining First People's Hospital | Dezhou People's ","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shandong Provincial Institute of Dermatology and Venereology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Provincial Institute of Dermatology and Venereology \/ Shandong Provincial Hospital | Jinan Central Hospital | Shandong Qianfo Hospital | Jinan Military General Hospital | Qingdao Hiser Medical Group | Liaocheng People's Hospital | Dongyuan People's Hospital | Jining First People's Hospital | Dezhou People's ","highestDevelopmentStatusID":"11","companyTruncated":"Shandong Provincial Institute of Dermatology and Venereology \/ Shandong Provincial Hospital | Jinan Central Hospital | Shandong Qianfo Hospital | Jinan Military General Hospital | Qingdao Hiser Medical Group | Liaocheng People's Hospital | Dongyuan People's Hospital | Jining First People's Hospital | Dezhou People's "},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Catawba Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase III","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torrent Pharmaceuticals Limited \/ Catawba Research","highestDevelopmentStatusID":"10","companyTruncated":"Torrent Pharmaceuticals Limited \/ Catawba Research"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"Almirall","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Almirall \/ Allergan","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Allergan"},{"orgOrder":0,"company":"SeegPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase III","graph3":"SeegPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"SeegPharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SeegPharm \/ Undisclosed"},{"orgOrder":0,"company":"Cook County Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Cook County Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cook County Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cook County Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase III","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"SeegPharm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ SeegPharm","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ SeegPharm"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Dermatology","graph2":"Phase II","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Wellcome Trust","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Wellcome Trust"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Maruho"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Roth Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Roth Capital Partners"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Rosalind Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biofrontera","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Biofrontera \/ Rosalind Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Biofrontera \/ Rosalind Advisors"},{"orgOrder":0,"company":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","sponsor":"P\u00e4ij\u00e4nne Tavastia Central Hospital | Tampere University Hospital | Vaasa Central Hospital, Vaasa, Finland | Tampere University | STUK - Radiation and Nuclear Safety Authority: Finland","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FINLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ P\u00e4ij\u00e4nne Tavastia Central Hospital | Tampere University Hospital | Vaasa Central Hospital, Vaasa, Finland | Tampere University | STUK - Radiation and Nuclear Safety Authority: Finland","highestDevelopmentStatusID":"11","companyTruncated":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ P\u00e4ij\u00e4nne Tavastia Central Hospital | Tampere University Hospital | Vaasa Central Hospital, Vaasa, Finland | Tampere University | STUK - Radiation and Nuclear Safety Authority: Finland"},{"orgOrder":0,"company":"George Washington University","sponsor":"DUSA Pharmaceuticals, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"George Washington University \/ DUSA Pharmaceuticals, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"George Washington University \/ DUSA Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Case Comprehensive Cancer Center","sponsor":"Cleveland Clinic | Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Case Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Case Comprehensive Cancer Center \/ Cleveland Clinic | Biofrontera","highestDevelopmentStatusID":"8","companyTruncated":"Case Comprehensive Cancer Center \/ Cleveland Clinic | Biofrontera"},{"orgOrder":0,"company":"Tennessee Clinical Research Center","sponsor":"Graceway Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Tennessee Clinical Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tennessee Clinical Research Center \/ Graceway Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Tennessee Clinical Research Center \/ Graceway Pharmaceuticals"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Dermatology","graph2":"Phase II","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA||Protoporphyrinogen oxidase; Delta-aminolevulinic acid dehydratase","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Biofrontera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Biofrontera","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Biofrontera"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Sciton | Sherrif Ibrahim","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Sciton | Sherrif Ibrahim","highestDevelopmentStatusID":"8","companyTruncated":"Biofrontera \/ Sciton | Sherrif Ibrahim"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Lidamycin Phosphate","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mayo Clinic \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Johnson & Johnson"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"University Hospital, Limoges","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Methyl Aminolevulinate","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"University Hospital, Limoges","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Limoges \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Limoges \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Methyl Aminolevulinate","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methyl Aminolevulinate","moa":"DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Delta-Aminolevulinic Acid Methyl Ester","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Delta-Aminolevulinic Acid Methyl Ester","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aleor Dermaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SLA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"SLA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"SLA Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SLA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Aptar Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aptar Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aptar Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aptar Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biorasi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorasi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Undisclosed"},{"orgOrder":0,"company":"Irma Bernadette","sponsor":"Center of Innovation Technologies for Human Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Dermatology","graph2":"Phase I","graph3":"Irma Bernadette","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Irma Bernadette \/ Center of Innovation Technologies for Human Health","highestDevelopmentStatusID":"6","companyTruncated":"Irma Bernadette \/ Center of Innovation Technologies for Human Health"},{"orgOrder":0,"company":"Nanometics (d.b.a. PHD Biosciences)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Uracil","moa":"DNA","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Nanometics (d.b.a. PHD Biosciences)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Nanometics (d.b.a. PHD Biosciences) \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nanometics (d.b.a. PHD Biosciences) \/ Undisclosed"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Golden Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chung Shan Medical University \/ Golden Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Chung Shan Medical University \/ Golden Biotechnology"},{"orgOrder":0,"company":"Golden Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Antroquinonol","moa":"DNA [cytosine-5]-methyltransferase 1 (DNMT1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Golden Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Golden Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Golden Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Durect","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DUR-928","moa":"DNMTs","graph1":"Dermatology","graph2":"Phase II","graph3":"Durect","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Durect \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Durect \/ Therapeutics, Inc."},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Dopamine transporter | Synaptic vesicular amine transporter | Norepinephrine transporter","graph1":"Dermatology","graph2":"Phase I","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brilaroxazine","moa":"DRD2","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"E6201","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Mitogen-activated protein kinase kinase kinase 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Syneos Health | Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Syneos Health | Innovaderm","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Syneos Health | Innovaderm"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Dermatology","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caliway Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Coacillium","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LH-8","moa":"E selectin expression","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Legacy Healthcare \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Columbus Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Columbus Venture Partners"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LUT-014","moa":"EGFR","graph1":"Dermatology","graph2":"Phase II","graph3":"Lutris Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lutris Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lutris Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BPR277","moa":"ELA2\/KLK7","graph1":"Dermatology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fusidic Acid","moa":"Elongation factor G","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Remetinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Dermatology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Betta Pharmaceuticals \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Quintiles Inc"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Betta Pharmaceuticals \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Tigermed"},{"orgOrder":0,"company":"Betta Pharmaceuticals","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Betta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Betta Pharmaceuticals \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Betta Pharmaceuticals \/ Tigermed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Dermatology","graph2":"Phase II","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ethinyl Estradiol","moa":"Estrogen receptor alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DLQ01","moa":"F2-alpha receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dermaliq Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"FASN","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Denifanstat","moa":"FASN","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Denifanstat","moa":"FASN","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Denifanstat","moa":"FASN","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Denifanstat","moa":"FASN","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TVB-3567","moa":"FASN","graph1":"Dermatology","graph2":"Phase I","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sagimet Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sagimet Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sagimet Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TVB-3567","moa":"FASN","graph1":"Dermatology","graph2":"Phase I","graph3":"Sagimet Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sagimet Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sagimet Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC40","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ASC40","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASC40","moa":"Fatty acid synthase","graph1":"Dermatology","graph2":"Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Alabama at Birmingham \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"AB Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Kiel","sponsor":"Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of Kiel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Kiel \/ Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"University of Kiel \/ Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"DPT Laboratories, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Viatris \/ DPT Laboratories, Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ DPT Laboratories, Ltd"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Par Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Emer, Jason, M.D.","sponsor":"Ferndale Laboratories, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Emer, Jason, M.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Emer, Jason, M.D. \/ Ferndale Laboratories, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Emer, Jason, M.D. \/ Ferndale Laboratories, Inc."},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Nobelpharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Narrows Institute for Biomedical Research \/ Nobelpharma","highestDevelopmentStatusID":"8","companyTruncated":"Narrows Institute for Biomedical Research \/ Nobelpharma"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"NEW ZEALAND","productType":"Antibiotic","year":"2021","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase II","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AFT Pharmaceuticals \/ Timber Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"AFT Pharmaceuticals \/ Timber Pharmaceuticals"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mankind Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec Limited","highestDevelopmentStatusID":"15","companyTruncated":"Mankind Pharma \/ Panacea Biotec Limited"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"MT10109","moa":"fluoroquinolone derivatives","graph1":"Dermatology","graph2":"Phase II","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fevipiprant","moa":"G protein-coupled receptor 44","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Atopix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"OC000459","moa":"G protein-coupled receptor 44","graph1":"Dermatology","graph2":"Phase II","graph3":"Atopix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atopix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Atopix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Setipiprant","moa":"G protein-coupled receptor 44","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Dermatology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Dermatology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Galectin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GEORGIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"GR-MD-02","moa":"Galectin-3","graph1":"Dermatology","graph2":"Phase II","graph3":"Galectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Galectin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galectin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicines Development for Global Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicines Development for Global Health \/ Undisclosed"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicines Development for Global Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicines Development for Global Health \/ Undisclosed"},{"orgOrder":0,"company":"Florida Academic Centers Research and Education, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Florida Academic Centers Research and Education, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Florida Academic Centers Research and Education, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Florida Academic Centers Research and Education, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"Glucagon-like peptide 1 receptor | Gastric inhibitory polypeptide receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Alclometasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"The University of Pittsburgh School of Medicine \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ Leo Pharma"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wake Forest University Health Sciences \/ Dermavant Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Wake Forest University Health Sciences \/ Dermavant Sciences"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"11","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Betamethasone Valerate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Hill Dermaceuticals, Inc.","sponsor":"Syneos Health | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Hill Dermaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Hill Dermaceuticals, Inc. \/ Syneos Health | Covance","highestDevelopmentStatusID":"7","companyTruncated":"Hill Dermaceuticals, Inc. \/ Syneos Health | Covance"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Amgen Inc \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Clocortolone Pivalate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Corticosteroid","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Desonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Siriraj Hospital","sponsor":"SPS MEDICAL CO.,LTD. | Siriraj Clinical Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"THAILAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Siriraj Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Siriraj Hospital \/ SPS MEDICAL CO.,LTD. | Siriraj Clinical Research Center","highestDevelopmentStatusID":"10","companyTruncated":"Siriraj Hospital \/ SPS MEDICAL CO.,LTD. | Siriraj Clinical Research Center"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Desoximetasone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DFD-03","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DFD-03","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DFD-04","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluocinonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wake Forest University Health Sciences \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University Health Sciences \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"Wake Forest University","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fluocinonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Wake Forest University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Wake Forest University \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Dermatology Consulting Services, PLLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Dermatology Consulting Services, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Consulting Services, PLLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dermatology Consulting Services, PLLC \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Halobetasol","moa":"||Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"11","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Skin Sciences, PLLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Skin Sciences, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Skin Sciences, PLLC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Skin Sciences, PLLC \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Halobetasol","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Hydrocortisone Probutate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"IDP-122","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"IDP-122","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"IDP-122","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"IDP-122","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mapracorat","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor||Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Libbs Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Libbs Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Libbs Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Libbs Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"ACOM Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"ACOM Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ACOM Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ACOM Labs \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"University of California, San Francisco \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Genentech"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Seton Healthcare Family \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Seton Healthcare Family \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ZK245186","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CD5024","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CD5024","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CD5024","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CD5024","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TURKEY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"University of California, San Diego \/ Galderma"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Wake Forest University Health Sciences \/ Galderma","highestDevelopmentStatusID":"8","companyTruncated":"Wake Forest University Health Sciences \/ Galderma"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Catawba Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Pharmaceuticals \/ Catawba Research, LLC","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Pharmaceuticals \/ Catawba Research, LLC"},{"orgOrder":0,"company":"Zydus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zydus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UNITED LABORATORIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase II","graph3":"UNITED LABORATORIES","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"UNITED LABORATORIES \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UNITED LABORATORIES \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glycerine","moa":"Glutamine","graph1":"Dermatology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"INJA Wellness","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Glutathione","moa":"Glutathione reductase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"INJA Wellness","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INJA Wellness \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"INJA Wellness \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Dermatology","graph2":"Phase IV","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Maxion Therapeutics","sponsor":"General Catalyst","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"MAX001","moa":"GPCR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Maxion Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Maxion Therapeutics \/ General Catalyst","highestDevelopmentStatusID":"4","companyTruncated":"Maxion Therapeutics \/ General Catalyst"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Namilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Basque Health Service","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Basque Health Service","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basque Health Service \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Basque Health Service \/ Undisclosed"},{"orgOrder":0,"company":"Skin Care and Laser Physicians of Beverly Hills","sponsor":"Eclipse Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Skin Care and Laser Physicians of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Skin Care and Laser Physicians of Beverly Hills \/ Eclipse Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Skin Care and Laser Physicians of Beverly Hills \/ Eclipse Aesthetics"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Eclipse Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Platelet Rich Plasma","moa":"Growth factor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Eclipse Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Eclipse Aesthetics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"World Orphan Drug Alliance","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ World Orphan Drug Alliance","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ World Orphan Drug Alliance"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2022","type":"Financing","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Marathon Asset Management"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Series B Financing","leadProduct":"EB005","moa":"Gut microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2021","type":"Collaboration","leadProduct":"EB005","moa":"Gut microbiome","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0.22,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ GSK"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CBP-174","moa":"H3 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LEO 152020","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JW Pharmaceutical \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"JW Pharmaceutical \/ Leo Pharma"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LEO 152020","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JW Pharmaceutical \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"JW Pharmaceutical \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LEO 152020","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ZPL389","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ZPL389","moa":"H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Pantovigar","moa":"Hair follicle","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merz Pharma \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Merz Pharma"},{"orgOrder":0,"company":"Haus Bioceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HAT1","moa":"HAT1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Haus Bioceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Haus Bioceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Haus Bioceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Haus Bioceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HAT1","moa":"HAT1","graph1":"Dermatology","graph2":"Phase II","graph3":"Haus Bioceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Haus Bioceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haus Bioceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Haus Bioceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HAT1","moa":"HAT1","graph1":"Dermatology","graph2":"Phase II","graph3":"Haus Bioceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Haus Bioceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haus Bioceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sodium Cromoglicate","moa":"Heat shock protein 90 alpha (HSP90A)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"VDA-1102","moa":"Hexokinase-2 (HK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vidac Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Therapeutics, Inc. | PharPoint Research | Medis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"VDA-1102","moa":"Hexokinase-2 (HK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vidac Pharma \/ Therapeutics, Inc. | PharPoint Research | Medis","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Therapeutics, Inc. | PharPoint Research | Medis"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Votucalis","moa":"Histamine","graph1":"Dermatology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akari Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bepotastine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Faes Farma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bilastine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Faes Farma","highestDevelopmentStatusID":"9","companyTruncated":"Charite University, Berlin, Germany \/ Faes Farma"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"OcuMension Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"OcuMension Therapeutics \/ Nicox SA"},{"orgOrder":0,"company":"Lunan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lunan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lunan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lunan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clemastine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"Organon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Organon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Organon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organon \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Desloratadine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Mantecorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dexchloropheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Mantecorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mantecorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mantecorp \/ Undisclosed"},{"orgOrder":0,"company":"Mantecorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dexchloropheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Mantecorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Mantecorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mantecorp \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Epinastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Epinastine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Syrup","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"OrchestratePharma","sponsor":"VidiLife Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"OrchestratePharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrchestratePharma \/ VidiLife Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"OrchestratePharma \/ VidiLife Clinical Research"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Levocetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Lucis Pharma","sponsor":"Rosemont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Alimemazine","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Lucis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lucis Pharma \/ Rosemont","highestDevelopmentStatusID":"15","companyTruncated":"Lucis Pharma \/ Rosemont"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"JNJ-38518168","moa":"Histamine H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Ziarco Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ZPL-3893787","moa":"Histamine H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ziarco Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziarco Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ziarco Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Ziarco Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ZPL-3893787","moa":"Histamine H4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ziarco Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ziarco Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ziarco Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Saypha Volume Lidocaine","moa":"Homeostasis","graph1":"Dermatology","graph2":"Phase III","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Saypha Volume Lidocaine","moa":"Homeostasis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Homeostasis","graph1":"Dermatology","graph2":"Phase I","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henry Ford Health System \/ Galderma","highestDevelopmentStatusID":"6","companyTruncated":"Henry Ford Health System \/ Galderma"},{"orgOrder":0,"company":"Suneva Medical","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Polymethylmethacrylate","moa":"Homeostasis","graph1":"Dermatology","graph2":"Phase III","graph3":"Suneva Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suneva Medical \/ ethica Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Suneva Medical \/ ethica Clinical Research"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SPF 50","moa":"Homeostasis","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"RODAN & FIELDS LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Termination","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ RODAN & FIELDS LLC","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ RODAN & FIELDS LLC"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Promura GmbH","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Promura GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Promura GmbH"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acyclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG557","moa":"ICOS","graph1":"Dermatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AMG811","moa":"IFN-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ligelizumab","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase IV","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"QGE031","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Quilizumab","moa":"Ig epsilon chain C region","graph1":"Dermatology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0.60999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AVT04","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT2206","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BAT2206","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"DMB-3115","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Meiji Seika Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Dong-A ST Co., Ltd. \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.47999999999999998,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG777","moa":"IL-13 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ASLAN004","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ASLAN004","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ASLAN004","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Johns Hopkins University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Johns Hopkins University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Johns Hopkins University School of Medicine"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Thermo Fisher Scientific","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Thermo Fisher Scientific","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Thermo Fisher Scientific"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ BVF Partners"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Zenyaku Kogyo","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Zenyaku Kogyo"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"ASLAN Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ASLAN Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ ASLAN Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ ASLAN Pharmaceuticals"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Gumokimab","moa":"IL-17","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PN-881","moa":"IL-17","graph1":"Dermatology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC50","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ASC50","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":2.3999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DC-806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"S011806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"S011806","moa":"IL-17 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"DICE Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Netakimab","moa":"IL-17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"SPH-BIOCAD (HK) Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Netakimab","moa":"IL-17A","graph1":"Dermatology","graph2":"Phase III","graph3":"SPH-BIOCAD (HK) Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SPH-BIOCAD (HK) Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SPH-BIOCAD (HK) Limited \/ Undisclosed"},{"orgOrder":0,"company":"Usynova Pharmaceuticals Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"UA026","moa":"IL-17A","graph1":"Dermatology","graph2":"Phase I","graph3":"Usynova Pharmaceuticals Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Usynova Pharmaceuticals Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Usynova Pharmaceuticals Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK111","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BAT2306","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BAT2306","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Vertex Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"IMG-20","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Vertex Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Vertex Ventures"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"||IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Xyngari","moa":"IL-17A receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Maxim Group LLC"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"DMT310","moa":"||IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DMT310","moa":"IL-17A\/F","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"DaxibotulinumtoxinA-lanm","moa":"||IL-17A\/F","graph1":"Dermatology","graph2":"Phase I","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Dermata Therapeutics \/ Revance Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dermata Therapeutics \/ Revance Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ORKA-002","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Covagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"COVA322","moa":"IL-17A\/TNF","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Covagen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Covagen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Covagen \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MOR106","moa":"IL-17C","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"MOR106","moa":"IL-17C","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ MorphoSys","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ MorphoSys"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MOR106","moa":"IL-17C","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MOR106","moa":"IL-17C","graph1":"Dermatology","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GSK1070806","moa":"IL-18","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CMK389","moa":"IL-18 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO301","moa":"IL-18 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Promore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Promore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Promore Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Pergamum AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ensereptide","moa":"IL-1-beta\/IL-6\/IL-8\/TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Promore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Promore Pharma \/ Pergamum AB","highestDevelopmentStatusID":"8","companyTruncated":"Promore Pharma \/ Pergamum AB"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Icon Plc | Covance | PHT Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"MEDI8968","moa":"IL-1R1","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Icon Plc | Covance | PHT Corporation","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Icon Plc | Covance | PHT Corporation"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"APVO210","moa":"IL-2\/IL-10 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aptevo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"BMS-986326","moa":"IL-2\/IL2-alpha receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Equillium","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Equillium","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Equillium"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"EQ101","moa":"IL-2\/IL-9\/IL-15 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Temtokibart","moa":"IL22RA1","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Argenx"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Temtokibart","moa":"IL22RA1","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Temtokibart","moa":"IL22RA1","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"LEO 138559","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LEO 138559","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LEO 138559","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"LEO 138559","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"LEO 138559","moa":"IL-22RA1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"AMG139","moa":"IL-23 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CT-P43","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IBI112","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI112","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IBI112","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IBI112","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Picankibart","moa":"IL-23-alpha receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.98999999999999999,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Protagonist Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Protagonist Therapeutics"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.98999999999999999,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Icotrokinra","moa":"IL23R","graph1":"Dermatology","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0.98999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.98999999999999999,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"XmAb564","moa":"IL-2-beta-receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ TCGX","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Rezpegaldesleukin","moa":"IL2RA","graph1":"Dermatology","graph2":"Phase II","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nektar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATTO-1310","moa":"IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"ATTO-1310","moa":"IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BMS-981164","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Brexogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BRE-AD01","moa":"IL-31 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brexogen \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Brexogen \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"MSTT1041A","moa":"IL-33 receptor (ST2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"BI655130","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Imsidolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ LEO Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ LEO Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK120","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2016","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Licensing Agreement","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AOBiome Therapeutics \/ Maruho","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Maruho"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Veristat"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Biorasi"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Biorasi"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Novella Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Novella Clinical","highestDevelopmentStatusID":"6","companyTruncated":"AOBiome Therapeutics \/ Novella Clinical"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"B244","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Connect Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Connect Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Connect Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Connect Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Series C Financing","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Public Offering","leadProduct":"Rademikibart","moa":"IL-4-alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BBT001","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bambusa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bambusa Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"BBT001","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Bambusa Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"Bambusa Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Bambusa Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Series C Financing","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":1.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Yellow Jersey Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Yellow Jersey Therapeutics","amount2":1.25,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Undisclosed","sponsorNew":"Yellow Jersey Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"5","companyTruncated":"Yellow Jersey Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"NM26-2198","moa":"IL-4R-alpha\/IL-31 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R\u03b1","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hunan Mabgeek Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chime Biologics \/ Hunan Mabgeek Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Hunan Mabgeek Biotechnology"},{"orgOrder":0,"company":"Hunan Mabgeek Biotechnology","sponsor":"Chime Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Hunan Mabgeek Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hunan Mabgeek Biotechnology \/ Chime Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Mabgeek Biotechnology \/ Chime Biologics"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R\u03b1","graph1":"Dermatology","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Stapokibart","moa":"IL-4R?","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BCD-085","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2018","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Horizon Technology Finance Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Agreement","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Horizon Technology Finance Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Horizon Technology Finance Corporation"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Merger","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology Medicines \/ Q32 Bio"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Q32 Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Homology Medicines \/ Q32 Bio","highestDevelopmentStatusID":"8","companyTruncated":"Homology Medicines \/ Q32 Bio"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL7R","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Linerixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linerixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linerixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linerixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mirum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medison Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Om Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OM-85 BV","moa":"Immune","graph1":"Dermatology","graph2":"Phase II","graph3":"Om Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Om Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Om Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"OM-85 BV","moa":"Immune","graph1":"Dermatology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Undisclosed"},{"orgOrder":0,"company":"Mastelli","sponsor":"Sintesi Research Srl","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Oligonucleotide","year":"2018","type":"Inapplicable","leadProduct":"Polydeoxyribonucleotides","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"Mastelli","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mastelli \/ Sintesi Research Srl","highestDevelopmentStatusID":"11","companyTruncated":"Mastelli \/ Sintesi Research Srl"},{"orgOrder":0,"company":"Bionou Research, S.L.","sponsor":"Biopolis S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bionou Research, S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionou Research, S.L. \/ Biopolis S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Bionou Research, S.L. \/ Biopolis S.L."},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Bionou Research, S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioithas SL \/ Bionou Research, S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Bionou Research, S.L."},{"orgOrder":0,"company":"Biopolis S.L.","sponsor":"Korott, S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Biopolis S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopolis S.L. \/ Korott, S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Biopolis S.L. \/ Korott, S.L."},{"orgOrder":0,"company":"Biopolis S.L.","sponsor":"Korott, S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Biopolis S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopolis S.L. \/ Korott, S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Biopolis S.L. \/ Korott, S.L."},{"orgOrder":0,"company":"Biopolis S.L.","sponsor":"Korott, S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Biopolis S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopolis S.L. \/ Korott, S.L.","highestDevelopmentStatusID":"1","companyTruncated":"Biopolis S.L. \/ Korott, S.L."},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"BioFortis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ BioFortis"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Microbiome labs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Skin Science and Research \/ Microbiome labs","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Microbiome labs"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Codex Labs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Skin Science and Research \/ Codex Labs","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Codex Labs"},{"orgOrder":0,"company":"Phytopharm Consulting","sponsor":"Laborat\u00f3rio Sa\u00fade","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Rue Extract","moa":"Immune","graph1":"Dermatology","graph2":"Phase III","graph3":"Phytopharm Consulting","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Phytopharm Consulting \/ Laborat\u00f3rio Sa\u00fade","highestDevelopmentStatusID":"10","companyTruncated":"Phytopharm Consulting \/ Laborat\u00f3rio Sa\u00fade"},{"orgOrder":0,"company":"Tongjitang Pharmaceutical","sponsor":"Beijing Bionovo Medicine Development","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Runzao Zhiyang","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"Tongjitang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tongjitang Pharmaceutical \/ Beijing Bionovo Medicine Development","highestDevelopmentStatusID":"11","companyTruncated":"Tongjitang Pharmaceutical \/ Beijing Bionovo Medicine Development"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"Molnlycke Health Care AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Sulfate","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"University Hospital, Clermont-Ferrand \/ Molnlycke Health Care AB","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ Molnlycke Health Care AB"},{"orgOrder":0,"company":"Piramal Enterprises Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Tinefcon","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"Piramal Enterprises Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Piramal Enterprises Limited \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Piramal Enterprises Limited \/ Undisclosed"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2013","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Dermatology","graph2":"Phase II","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coronado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coronado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Talaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCR001","moa":"Immune tolerance","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Talaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Talaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Talaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EC-18","moa":"immunomodulators","graph1":"Dermatology","graph2":"Phase II","graph3":"Enzychem Lifesciences Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enzychem Lifesciences Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Enzychem Lifesciences Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Broc Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"Inactive rhomboid protein 2 (RHBDF2)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Broc Shot","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Broc Shot \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Broc Shot \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Teprotumumab","moa":"Insulin-like growth factor I receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Dermatology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ AstraZeneca"},{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Anifrolumab","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Dermatology","graph2":"Phase II","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Hospital, Bordeaux \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Bordeaux \/ AstraZeneca"},{"orgOrder":0,"company":"Affibody","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affibody \/ TFS Trial Form Support","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Affibody","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Covance"},{"orgOrder":0,"company":"Affibody","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ABY-035","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affibody \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"AIN457","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"AIN457","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CJM112","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CJM112","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CJM112","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Health and Science University \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Affibody","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Affibody","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Affibody \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Affibody \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.62,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.62,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0.54000000000000004,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.62,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Morgan Stanley"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase I","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radboud University Medical Center \/ ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent","highestDevelopmentStatusID":"11","companyTruncated":"Radboud University Medical Center \/ ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Miami","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Miami \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Narrows Institute for Biomedical Research","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Narrows Institute for Biomedical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Narrows Institute for Biomedical Research \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Narrows Institute for Biomedical Research \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Atridia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase I","graph3":"Atridia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atridia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atridia \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Vunakizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Approved FDF","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ UCB Pharma S.A | Psoriasis Treatment Center of Central New Jersey"},{"orgOrder":0,"company":"Innovaderm","sponsor":"CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ CIUSSS de l'Est-de-l'\u00cele-de-Montr\u00e9al"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"UCB4940","moa":"Interleukin 17A | Interleukin-17F","graph1":"Dermatology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Dermatology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tibulizumab","moa":"Interleukin 17A | Tumor necrosis factor ligand superfamily member 13B","graph1":"Dermatology","graph2":"Phase II","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CBP-201","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CBP-201","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CBP-201","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Connect Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CBP-201","moa":"Interleukin 4 receptor alpha (IL4R)","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ADX-914","moa":"Interleukin 7 receptor alpha (IL7R)","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q32 Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"XBiotech","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Divestment","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"XBiotech","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"XBiotech \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ GSK"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bermekimab","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"RA-18C3","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"RA-18C3","moa":"Interleukin-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lutikizumab","moa":"Interleukin-1 alpha | Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"XOMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Gevokizumab","moa":"Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"XOMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Undisclosed"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Rilonacept","moa":"Interleukin-1 beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PF-06650833","moa":"Interleukin-1 receptor-associated kinase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Yoshindo","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Yoshindo","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Yoshindo"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Sandoz B2B"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Nipro Pharma Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Nipro Pharma Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Nipro Pharma Corporation"},{"orgOrder":0,"company":"Biocon","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Biocon \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Dong-A ST Co., Ltd. \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Johnson & Johnson","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Johnson & Johnson"},{"orgOrder":0,"company":"Biocon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocon \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Biomm","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Biomm"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Pharmapark","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Pharmapark","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Pharmapark"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Bio-Thera Solutions \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Dong-A Socio Holdings"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meiji Seika Pharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Yoshindo","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Yoshindo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yoshindo \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Yoshindo \/ Biocon"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Medical Center Groningen \/ Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ Janssen-Cilag"},{"orgOrder":0,"company":"Bioeq IP AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Bioeq IP AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioeq IP AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioeq IP AG \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ IQVIA"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AG \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Formycon"},{"orgOrder":0,"company":"Formycon","sponsor":"Bioeq IP AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Formycon","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Formycon \/ Bioeq IP AG","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/ Bioeq IP AG"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Demerger","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Samsung Bioepis"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accord healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Accord healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Samsung Bioepis","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Samsung Bioepis"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"ATP Holdings","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Private Placement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Alvotech \/ ATP Holdings","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ ATP Holdings"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Formycon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius SE & Co. KGaA \/ Formycon","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Formycon"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Alvotech","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Alvotech"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwestern University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Northwestern University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Centocor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tufts Medical Center \/ Centocor","highestDevelopmentStatusID":"1","companyTruncated":"Tufts Medical Center \/ Centocor"},{"orgOrder":0,"company":"JANSSEN BIOTECH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"JANSSEN BIOTECH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JANSSEN BIOTECH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JANSSEN BIOTECH \/ Undisclosed"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Celltrion","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Celltrion"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovaderm \/ Janssen Ortho LLC","highestDevelopmentStatusID":"10","companyTruncated":"Innovaderm \/ Janssen Ortho LLC"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accord BioPharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Accord BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Accord BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Accord BioPharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Accord BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ATHOS","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"ATHOS","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injection","sponsorNew":"ATHOS \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"ATHOS \/ Formycon"},{"orgOrder":0,"company":"ATHOS","sponsor":"Formycon","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"ATHOS","amount2":0.71999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.71999999999999997,"dosageForm":"Injection","sponsorNew":"ATHOS \/ Formycon","highestDevelopmentStatusID":"10","companyTruncated":"ATHOS \/ Formycon"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CC-93538","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Eli Lilly"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Dermira","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Dermira"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"||Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"PF-07275315","moa":"Interleukin-13 (IL13)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"||Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tralokinumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | PPD | Rho, Inc | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AMG714","moa":"Interleukin-15","graph1":"Dermatology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | PPD | Rho, Inc | Amgen Inc"},{"orgOrder":0,"company":"Equillium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"BNZ-1","moa":"Interleukin-15 (IL15)","graph1":"Dermatology","graph2":"Phase II","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equillium \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Equillium \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Kyowa Kirin","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A||Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aarhus University Hospital \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Aarhus University Hospital \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MedDerm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase III","graph3":"MedDerm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedDerm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MedDerm \/ Undisclosed"},{"orgOrder":0,"company":"Florida Academic Dermatology Centers","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase II","graph3":"Florida Academic Dermatology Centers","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Florida Academic Dermatology Centers \/ Ortho Dermatologics","highestDevelopmentStatusID":"8","companyTruncated":"Florida Academic Dermatology Centers \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Rockefeller University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase I","graph3":"Rockefeller University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockefeller University \/ Bausch Health","highestDevelopmentStatusID":"6","companyTruncated":"Rockefeller University \/ Bausch Health"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Brodalumab","moa":"Interleukin-17 receptor A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Helix BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Helix BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Helix BioPharma"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"MoonLake Immunotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"||Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ SVB Securities"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Vetter Pharma-Fertigung GmbH & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Vetter Pharma-Fertigung GmbH & Co"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avillion LLP \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Undisclosed"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avillion LLP \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Merck & Co"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MoonLake Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"MoonLake Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MoonLake Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MoonLake Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Komodo Health","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Komodo Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Komodo Health \/ MoonLake Immunotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Komodo Health \/ MoonLake Immunotherapeutics"},{"orgOrder":0,"company":"Bond Avillion 2 Development","sponsor":"Avillion LLP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Bond Avillion 2 Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bond Avillion 2 Development \/ Avillion LLP","highestDevelopmentStatusID":"8","companyTruncated":"Bond Avillion 2 Development \/ Avillion LLP"},{"orgOrder":0,"company":"Apollo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Camoteskimab","moa":"Interleukin-18","graph1":"Dermatology","graph2":"Phase II","graph3":"Apollo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apollo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apollo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"Interleukin-21","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Almirall"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"BI655066","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"CNTO 1959","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"CNTO 1959","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"CNTO 1959","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"CNTO 1959","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Medical Center Groningen \/ Janssen-Cilag","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ Janssen-Cilag"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Human Drug Research \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ JANSSEN BIOTECH","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ JANSSEN BIOTECH"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Yale University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yale University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Rockefeller University","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase I","graph3":"Rockefeller University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rockefeller University \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Rockefeller University \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"MK-3222","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Medical Research Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Oregon Medical Research Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Medical Research Center \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Medical Research Center \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Shenzhen Kangzhe Pharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Kangzhe Pharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"BI 655066","moa":"Interleukin-23 (IL23)","graph1":"Dermatology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK101","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AK101","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK101","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Akeso","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Akeso"},{"orgOrder":0,"company":"Akeso","sponsor":"Akeso","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"AK101","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akeso \/ Akeso","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Akeso"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Briakinumab","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Phase I","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ebdarokimab","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Akeso","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ebdarokimab","moa":"Interleukin-23 | Interleukin-12","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Akeso \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Akeso \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CD14152","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Maruho","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Maruho \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruho \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Galderma"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Etokimab","moa":"Interleukin-33","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LY3375880","moa":"Interleukin-33","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"REGN3500","moa":"Interleukin-33","graph1":"Dermatology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"REGN3500","moa":"Interleukin-33","graph1":"Dermatology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"SteinCares","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ SteinCares","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ SteinCares"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Sanofi | Proinnovera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Charite University, Berlin, Germany \/ Sanofi | Proinnovera","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Sanofi | Proinnovera"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Medical Center Groningen \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University Medical Center Groningen \/ Sanofi"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Prothya Biosolutions"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Brigham and Women's Hospital \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Rockefeller University | Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Rockefeller University | Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Rockefeller University | Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"OptiSkin Medical","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"OptiSkin Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OptiSkin Medical \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"OptiSkin Medical \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Akron Children's Hospital","sponsor":"Regeneron Pharmaceuticals | Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Akron Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akron Children's Hospital \/ Regeneron Pharmaceuticals | Ohio State University","highestDevelopmentStatusID":"8","companyTruncated":"Akron Children's Hospital \/ Regeneron Pharmaceuticals | Ohio State University"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mayo Clinic \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Regeneron Pharmaceuticals | Sanofi | Atopic Dermatitis Research Network | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals | Sanofi | Atopic Dermatitis Research Network | Rho, Inc","highestDevelopmentStatusID":"11","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals | Sanofi | Atopic Dermatitis Research Network | Rho, Inc"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Mepolizumab","moa":"Interleukin-5","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"McMaster University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"McMaster University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"McMaster University \/ AstraZeneca"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Massachusetts General Hospital \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Renovo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Prevascar","moa":"interleukins: interleukin-10 analogues and derivatives","graph1":"Dermatology","graph2":"Phase I","graph3":"Renovo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Renovo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Renovo \/ Undisclosed"},{"orgOrder":0,"company":"Arix Bioscience Plc","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Arix Bioscience Plc","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Cream","sponsorNew":"Arix Bioscience Plc \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arix Bioscience Plc \/ EQT Life Sciences"},{"orgOrder":0,"company":"Virginia Clinical Research, Inc.","sponsor":"Evommune","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase I","graph3":"Virginia Clinical Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Virginia Clinical Research, Inc. \/ Evommune","highestDevelopmentStatusID":"6","companyTruncated":"Virginia Clinical Research, Inc. \/ Evommune"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EVO101","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28999999999999998,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"KT-474","moa":"IRAK4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kymera Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Polymed Biopharmaceuticals","sponsor":"Photys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"PROTACs","year":"2025","type":"Licensing Agreement","leadProduct":"PHT-776","moa":"IRAK4","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Polymed Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polymed Biopharmaceuticals \/ Photys Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Polymed Biopharmaceuticals \/ Photys Therapeutics"},{"orgOrder":0,"company":"TauTona Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"TauTona Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"TauTona Group \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TauTona Group \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"ITK","graph1":"Dermatology","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ATI-2138","moa":"ITK\/TXK\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series C Financing","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Sanofi"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"ENV-294","moa":"JAK","graph1":"Dermatology","graph2":"Phase I","graph3":"Enveda Bioscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Pill","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"6","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FMX114","moa":"JAK","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MH004","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tofacitinib Etocomil","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Maxinovel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MAX-40070","moa":"JAK\/TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Maxinovel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maxinovel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maxinovel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alys Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ALY-101","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Alys Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alys Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alys Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-252","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"INCB054707","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"INCB054707","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB054707","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB054707","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INCB054707","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1||Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase I","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01001","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VC005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Huadong Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Partnership","leadProduct":"VC005","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Huadong Medicine","highestDevelopmentStatusID":"10","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Huadong Medicine"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Suzhou Zelgen Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Jaktinib HCl","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Suzhou Zelgen Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suzhou Zelgen Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Terran Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Terran Biosciences"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Aclaris Therapeutics \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0.57999999999999996,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.57999999999999996,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TLL018","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TLL018","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATI-1777","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ATI-502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ATI-502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ATI-502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ATI-502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ATI-502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ATI502","moa":"JAK1\/JAK3","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Diacerein","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accro Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accro Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Diacerein","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Accro Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Accro Bioscience \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Accro Bioscience \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Accro Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diacerein","moa":"IL-1?","graph1":"Dermatology","graph2":"Phase II","graph3":"Accro Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accro Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accro Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Sareum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SDC-1801","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ Undisclosed"},{"orgOrder":0,"company":"Sareum","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SDC-1801","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sareum","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sareum \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sareum \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Therapeutics, Inc."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TDM-180935","moa":"JAK1\/TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deuruxolitinib phosphate","moa":"JAK1|JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ DKSH"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Japan Tobacco Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Delgocitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Peficitinib","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"CAGE Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ Undisclosed"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"CAGE Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ Undisclosed"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"CAGE Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"||Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ATI-501","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CTP-543","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2586184","moa":"Janus kinase 1 (JAK-1)","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ICP-488","moa":"JH2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Tioga Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Asimadoline","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Tioga Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tioga Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tioga Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CR845","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Vifor \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Financing","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"CARA Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"8","companyTruncated":"CARA Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0.44,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.44,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Enteris Biopharma Inc","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Enteris Biopharma Inc"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CARA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CARA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ CARA Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ CARA Therapeutics"},{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Peptide, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Molteni Farmaceutici","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"4","companyTruncated":"Molteni Farmaceutici \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Titan Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"JT Pharmaceuticals","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"JT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MR13A9","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kissei Pharmaceutical","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"MR13A9","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kissei Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kissei Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kissei Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nalfurafine","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Immunis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Nalfurafine","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Immunis","highestDevelopmentStatusID":"6","companyTruncated":"Toray Industries \/ Immunis"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Toray Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SK Chemicals \/ Toray Industries","highestDevelopmentStatusID":"10","companyTruncated":"SK Chemicals \/ Toray Industries"},{"orgOrder":0,"company":"Shenyang Sunshine Pharmaceutical Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Shenyang Sunshine Pharmaceutical Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Sunshine Pharmaceutical Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Toray Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nalfurafine HCl","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Toray Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toray Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Toray Industries \/ Undisclosed"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"MUSC Foundation for Research Development","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"TP-2021","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development"},{"orgOrder":0,"company":"Forward Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase III","graph3":"Forward Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forward Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forward Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Forward Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase III","graph3":"Forward Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Forward Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Forward Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Almirall | Harrison Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Almirall | Harrison Clinical Research","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Almirall | Harrison Clinical Research"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dimethyl Fumarate","moa":"Kelch-like ECH-associated protein 1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Proinnovera","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Proinnovera","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Proinnovera"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Cream","sponsorNew":"Galderma \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Perrigo Company plc \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Perrigo Company plc \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Galderma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Jefferies"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Mayne Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"||Keratinocyte","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"Microdermis Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henry Ford Health System \/ Microdermis Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Henry Ford Health System \/ Microdermis Corporation"},{"orgOrder":0,"company":"Alchemee","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alchemee","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alchemee \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Alchemee \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Zurita Laboratorio Farmaceutico Ltda.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ECUADOR","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Phase IV","graph3":"Zurita Laboratorio Farmaceutico Ltda.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Zurita Laboratorio Farmaceutico Ltda. \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LNK01004","moa":"kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lynk Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lynk Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"SNK01","moa":"KIRS","graph1":"Dermatology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Public Offering","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase III","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Barzolvolimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase II","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celldex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celldex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jasper Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vestige Marketing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Vestige Marketing","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vestige Marketing \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vestige Marketing \/ Undisclosed"},{"orgOrder":0,"company":"Nutra Harmony LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutra Harmony LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutra Harmony LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutra Harmony LLC \/ Undisclosed"},{"orgOrder":0,"company":"Nutrition 21, Inc.","sponsor":"ALS Beauty and Personal Care","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Biotin","moa":"Krebs cycle activatior","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutrition 21, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutrition 21, Inc. \/ ALS Beauty and Personal Care","highestDevelopmentStatusID":"1","companyTruncated":"Nutrition 21, Inc. \/ ALS Beauty and Personal Care"},{"orgOrder":0,"company":"selectION","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SI-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ FGK Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ FGK Clinical Research"},{"orgOrder":0,"company":"selectION","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"SI-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ FGK Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ FGK Clinical Research"},{"orgOrder":0,"company":"selectION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"si-544","moa":"Kv1.3","graph1":"Dermatology","graph2":"Phase I","graph3":"selectION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"selectION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"selectION \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Horizon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Horizon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Daxdilimab","moa":"Leukocyte immunoglobulin-like receptor subfamily A member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Celtaxsys, Inc.","sponsor":"Clinical Network Services | Celtaxsys Aus Pty Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Acebilustat","moa":"Leukotriene A4 hydrolase","graph1":"Dermatology","graph2":"Phase II","graph3":"Celtaxsys, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celtaxsys, Inc. \/ Clinical Network Services | Celtaxsys Aus Pty Limited","highestDevelopmentStatusID":"8","companyTruncated":"Celtaxsys, Inc. \/ Clinical Network Services | Celtaxsys Aus Pty Limited"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"LYS006","moa":"Leukotriene A-4 hydrolase (LTA4H)","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"SCF Pharma","sponsor":"Institut de recherche clinique du littoral","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Omega-3 Monoglyceride","moa":"Lipid","graph1":"Dermatology","graph2":"Undisclosed","graph3":"SCF Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SCF Pharma \/ Institut de recherche clinique du littoral","highestDevelopmentStatusID":"1","companyTruncated":"SCF Pharma \/ Institut de recherche clinique du littoral"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"RT001","moa":"Lipid peroxidation","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Dermatology","graph2":"Phase II","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Raziel Therapeutics \/ University of Arizona","highestDevelopmentStatusID":"8","companyTruncated":"Raziel Therapeutics \/ University of Arizona"},{"orgOrder":0,"company":"Ralexar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ALX-101","moa":"Liver X receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ralexar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ralexar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ralexar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ralexar Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ALX-101","moa":"Liver X receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Ralexar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ralexar Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ralexar Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Leukotriene B4","moa":"LTB4R","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"VTP-38543","moa":"LXR","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HZN-825","moa":"LyLPAR1","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HZN-825","moa":"LyLPAR1","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Curzion Pharmaceuticals","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"HZN-825","moa":"LyLPAR1","graph1":"Dermatology","graph2":"Phase II","graph3":"Curzion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curzion Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Curzion Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"IMP731","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BMS-986202","moa":"Lysophosphatidic acid receptor 1 (LPAR1)","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Dermatology","graph2":"Phase II","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MetrioPharm \/ Parexel","highestDevelopmentStatusID":"8","companyTruncated":"MetrioPharm \/ Parexel"},{"orgOrder":0,"company":"MetrioPharm","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Dermatology","graph2":"Phase II","graph3":"MetrioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MetrioPharm \/ Bioskin","highestDevelopmentStatusID":"8","companyTruncated":"MetrioPharm \/ Bioskin"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ATI-450","moa":"MAPK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zunsemetinib","moa":"MAPKAPK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase I","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Vienna \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Medical University of Vienna \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Fundaci\u00f3n CRIS","sponsor":"Amgen Inc | Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase II","graph3":"Fundaci\u00f3n CRIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fundaci\u00f3n CRIS \/ Amgen Inc | Apices Soluciones","highestDevelopmentStatusID":"8","companyTruncated":"Fundaci\u00f3n CRIS \/ Amgen Inc | Apices Soluciones"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Nexgen Dermatologics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Nexgen Dermatologics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexgen Dermatologics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexgen Dermatologics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"WFH MEDICAL, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Derm Research \/ WFH MEDICAL, LLC","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ WFH MEDICAL, LLC"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ 10229570","moa":"MC1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ 10229570-AAA","moa":"MC1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM4","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM4","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM4","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Phase III","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Rioja Salud","sponsor":"Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Fundacion Rioja Salud","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III","highestDevelopmentStatusID":"1","companyTruncated":"Fundacion Rioja Salud \/ Pharmamel | Universidad de Granada | Instituto de Salud Carlos III"},{"orgOrder":0,"company":"PolyMedix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Brilacidin","moa":"Membrane","graph1":"Dermatology","graph2":"Phase II","graph3":"PolyMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyMedix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PolyMedix \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Accelovance | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Accelovance | Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Accelovance | Syneos Health"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Accelovance | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Accelovance | Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Accelovance | Syneos Health"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abametapir","moa":"Metalloproteinase | Iron | Zinc | Copper","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"FCX-013","moa":"MMP1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Castle Creek Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Castle Creek Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"FCX-013","moa":"||MMP1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Castle Creek Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Castle Creek Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VNLG 152","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JNJ-64304500","moa":"monoclonal antibodies: immunomodulating","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"PRX003","moa":"monoclonal antibodies: immunomodulating","graph1":"Dermatology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"Prothena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"PRX003","moa":"monoclonal antibodies: immunomodulating","graph1":"Dermatology","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"MEDI3506","moa":"monoclonal antibodies: interleukins","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"VBL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"VB-201","moa":"Monocyte differentiation antigen CD14 | Toll-like receptor 2","graph1":"Dermatology","graph2":"Phase II","graph3":"VBL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VBL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VBL Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Incyte Corporation"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP262","moa":"MRGPX2 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"Escient Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Escient Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escient Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Escient Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tharimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Tharimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Tharimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tharimmune \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pariser, Robert J., M.D.","sponsor":"Virginia Clinical Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Pariser, Robert J., M.D.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pouch","sponsorNew":"Pariser, Robert J., M.D. \/ Virginia Clinical Research, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Pariser, Robert J., M.D. \/ Virginia Clinical Research, Inc."},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Journey Medical Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Journey Medical Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Journey Medical Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Eli Lilly \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Maruho"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Glycopyrronium Tosylate","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Maruho"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Kaken Pharmaceuticals \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Botanix Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Botanix Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Botanix Pharma"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bodor Laboratories","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Bodor Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bodor Laboratories \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Bodor Laboratories \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"DR. AUGUST WOLFF GMBH & CO. KG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase II","graph3":"DR. AUGUST WOLFF GMBH & CO. KG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DR. AUGUST WOLFF GMBH & CO. KG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DR. AUGUST WOLFF GMBH & CO. KG \/ Undisclosed"},{"orgOrder":0,"company":"Cristalia Produtos Quimicos Farma. Ltda","sponsor":"Hospital Israelita Albert Einstein | University of Sao Paulo","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oxybutynin","moa":"Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase III","graph3":"Cristalia Produtos Quimicos Farma. Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo","highestDevelopmentStatusID":"10","companyTruncated":"Cristalia Produtos Quimicos Farma. Ltda \/ Hospital Israelita Albert Einstein | University of Sao Paulo"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Umeclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Umeclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Dermatology","graph2":"Phase II","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1","graph1":"Dermatology","graph2":"Phase II","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Wipes","sponsorNew":"Journey Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Journey Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"14-C Umeclidinium","moa":"Muscarinic receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Niagen Bioscience","sponsor":"MyPharma2Go Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Partnership","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Niagen Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Niagen Bioscience \/ MyPharma2Go Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Niagen Bioscience \/ MyPharma2Go Corporation"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"SRT2104","moa":"NAD-dependent deacetylase sirtuin 1","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"SRT2104","moa":"NAD-dependent deacetylase sirtuin 1","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"TrialSpark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TrialSpark \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TrialSpark \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation Bio \/ Sanofi"},{"orgOrder":0,"company":"TrialSpark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TrialSpark \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TrialSpark \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Eli Lilly"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Artax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AX-158","moa":"Nck-SH3.1 domain","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Artax Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Artax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Artax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Creabilis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CT327","moa":"Nerve growth factor receptor Trk-A","graph1":"Dermatology","graph2":"Phase II","graph3":"Creabilis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Creabilis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Creabilis \/ Undisclosed"},{"orgOrder":0,"company":"Creabilis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CT327","moa":"Nerve growth factor receptor Trk-A","graph1":"Dermatology","graph2":"Phase II","graph3":"Creabilis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Creabilis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Creabilis \/ Undisclosed"},{"orgOrder":0,"company":"Creabilis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"CT327","moa":"Nerve growth factor receptor Trk-A","graph1":"Dermatology","graph2":"Phase II","graph3":"Creabilis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Creabilis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Creabilis \/ Undisclosed"},{"orgOrder":0,"company":"Sienna Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"SNA-120","moa":"Nerve growth factor receptor Trk-A","graph1":"Dermatology","graph2":"Phase II","graph3":"Sienna Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Sienna Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sienna Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sienna Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SNA-120","moa":"Nerve growth factor receptor Trk-A","graph1":"Dermatology","graph2":"Phase II","graph3":"Sienna Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Sienna Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sienna Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"George Washington University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"George Washington University \/ Hoth Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"George Washington University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Camargo Pharmaceutical","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Camargo Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Camargo Pharmaceutical \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Camargo Pharmaceutical \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Orvepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"NeRRe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NeRRe Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeRRe Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Menlo Therapeutics"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"UNITED LABORATORIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Astaxanthin","moa":"NF-kappa-B inhibitor alpha","graph1":"Dermatology","graph2":"Undisclosed","graph3":"UNITED LABORATORIES","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNITED LABORATORIES \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"UNITED LABORATORIES \/ Undisclosed"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ AmbioPharm"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Series A Financing","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"ParaPRO \/ Undisclosed"},{"orgOrder":0,"company":"CIPHER PHARMS INC","sponsor":"Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"CIPHER PHARMS INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix","highestDevelopmentStatusID":"11","companyTruncated":"CIPHER PHARMS INC \/ Concentrics Research | IQVIA | Medpace, Inc | Inotiv | BioAgilytix"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Concentrics Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Concentrics Research","highestDevelopmentStatusID":"10","companyTruncated":"ParaPRO \/ Concentrics Research"},{"orgOrder":0,"company":"ParaPRO","sponsor":"Concentrics Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Spinosyn D","moa":"Nicotinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"ParaPRO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ParaPRO \/ Concentrics Research","highestDevelopmentStatusID":"10","companyTruncated":"ParaPRO \/ Concentrics Research"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HT-001","moa":"NK-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hoth Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Hoth Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Dermatology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Yardley Dermatology Associates","sponsor":"Topix Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Yardley Dermatology Associates","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yardley Dermatology Associates \/ Topix Pharmaceuticals, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Yardley Dermatology Associates \/ Topix Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Linda Fu","sponsor":"Avadim Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Magnesium Sulfate","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Linda Fu","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Linda Fu \/ Avadim Technologies","highestDevelopmentStatusID":"11","companyTruncated":"Linda Fu \/ Avadim Technologies"},{"orgOrder":0,"company":"Derm Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Hydrogel","moa":"None","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Derm Research \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Bayer AG"},{"orgOrder":0,"company":"Center for Clinical and Cosmetic Research","sponsor":"Onset Dermatologics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Hydrogel","moa":"None","graph1":"Dermatology","graph2":"Phase II","graph3":"Center for Clinical and Cosmetic Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Center for Clinical and Cosmetic Research \/ Onset Dermatologics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Center for Clinical and Cosmetic Research \/ Onset Dermatologics, Inc."},{"orgOrder":0,"company":"Allerderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Hydroxyisohexyl 3-cyclohexene Carboxaldehyde","moa":"None","graph1":"Dermatology","graph2":"Phase II","graph3":"Allerderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allerderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allerderm \/ Undisclosed"},{"orgOrder":0,"company":"Embody Beauty, Inc.","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Embody Beauty, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embody Beauty, Inc. \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Embody Beauty, Inc. \/ Citruslabs"},{"orgOrder":0,"company":"Chemist Confessions, Inc.","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Chemist Confessions, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chemist Confessions, Inc. \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Chemist Confessions, Inc. \/ Citruslabs"},{"orgOrder":0,"company":"Clearstem Skincare","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Clearstem Skincare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clearstem Skincare \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Clearstem Skincare \/ Citruslabs"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"QVC Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Partnership","leadProduct":"Vitamin A","moa":"NR1B","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pressure BioSciences \/ QVC Skincare","highestDevelopmentStatusID":"1","companyTruncated":"Pressure BioSciences \/ QVC Skincare"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cedirogant","moa":"NR1F3||ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Termination","leadProduct":"Cedirogant","moa":"NR1F3","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Cedirogant","moa":"NR1F3","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inventiva Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cedirogant","moa":"NR1F3","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Clobetasone Butyrate","moa":"NR3C1","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2981278","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"GSK2981278","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"JTE-451","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"JTE-451","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VTP-43742","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"VTP-43742","moa":"Nuclear receptor ROR-gamma (RORG)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"TA-102 A","moa":"Ocular surface","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0.69999999999999996,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.69999999999999996,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Genentech"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Vixarelimab","moa":"Oncostatin-M-specific receptor subunit beta","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Davita Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevi Therapeutics \/ Davita Clinical Research","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Davita Clinical Research"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Trevi Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BAT6026","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BAT6026","moa":"||OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inmagene Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Hutchmed","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.46000000000000002,"dosageForm":"Infusion","sponsorNew":"Hutchmed \/ Inmagene Biopharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Hutchmed \/ Inmagene Biopharmaceuticals"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Ikena Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Ikena Oncology"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"IMG-007","moa":"OX40 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inmagene Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inmagene Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IBI356","moa":"OX40L","graph1":"Dermatology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Abcentra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Orticumab","moa":"Oxidized LDL","graph1":"Dermatology","graph2":"Phase II","graph3":"Abcentra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abcentra \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Abcentra \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hypericin","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Alliance Global Partners"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"Soligenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hypericin Sodium","moa":"Oxygen radical","graph1":"Dermatology","graph2":"Phase II","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Soligenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soligenix \/ Undisclosed"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BLU-5937","moa":"P2X purinoceptor 3","graph1":"Dermatology","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BIRB 796","moa":"p38 MAPK","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Dermatology","graph2":"Phase I","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pharmaxis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmaxis \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RBN-3143","moa":"PARP-14","graph1":"Dermatology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ribon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LFX453","moa":"PCSK9","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"CC-90006","moa":"PD-1","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JS005","moa":"PD-1","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JS005","moa":"PD-1","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Junshi Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Claruvis Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YY001","moa":"PD-1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Chongqing Claruvis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chongqing Claruvis Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chongqing Claruvis Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rosnilimab","moa":"PDCD1","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnaptysBio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Undisclosed"},{"orgOrder":0,"company":"PurGenesis Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"PurGenesis Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PurGenesis Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PurGenesis Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"PurGenesis Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ PurGenesis Technologies","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ PurGenesis Technologies"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ TSX Venture Exchange","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2025","type":"Private Placement","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"vTv Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Newsoara Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HPP737","moa":"PDE4","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Newsoara Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newsoara Biopharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Newsoara Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Union Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovent Biologics \/ Union Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Innovent Biologics \/ Union Therapeutics"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.27000000000000002,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Innovent Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Innovent Biologics"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Union Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Union Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Union Therapeutics"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Dow Pharmaceutical Sciences, Inc"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IDP-118","moa":"PDE4 \/ Corticosteroid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK44459","moa":"PDE4B","graph1":"Dermatology","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Huabo Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HB0017","moa":"PD-L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Huabo Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huabo Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huabo Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Huabo Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HB0017","moa":"PD-L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Huabo Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huabo Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huabo Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Huabo Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HB0017","moa":"PD-L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Huabo Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huabo Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huabo Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Huabo Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HB0017","moa":"PD-L1","graph1":"Dermatology","graph2":"Phase III","graph3":"Huabo Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Huabo Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huabo Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Kineta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dalazatide","moa":"peptides","graph1":"Dermatology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kineta \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Undisclosed"},{"orgOrder":0,"company":"Biocomposites","sponsor":"MCRA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Dermatology","graph2":"Phase II","graph3":"Biocomposites","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Biocomposites \/ MCRA","highestDevelopmentStatusID":"8","companyTruncated":"Biocomposites \/ MCRA"},{"orgOrder":0,"company":"Biocomposites","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Dermatology","graph2":"Phase II","graph3":"Biocomposites","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Biocomposites \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biocomposites \/ Undisclosed"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lanifibranor","moa":"Peroxisome proliferator-activated receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Inventiva Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inventiva Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Torqur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torqur \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Undisclosed"},{"orgOrder":0,"company":"Torqur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torqur \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Undisclosed"},{"orgOrder":0,"company":"Aquinox Pharmaceuticals","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"AQX-1125","moa":"Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1","graph1":"Dermatology","graph2":"Phase II","graph3":"Aquinox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aquinox Pharmaceuticals \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"Aquinox Pharmaceuticals \/ Innovaderm"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Unichem Laboratories Limited \/ Undisclosed"},{"orgOrder":0,"company":"Technical University of Munich","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Technical University of Munich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technical University of Munich \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Technical University of Munich \/ Celgene Corporation"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Celgene Corporation | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Oslo University Hospital \/ Celgene Corporation | Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Celgene Corporation | Amgen Inc"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TURKEY","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"George Washington University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"George Washington University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Washington University \/ Celgene Corporation","highestDevelopmentStatusID":"11","companyTruncated":"George Washington University \/ Celgene Corporation"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tufts Medical Center \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Tufts Medical Center \/ Amgen Inc"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Celgene Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Celgene Corporation"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase I","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University Health Sciences \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Wake Forest University Health Sciences \/ Amgen Inc"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Health and Science University \/ Celgene Corporation"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Celgene Corporation | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Pennsylvania \/ Celgene Corporation | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ Celgene Corporation | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Virginia Clinical Research, Inc.","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Virginia Clinical Research, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virginia Clinical Research, Inc. \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Virginia Clinical Research, Inc. \/ Celgene Corporation"},{"orgOrder":0,"company":"Bellevue Dermatology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bellevue Dermatology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellevue Dermatology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Bellevue Dermatology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2014","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Celgene Corporation"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ARQ-151","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase I","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"University of California, Irvine \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Irvine \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"University of Colorado, Denver \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Pfizer Inc"},{"orgOrder":0,"company":"Ann & Robert H Lurie Children's Hospital of Chicago","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Ann & Robert H Lurie Children's Hospital of Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Ann & Robert H Lurie Children's Hospital of Chicago \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Ann & Robert H Lurie Children's Hospital of Chicago \/ Pfizer Inc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Johns Hopkins University \/ Pfizer Inc"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Tufts Medical Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tufts Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"Boston University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Boston University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston University \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Boston University \/ Pfizer Inc"},{"orgOrder":0,"company":"Duke University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Duke University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Massachusetts General Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"Massachusetts General Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Crisaborole","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"MEDIMETRIKS PHARMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Difamilast","moa":"Multidrug resistance protein (MDR)||Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"MEDIMETRIKS PHARMS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"MEDIMETRIKS PHARMS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDIMETRIKS PHARMS \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Medimetriks Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Medimetriks Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Medimetriks Pharmaceuticals"},{"orgOrder":0,"company":"Medimetriks Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Medimetriks Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medimetriks Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Medimetriks Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lotamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MK-0873","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MK-0873","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Zhongmei Huadong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Hangzhou Zhongmei Huadong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hangzhou Zhongmei Huadong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Padagis \/ Sol-Gel Technologies","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Sol-Gel Technologies"},{"orgOrder":0,"company":"Tulane University","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Tulane University \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tulane University \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Dermatology Consulting Services, PLLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermatology Consulting Services, PLLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dermatology Consulting Services, PLLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermatology Consulting Services, PLLC \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Hangzhou Huadong Medicine Group Kangrun Pharmaceutical"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.17000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Kowa Pharmaceuticals America","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Sato Yakuhin Kogyo Co., Ltd"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.17000000000000001,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ SLR Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ SLR Capital Partners"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Derm Texas","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Roflumilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Derm Texas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Derm Texas \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Derm Texas \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ARQ-154","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ARQ-154","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Arcutis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"PF-07038124","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PF-07038124","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PF-07038124","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PF-07038124","moa":"Phosphodiesterase 4 (PDE4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Celsus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MRX-6","moa":"Phospholipase A2 (PLA2G1B)","graph1":"Dermatology","graph2":"Phase II","graph3":"Celsus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celsus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celsus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"UCB5857","moa":"PI3-kinase p110-delta subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"UCB Pharma S.A \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"UCB Pharma S.A \/ Parexel"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingenol Disoxate","moa":"PKC","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ingenol","moa":"PKC\/Unknown","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SM-030","moa":"PKC?","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Aswan University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Egymedicalpedia \/ Aswan University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Aswan University"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Chiltern International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Chiltern International","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Chiltern International"},{"orgOrder":0,"company":"Novan","sponsor":"Chiltern International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Chiltern International","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Chiltern International"},{"orgOrder":0,"company":"Novan","sponsor":"Chiltern International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Chiltern International","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Chiltern International"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Spaulding Clinical, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Spaulding Clinical, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Spaulding Clinical, LLC"},{"orgOrder":0,"company":"Novan","sponsor":"WCCT Global","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ WCCT Global","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ WCCT Global"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sb208","moa":"polymers","graph1":"Dermatology","graph2":"Phase II","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sb208","moa":"polymers","graph1":"Dermatology","graph2":"Phase II","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sb208","moa":"polymers","graph1":"Dermatology","graph2":"Phase II","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Sb208","moa":"polymers","graph1":"Dermatology","graph2":"Phase II","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Sb208","moa":"polymers","graph1":"Dermatology","graph2":"Phase II","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Syntrix Pharmaceuticals","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Aminopterin","moa":"Polypeptide deformylase (PDF)","graph1":"Dermatology","graph2":"Phase II","graph3":"Syntrix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syntrix Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Syntrix Pharmaceuticals \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Dermatology","graph2":"Phase IV","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"EHP-101","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emerald Health Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nogra Pharma","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"NAC-GED-0507","moa":"PPA-gamma receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Nogra Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Nogra Pharma \/ Torii Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Nogra Pharma \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"||PPA-gamma receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"15","companyTruncated":"DS Biopharma \/ Nuvothera"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CKDB-501B","moa":"PPAR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CKD Bio Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion IMIM","sponsor":"Adknoma | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Methylprednisolone Aceponate","moa":"prednisone and prednisolone derivatives","graph1":"Dermatology","graph2":"Phase I","graph3":"Fundacion IMIM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Fundacion IMIM \/ Adknoma | Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Fundacion IMIM \/ Adknoma | Bayer AG"},{"orgOrder":0,"company":"Stemedica Cell Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Bone Marrow Cell","moa":"Progenitor cell","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Stemedica Cell Technologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stemedica Cell Technologies \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Stemedica Cell Technologies \/ Undisclosed"},{"orgOrder":0,"company":"CERM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Autologous Adipose Cell Therapy","moa":"Progenitor cell","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"CERM","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CERM \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CERM \/ Undisclosed"},{"orgOrder":0,"company":"Antria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Stromal Vascular Fraction","moa":"Progenitor cell","graph1":"Dermatology","graph2":"Phase II","graph3":"Antria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Antria \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Progestogen","moa":"Progesterone receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Aditxt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Undisclosed"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Prostaglandin F2a Analogue","moa":"Prostaglandin","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dermaliq Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dermaliq Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dermaliq Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BBI-5000","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"LAROPIPRANT","moa":"Prostanoid DP receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2015","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Northwestern University \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Allergan"},{"orgOrder":0,"company":"Tulane University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tulane University \/ Allergan","highestDevelopmentStatusID":"6","companyTruncated":"Tulane University \/ Allergan"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rose Bengal","moa":"Protein","graph1":"Dermatology","graph2":"Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPX-01","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DFD-29","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DFD-29","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase III","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Journey Medical Corporation \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Journey Medical Corporation \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruboxistaurin","moa":"Protein kinase C beta","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"Chroma Dermatology","sponsor":"DermBiont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Ruboxistaurin","moa":"Protein kinase C beta","graph1":"Dermatology","graph2":"Phase I","graph3":"Chroma Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chroma Dermatology \/ DermBiont","highestDevelopmentStatusID":"6","companyTruncated":"Chroma Dermatology \/ DermBiont"},{"orgOrder":0,"company":"Korea University","sponsor":"Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Korea University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Korea University \/ Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho","highestDevelopmentStatusID":"11","companyTruncated":"Korea University \/ Leo Pharma | Chonnam National University Hospital | Severance Hospital | Ajou University School of Medicine | Asan Medical Center | Samsung Medical Center | Seoul National University Bundang Hospital | Dong-A University Hospital | Korea University Anam Ho"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Peplin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase II","graph3":"Peplin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Peplin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Peplin \/ Undisclosed"},{"orgOrder":0,"company":"Pacific Dermaesthetics","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase II","graph3":"Pacific Dermaesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pacific Dermaesthetics \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pacific Dermaesthetics \/ Leo Pharma"},{"orgOrder":0,"company":"Skin Laser & Surgery Specialists","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Skin Laser & Surgery Specialists","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Skin Laser & Surgery Specialists \/ Leo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Skin Laser & Surgery Specialists \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Leo Pharma"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Sao Paulo \/ Leo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Sao Paulo \/ Leo Pharma"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"KB105","moa":"Protein-glutamine gamma-glutamyltransferase K (TGM1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"KB105","moa":"Protein-glutamine gamma-glutamyltransferase K (TGM1)","graph1":"Dermatology","graph2":"Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"KB105","moa":"Protein-glutamine gamma-glutamyltransferase K (TGM1)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"KB105","moa":"Protein-glutamine gamma-glutamyltransferase K (TGM1)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hematoporphyrins","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hematoporphyrins","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hematoporphyrins","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hematoporphyrins","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FINLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase IV","graph3":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Accovion","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Accovion","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Accovion"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BF-200 ALA","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase III","graph3":"Biofrontera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biofrontera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biofrontera \/ Undisclosed"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Photocure","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Aminolevulinic Acid Hexylester","moa":"Protoporphyrin IX","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oslo University Hospital \/ Photocure","highestDevelopmentStatusID":"9","companyTruncated":"Oslo University Hospital \/ Photocure"},{"orgOrder":0,"company":"AbGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"AbGn-168H","moa":"P-selectin glycoprotein ligand 1","graph1":"Dermatology","graph2":"Phase II","graph3":"AbGenomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbGenomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbGenomics \/ Undisclosed"},{"orgOrder":0,"company":"AbGenomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"AbGn-168H","moa":"P-selectin glycoprotein ligand 1","graph1":"Dermatology","graph2":"Phase II","graph3":"AbGenomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbGenomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbGenomics \/ Undisclosed"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"14-C SK-1405","moa":"PSMA","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Undisclosed"},{"orgOrder":0,"company":"Paracrine Therapeutics Dermatology Pte. Ltd.","sponsor":"National University Hospital, Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Dermatology","graph2":"Phase I","graph3":"Paracrine Therapeutics Dermatology Pte. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Paracrine Therapeutics Dermatology Pte. Ltd. \/ National University Hospital, Singapore","highestDevelopmentStatusID":"6","companyTruncated":"Paracrine Therapeutics Dermatology Pte. Ltd. \/ National University Hospital, Singapore"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Dermatology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangzhou Bio-gene Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Undisclosed"},{"orgOrder":0,"company":"Levit Dermatology","sponsor":"ResilielleTM Age ZeroTM Exosomes | Dorisca Research Consulting, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Dermatology","graph2":"Phase I","graph3":"Levit Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Levit Dermatology \/ ResilielleTM Age ZeroTM Exosomes | Dorisca Research Consulting, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Levit Dermatology \/ ResilielleTM Age ZeroTM Exosomes | Dorisca Research Consulting, LLC"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"Next Science","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hydrogen Peroxide","moa":"PTPN1 messenger RNA (PTPN1 mRNA)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henry Ford Health System \/ Next Science","highestDevelopmentStatusID":"1","companyTruncated":"Henry Ford Health System \/ Next Science"},{"orgOrder":0,"company":"AmDerma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"AM001","moa":"Rap guanine nucleotide exchange factor 3 (RAPGEF3)","graph1":"Dermatology","graph2":"Phase II","graph3":"AmDerma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmDerma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmDerma \/ Undisclosed"},{"orgOrder":0,"company":"AmDerma","sponsor":"International Dermatology Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AM001","moa":"Rap guanine nucleotide exchange factor 3 (RAPGEF3)","graph1":"Dermatology","graph2":"Phase II","graph3":"AmDerma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmDerma \/ International Dermatology Research","highestDevelopmentStatusID":"8","companyTruncated":"AmDerma \/ International Dermatology Research"},{"orgOrder":0,"company":"AmDerma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AM001","moa":"Rap guanine nucleotide exchange factor 3 (RAPGEF3)","graph1":"Dermatology","graph2":"Phase II","graph3":"AmDerma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmDerma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AmDerma \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AUR101","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AUR101","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AUR101","moa":"RAR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ADX-629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GSK2982772","moa":"Receptor-interacting serine\/threonine-protein kinase 1","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BAY1834845","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Dermatology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KT-474","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Kymera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"KT-474","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Kymera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Kymera Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zabedosertib","moa":"Renal carcinoma antigen NY-REN-64 (IRAK-4)","graph1":"Dermatology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Catawba Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aleor Dermaceuticals \/ Catawba Research, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Aleor Dermaceuticals \/ Catawba Research, LLC"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Adapalene","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Adapalene","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Altaris Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":1.55,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":1.55,"dosageForm":"Cream","sponsorNew":"Perrigo Company plc \/ Altaris Capital Partners","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Altaris Capital Partners"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Padagis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Wake Forest University","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Wake Forest University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Wake Forest University \/ Galderma","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University \/ Galderma"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Wake Forest University Health Sciences \/ Bausch Health","highestDevelopmentStatusID":"6","companyTruncated":"Wake Forest University Health Sciences \/ Bausch Health"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"VICHY CANADA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"VICHY CANADA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VICHY CANADA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"VICHY CANADA \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Merete Haedersdal","sponsor":"Sebacia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Merete Haedersdal","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merete Haedersdal \/ Sebacia","highestDevelopmentStatusID":"1","companyTruncated":"Merete Haedersdal \/ Sebacia"},{"orgOrder":0,"company":"Patagonia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Patagonia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Patagonia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Patagonia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Journey Medical Corporation","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Journey Medical Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Journey Medical Corporation \/ Fortress Biotech","highestDevelopmentStatusID":"15","companyTruncated":"Journey Medical Corporation \/ Fortress Biotech"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Douglas CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Douglas CDMO","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Douglas CDMO"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Mayne Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Mayne Pharma"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"US Food & Drug Administration","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ US Food & Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ US Food & Drug Administration"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Leo Pharma"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Leo Pharma"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ BioPharmX"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"BioPharmX","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ BioPharmX"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Timber Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Universidade Federal de Goias","sponsor":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | Theraskin | Germed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Universidade Federal de Goias","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Universidade Federal de Goias \/ Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | Theraskin | Germed","highestDevelopmentStatusID":"8","companyTruncated":"Universidade Federal de Goias \/ Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico | Theraskin | Germed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"G & W Laboratories Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"G & W Laboratories Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"G & W Laboratories Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G & W Laboratories Inc. \/ Undisclosed"},{"orgOrder":0,"company":"G & W Laboratories Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"G & W Laboratories Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"G & W Laboratories Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G & W Laboratories Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Dermatology Consulting Services, PLLC","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Dermatology Consulting Services, PLLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dermatology Consulting Services, PLLC \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Dermatology Consulting Services, PLLC \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Cosette Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Cosette Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Cosette Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cosette Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"15","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Timber Pharmaceuticals","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TMB-001","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Timber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Timber Pharmaceuticals \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Timber Pharmaceuticals \/ Leo Pharma"},{"orgOrder":0,"company":"Spear Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Spear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spear Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spear Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spear Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Spear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spear Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spear Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spear Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Spear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spear Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spear Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alembic Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Carrick Therapeutics","sponsor":"Arvinas","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Carrick Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Carrick Therapeutics \/ Arvinas","highestDevelopmentStatusID":"7","companyTruncated":"Carrick Therapeutics \/ Arvinas"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Beimei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Beimei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ Beimei Pharma"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"MagnaPharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ MagnaPharm","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ MagnaPharm"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"SEARCHLIGHT PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sol-Gel Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"Sol-Gel Technologies \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"ConBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"ConBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ConBio \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ConBio \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GALDERMA LABS LP \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GALDERMA LABS LP \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Certara","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Certara \/ Galderma"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Undisclosed"},{"orgOrder":0,"company":"Io Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IRX4204","moa":"Retinoic acid receptor RXR (RXR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Io Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Io Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Io Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Aralez Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovaderm \/ Aralez Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Innovaderm \/ Aralez Pharmaceuticals"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ OSI PHARMS","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ OSI PHARMS"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alitretinoin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Medical Center Groningen \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ ZonMw"},{"orgOrder":0,"company":"GSK","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Alitretinoin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"ASIS Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"ASIS Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASIS Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ASIS Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"AZD0284","moa":"RORG","graph1":"Dermatology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AZD0284","moa":"RORG","graph1":"Dermatology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AZD0284","moa":"RORG","graph1":"Dermatology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"BI730357","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BI730357","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Dermatology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Arxx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AX-202","moa":"S100A4","graph1":"Dermatology","graph2":"Phase I","graph3":"Arxx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arxx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arxx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SCD-044","moa":"S1P1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SCD-044","moa":"S1P1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Undisclosed"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Alethea Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Dermatology","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Lipidio Pharmaceuticals \/ Alethea Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Alethea Capital"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DRM02","moa":"Sebaceous glands","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DRM02","moa":"Sebaceous glands","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DRM02","moa":"Sebaceous glands","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bismuth","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"PF-06263276","moa":"SGLT2","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AK002","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Dermatology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"Allakos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lirentelimab","moa":"Sialic acid-binding Ig-like lectin 8","graph1":"Dermatology","graph2":"Phase II","graph3":"Allakos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allakos \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allakos \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Colloidal Oatmeal","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Colloidal Oatmeal","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Colloidal Oatmeal","moa":"Skin barrier","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Pohl Boskamp","sponsor":"Universit\u00e4tsklinikum Hamburg-Eppendorf","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dimethicone","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase II","graph3":"Pohl Boskamp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pohl Boskamp \/ Universit\u00e4tsklinikum Hamburg-Eppendorf","highestDevelopmentStatusID":"8","companyTruncated":"Pohl Boskamp \/ Universit\u00e4tsklinikum Hamburg-Eppendorf"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Gesellschaft f\u00fcr Therapieforschung mbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sanacutan Basiscreme","moa":"Skin barrier","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ Gesellschaft f\u00fcr Therapieforschung mbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Gesellschaft f\u00fcr Therapieforschung mbH"},{"orgOrder":0,"company":"Jetema","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JTM201","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Jetema","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jetema \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jetema \/ Undisclosed"},{"orgOrder":0,"company":"Sisram Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sisram Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sisram Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sisram Medical \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Barclays","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Barclays","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Barclays"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.23000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Crown Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.92000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.92000000000000004,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Crown Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Crown Laboratories"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Athyrium Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Athyrium Capital","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Athyrium Capital"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ajinomoto Bio-Pharma \/ Revance Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Revance Therapeutics"},{"orgOrder":0,"company":"BMI Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BMI2006","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"BMI Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BMI Korea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BMI Korea \/ Undisclosed"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CKDB-501A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CKDB-501A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Clostridium Botulinum A Toxin","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Clostridium Botulinum A Toxin","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Clostridium Botulinum A Toxin","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"HU-014","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"HU-014","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Huons Global","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"HU-045","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Huons Global","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Huons Global \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huons Global \/ Undisclosed"},{"orgOrder":0,"company":"Huons CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HU-045","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Huons CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Huons CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Huons CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"The Maas Clinic","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase IV","graph3":"The Maas Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Maas Clinic \/ Merz Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"The Maas Clinic \/ Merz Therapeutics"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase I","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Merz Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Clinical Testing of Beverly Hills \/ Merz Therapeutics"},{"orgOrder":0,"company":"DeNova Research","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"DeNova Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"DeNova Research \/ Merz Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"DeNova Research \/ Merz Therapeutics"},{"orgOrder":0,"company":"Zel Skin and Laser Specialists","sponsor":"Merz Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase II","graph3":"Zel Skin and Laser Specialists","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zel Skin and Laser Specialists \/ Merz Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Zel Skin and Laser Specialists \/ Merz Aesthetics"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"JHM BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JHM03","moa":"SNAP-25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"JHM BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JHM BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"JHM BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Croma-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Croma-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Croma-Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Croma-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"IntegraGen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University Hospital, Montpellier \/ IntegraGen","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Montpellier \/ IntegraGen"},{"orgOrder":0,"company":"Fillmed Laboratories","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fillmed Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fillmed Laboratories \/ Crescita Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fillmed Laboratories \/ Crescita Therapeutics"},{"orgOrder":0,"company":"Ulthera, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ulthera, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Ulthera, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ulthera, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"||Sodium channel alpha subunit","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"15","companyTruncated":"Crescita Therapeutics \/ Juyou Biotechnology"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Amiselimod","moa":"Sphingosine 1-phosphate receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ponesimod","moa":"Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Azitra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ATR-04","moa":"SPINK5","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azitra \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Undisclosed"},{"orgOrder":0,"company":"Azitra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"SPINK5","graph1":"Dermatology","graph2":"Phase I","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Azitra \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azitra \/ Undisclosed"},{"orgOrder":0,"company":"Azitra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"SPINK5","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Undisclosed"},{"orgOrder":0,"company":"Azitra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Staphylococcus Epidermidis","moa":"SPINK5","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Undisclosed"},{"orgOrder":0,"company":"Coegin Pharma","sponsor":"Studies&Me | Bispebjerg Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AVX001","moa":"sPLA2","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Coegin Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Coegin Pharma \/ Studies&Me | Bispebjerg Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Coegin Pharma \/ Studies&Me | Bispebjerg Hospital"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2?","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2?","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2?","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2?","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amorolfine Hydrochloride","moa":"squalene","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Swab","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amorolfine Hydrochloride","moa":"squalene","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amorolfine Hydrochloride","moa":"squalene","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Dermatology","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Dermatology","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Butenafine Hydrochloride","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NAFTIFINE HCL","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Phase II","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Resilia Pharmaceuticals","sponsor":"Pelle Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Terbinafine","moa":"Squalene monooxygenase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Resilia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Resilia Pharmaceuticals \/ Pelle Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Resilia Pharmaceuticals \/ Pelle Ventures"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Maruho","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Maruho"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Atopic Dermatitis Research Network | Rho, Inc | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ShA9","moa":"Staphylococcus aureus load","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Atopic Dermatitis Research Network | Rho, Inc | PPD","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Atopic Dermatitis Research Network | Rho, Inc | PPD"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"KP-723","moa":"STAT6","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kaken Pharmaceuticals","amount2":1.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Undisclosed","sponsorNew":"Kaken Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Kaken Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuyu Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dutasteride","moa":"Steroid 5-alpha-reductase","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase I","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polichem S.A. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Polichem S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"HairDx, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase I","graph3":"HairDx, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HairDx, LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HairDx, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Elorac, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Finasteride","moa":"Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Elorac, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Elorac, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Elorac, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Trophea Development AB","sponsor":"Uppsala University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Dehydroepiandrosterone","moa":"steroids (androgens","graph1":"Dermatology","graph2":"Phase I","graph3":"Trophea Development AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trophea Development AB \/ Uppsala University","highestDevelopmentStatusID":"6","companyTruncated":"Trophea Development AB \/ Uppsala University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ George Washington University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Substance P","moa":"Substance-P receptor (TACR1)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"AMOREPACIFIC CORPORATION","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"Succinate semialdehyde dehydrogenase","graph1":"Dermatology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ AMOREPACIFIC CORPORATION"},{"orgOrder":0,"company":"Zhejiang Sunshine Mandi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Zhejiang Sunshine Mandi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Sunshine Mandi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Industrial Farmac\u00e9utica Cantabria","sponsor":"Bioskin | BioClever 2005","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Industrial Farmac\u00e9utica Cantabria","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Industrial Farmac\u00e9utica Cantabria \/ Bioskin | BioClever 2005","highestDevelopmentStatusID":"10","companyTruncated":"Industrial Farmac\u00e9utica Cantabria \/ Bioskin | BioClever 2005"},{"orgOrder":0,"company":"Aneira Pharma","sponsor":"DataPharm Australia | CMAX Clinical Research | Agilex Australia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase I","graph3":"Aneira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aneira Pharma \/ DataPharm Australia | CMAX Clinical Research | Agilex Australia","highestDevelopmentStatusID":"6","companyTruncated":"Aneira Pharma \/ DataPharm Australia | CMAX Clinical Research | Agilex Australia"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Samson Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Samson Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Samson Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Samson Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Johnson & Johnson \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Johnson & Johnson"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ViaDerma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"ViaDerma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ViaDerma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"ViaDerma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ViaDerma \/ Undisclosed"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Safety Shot","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Safety Shot \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Safety Shot \/ Undisclosed"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eurofarma Laboratorios S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Undisclosed"},{"orgOrder":0,"company":"Maja Kovacevic, MD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Maja Kovacevic, MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Maja Kovacevic, MD \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Maja Kovacevic, MD \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase II","graph3":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Dayspring Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Dayspring Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BMX-010","moa":"Superoxide Radical","graph1":"Dermatology","graph2":"Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"BioMimetix JV \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"BioMimetix JV \/ Innovaderm"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BMX-010","moa":"Superoxide Radical","graph1":"Dermatology","graph2":"Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMimetix JV \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMimetix JV \/ Undisclosed"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BMX-010","moa":"Superoxide Radical","graph1":"Dermatology","graph2":"Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMimetix JV \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMimetix JV \/ Undisclosed"},{"orgOrder":0,"company":"BioMimetix JV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"BMX-010","moa":"Superoxide Radical","graph1":"Dermatology","graph2":"Phase II","graph3":"BioMimetix JV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMimetix JV \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioMimetix JV \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AGN-151586","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Anterios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"ANT-1401","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Anterios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterios \/ Undisclosed"},{"orgOrder":0,"company":"Anterios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"ANT-1401","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Anterios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterios \/ Undisclosed"},{"orgOrder":0,"company":"Anterios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"ANT-1403","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Anterios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterios \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Henry Ford Health System \/ Galderma","highestDevelopmentStatusID":"9","companyTruncated":"Henry Ford Health System \/ Galderma"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Allergan"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DWP450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DWP-450","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evolus \/ PPD","highestDevelopmentStatusID":"8","companyTruncated":"Evolus \/ PPD"},{"orgOrder":0,"company":"Bonti","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"EB-001","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"Bonti","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bonti \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bonti \/ Undisclosed"},{"orgOrder":0,"company":"Lupo Center for Dermatology","sponsor":"Evolus","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Lupo Center for Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupo Center for Dermatology \/ Evolus","highestDevelopmentStatusID":"6","companyTruncated":"Lupo Center for Dermatology \/ Evolus"},{"orgOrder":0,"company":"Evolus","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ ethica Clinical Research","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ ethica Clinical Research"},{"orgOrder":0,"company":"Evolus","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Evolus \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Leerink Partners"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Evolus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Prabotulinumtoxin A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evolus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Testing of Beverly Hills","sponsor":"Evolus","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Prabotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Clinical Testing of Beverly Hills","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clinical Testing of Beverly Hills \/ Evolus","highestDevelopmentStatusID":"6","companyTruncated":"Clinical Testing of Beverly Hills \/ Evolus"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"TrenibotulinumtoxinE","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas","sponsor":"Biolab Sanus Farmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dapaconazole","moa":"systemic antifungals (miconazole type)","graph1":"Dermatology","graph2":"Phase II","graph3":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas \/ Biolab Sanus Farmaceutica","highestDevelopmentStatusID":"8","companyTruncated":"Galeno Desenvolvimento de Pesquisas Cl\u00ednicas \/ Biolab Sanus Farmaceutica"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR442970","moa":"TAX transcriptionally-activated glycoprotein 1 (OX40)","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"HCW9302","moa":"T-cell","graph1":"Dermatology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Maxim Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"HCW9302","moa":"T-cell","graph1":"Dermatology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HCW Biologics \/ Maxim Group","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Maxim Group"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"HCW9302","moa":"T-cell","graph1":"Dermatology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HCW Biologics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Dermatology","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"Biotech Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"T1h","moa":"T-cell differentiation antigen CD6","graph1":"Dermatology","graph2":"Phase I","graph3":"Biotech Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotech Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biotech Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"ITBMed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Siplizumab","moa":"T-cell surface antigen CD2","graph1":"Dermatology","graph2":"Phase I","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ ITBMed","highestDevelopmentStatusID":"6","companyTruncated":"University of Alabama at Birmingham \/ ITBMed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PF-07242813","moa":"T-cell surface glycoprotein CD1a (CD1A)","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Akros Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"JTE-051","moa":"T-cell-specific kinase (ITK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Akros Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akros Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Akros Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Theramab LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"TAB08","moa":"T-cell-specific surface glycoprotein CD28","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Theramab LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theramab LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theramab LLC \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF-beta-1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Sagesse Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Cotsiranib","moa":"||TGF-beta-1\/COX-2","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Sagesse Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Sagesse Bio"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection, Powder","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Dermatology","graph2":"Phase II","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"TGR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"TGR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"TGR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"Hudson Therapeutics","sponsor":"Shaperon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Taurodeoxycholic Acid","moa":"TGR5","graph1":"Dermatology","graph2":"Phase II","graph3":"Hudson Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hudson Therapeutics \/ Shaperon","highestDevelopmentStatusID":"8","companyTruncated":"Hudson Therapeutics \/ Shaperon"},{"orgOrder":0,"company":"University of Magdeburg","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Magdeburg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Magdeburg \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"University of Magdeburg \/ Bayer AG"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Padagis","sponsor":"DPT Laboratories, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase III","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Padagis \/ DPT Laboratories, Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Padagis \/ DPT Laboratories, Ltd"},{"orgOrder":0,"company":"Wake Forest University Health Sciences","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Wake Forest University Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Wake Forest University Health Sciences \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Wake Forest University Health Sciences \/ Bayer AG"},{"orgOrder":0,"company":"Clinical Research Center of the Carolinas","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"Clinical Research Center of the Carolinas","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Clinical Research Center of the Carolinas \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Clinical Research Center of the Carolinas \/ Bayer AG"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Derm Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm Research \/ Bayer AG","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Bayer AG"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Dermatology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"MEDI9929","moa":"Thymic stromal lymphopoietin (TSLP)","graph1":"Dermatology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"Spear Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH AFRICA","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Spear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Spear Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spear Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Encube Ethicals \/ CBCC Global","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ CBCC Global"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Clinact","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Clinact","highestDevelopmentStatusID":"11","companyTruncated":"Pierre Fabre \/ Clinact"},{"orgOrder":0,"company":"Almirall","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Almirall","highestDevelopmentStatusID":"10","companyTruncated":"Almirall \/ Almirall"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Skin Laser & Surgery Specialists","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Skin Laser & Surgery Specialists","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skin Laser & Surgery Specialists \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Skin Laser & Surgery Specialists \/ Sanofi"},{"orgOrder":0,"company":"SKNV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SKNV","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SKNV \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SKNV \/ Undisclosed"},{"orgOrder":0,"company":"Extrovis AG","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Extrovis AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Extrovis AG \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Extrovis AG \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3|TIM-3","graph1":"Dermatology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"LAPIX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Photocure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Visonac","moa":"TLR-2\/TLR-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Photocure","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Photocure \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photocure \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase I","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Brigham and Women's Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dinesh Khanna, MD, MS","sponsor":"Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase II","graph3":"Dinesh Khanna, MD, MS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dinesh Khanna, MD, MS \/ Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Dinesh Khanna, MD, MS \/ Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Centro Dermatol\u00f3gico Dr. Ladislao de la Pascua","sponsor":"Grupo Medifarma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Dermatology","graph2":"Phase III","graph3":"Centro Dermatol\u00f3gico Dr. Ladislao de la Pascua","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro Dermatol\u00f3gico Dr. Ladislao de la Pascua \/ Grupo Medifarma","highestDevelopmentStatusID":"10","companyTruncated":"Centro Dermatol\u00f3gico Dr. Ladislao de la Pascua \/ Grupo Medifarma"},{"orgOrder":0,"company":"University of Guadalajara","sponsor":"Hospital Civil de Guadalajara | Cell Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"MEXICO","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"University of Guadalajara","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"University of Guadalajara \/ Hospital Civil de Guadalajara | Cell Pharma","highestDevelopmentStatusID":"7","companyTruncated":"University of Guadalajara \/ Hospital Civil de Guadalajara | Cell Pharma"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BCD-057","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"BI695501","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"CHS-0214","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ SHIRE PLC","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ SHIRE PLC"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"CHS-1420","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CT-P17","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Celgen Bio-Pharmaceutical Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang University","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang University \/ Sunshine Guojian Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Zhejiang University \/ Sunshine Guojian Pharmaceutical"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":2.2999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":2.2999999999999998,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Samsung Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Samsung Biologics"},{"orgOrder":0,"company":"Pantec Biosolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"LIECHTENSTEIN","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase I","graph3":"Pantec Biosolutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pantec Biosolutions \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pantec Biosolutions \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Amgen Inc"},{"orgOrder":0,"company":"Florida Academic Dermatology Centers","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Florida Academic Dermatology Centers","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Florida Academic Dermatology Centers \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"Florida Academic Dermatology Centers \/ Amgen Inc"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Michigan \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Michigan \/ Amgen Inc"},{"orgOrder":0,"company":"OptiSkin Medical","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"OptiSkin Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OptiSkin Medical \/ Amgen Inc","highestDevelopmentStatusID":"11","companyTruncated":"OptiSkin Medical \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Divestment","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biogen","amount2":2.3500000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":2.3500000000000001,"dosageForm":"Injection","sponsorNew":"Biogen \/ Samsung Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Samsung Biologics"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Etanercept","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Amgen Inc"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"HLX03","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Gentofte, Copenhagen","sponsor":"Michaelsen Foundation | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University Hospital Gentofte, Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Gentofte, Copenhagen \/ Michaelsen Foundation | Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital Gentofte, Copenhagen \/ Michaelsen Foundation | Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"MSB11022","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Merck Group","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Merck Group"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"TA-650","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of North Carolina \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of North Carolina \/ AbbVie Inc"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Organon","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Organon"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Viatris | IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Viatris | IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Biocon Biologics \/ Viatris | IQVIA"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Samsung Bioepis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Samsung Bioepis \/ Undisclosed"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Innovent Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Hexal AG","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sandoz B2B \/ Hexal AG","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Hexal AG"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Bioventure Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Bioventure Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Bioventure Healthcare"},{"orgOrder":0,"company":"Alvotech","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Cipla","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Cipla"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Alvotech","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Assia Chemical Industries Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Assia Chemical Industries Ltd"},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Private Placement","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Alvotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alvotech \/ Undisclosed"},{"orgOrder":0,"company":"Wayne State University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Wayne State University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wayne State University \/ Abbott Laboratories","highestDevelopmentStatusID":"7","companyTruncated":"Wayne State University \/ Abbott Laboratories"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"University of Pennsylvania \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories | Montreal Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories | Montreal Heart Institute"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coherus Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Coherus Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"Viatris","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viatris \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Viatris"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Abbott Laboratories"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions","highestDevelopmentStatusID":"11","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions"},{"orgOrder":0,"company":"Mabscale","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Mabscale","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabscale \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabscale \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tulisokibart","moa":"TNFSF15","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG3970","moa":"TOL2\/TOL3","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"SIRO Clinpharm | Accovion","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Viatris \/ SIRO Clinpharm | Accovion","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ SIRO Clinpharm | Accovion"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IMO-3100","moa":"Toll-like receptor 7 (TLR7)","graph1":"Dermatology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spirig Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Resiquimod","moa":"Toll-like receptor 8 | Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Spirig Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spirig Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spirig Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Dermatology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"VB-1953","moa":"Toll-like receptor\/MD2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vyome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vyome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"VB-1953","moa":"Toll-like receptor\/MD2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Vyome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vyome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vyome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Forte Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Forte Biosciences \/ Forte Biosciences"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"Toll-like-5 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Tocagen","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ Tocagen"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"JNJ-32729463","moa":"Topoisomerse IV","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PF-06763809","moa":"Transcription factor unspecific (TF)","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"AVID200","moa":"Transforming growth factor beta (TGFB)","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Therapeutics, Inc."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Therapeutics, Inc."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Therapeutics, Inc."},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"TechnoDerma Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TDM-105795","moa":"TR-beta-1","graph1":"Dermatology","graph2":"Phase II","graph3":"TechnoDerma Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TechnoDerma Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TechnoDerma Medicines \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BEN-2293","moa":"TRK receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BEN-2293","moa":"TRK receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"Biosion","sponsor":"Aclaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosion \/ Aclaris Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Aclaris Therapeutics"},{"orgOrder":0,"company":"Biosion","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bosakitug","moa":"||TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosion \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Sanofi"},{"orgOrder":0,"company":"Biosion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biosion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Aclaris Therapeutics \/ Vivo Capital","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Vivo Capital"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bosakitug","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biosion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BSI-045B","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Undisclosed"},{"orgOrder":0,"company":"Biosion","sponsor":"Southern Star Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BSI-045B","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Biosion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosion \/ Southern Star Research","highestDevelopmentStatusID":"8","companyTruncated":"Biosion \/ Southern Star Research"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CM326","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CM326","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CM326","moa":"TSLP","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ATx201","moa":"Tubulin","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATx201","moa":"Tubulin","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"ATx201","moa":"Tubulin","graph1":"Dermatology","graph2":"Phase I","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Union Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Union Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DFB Soria","sponsor":"US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Dermatology","graph2":"Phase II","graph3":"DFB Soria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"DFB Soria \/ US Biotest, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"DFB Soria \/ US Biotest, Inc."},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SAR441566","moa":"Tumor necrosis factor (TNF)","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":1.45,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.45,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Amlitelimab","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"KY1005","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"KY1005","moa":"Tumor necrosis factor ligand superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Ianalumab","moa":"Tumor necrosis factor receptor superfamily member 13C","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"GBR 830","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ISB 830","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"KHK4083","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Kyowa Kirin"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"KHK4083","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Amgen Inc"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Kyowa Kirin"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Kyowa Kirin"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rocatinlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Telazorlimab","moa":"Tumor necrosis factor receptor superfamily member 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"ASKP1240","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Dermatology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"CFZ533","moa":"Tumor necrosis factor receptor superfamily member 5","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Dermatology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Dermatology","graph2":"Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Pfizer Inc"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Immune Tolerance Network | Pfizer Inc | PPD | Rho, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Pfizer Inc | PPD | Rho, Inc","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Immune Tolerance Network | Pfizer Inc | PPD | Rho, Inc"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-986322","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CS32582","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CS32582","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"Alumis","sponsor":"AyurMaya","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Alumis \/ AyurMaya","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ AyurMaya"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acelyrin \/ Alumis","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Alumis"},{"orgOrder":0,"company":"Alumis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Undisclosed"},{"orgOrder":0,"company":"Alumis","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acelyrin \/ Alumis","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Alumis"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Alumis","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acelyrin \/ Alumis","highestDevelopmentStatusID":"10","companyTruncated":"Acelyrin \/ Alumis"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Alumis","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Morgan Stanley"},{"orgOrder":0,"company":"Alumis","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"ESK-001","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Alumis","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Alumis \/ Foresite Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alumis \/ Foresite Capital"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"Galapagos","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GLPG3667","moa":"TYK2","graph1":"Dermatology","graph2":"Phase I","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Galapagos \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Galapagos \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ICP-332","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Soficitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InnoCare Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InnoCare Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Private Placement","leadProduct":"VTX958","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Ventyx Biosciences","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Ventyx Biosciences \/ Redmile Group","highestDevelopmentStatusID":"8","companyTruncated":"Ventyx Biosciences \/ Redmile Group"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zasocitinib","moa":"TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Innovaderm | Nimbus Lakshmi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Innovaderm | Nimbus Lakshmi","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Innovaderm | Nimbus Lakshmi"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NDI-034858","moa":"TYK2 tyrosine kinase (TYK2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Nimbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimbus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nimbus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Highlightll Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"Phase I","graph3":"Hangzhou Highlightll Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hangzhou Highlightll Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TLL-018","moa":"TYK2\/JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Vial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vial \/ Undisclosed"},{"orgOrder":0,"company":"Mesoestetic Pharma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Hydroquinone","moa":"TYR","graph1":"Dermatology","graph2":"Phase III","graph3":"Mesoestetic Pharma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mesoestetic Pharma Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoestetic Pharma Group \/ Undisclosed"},{"orgOrder":0,"company":"Lutronic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hydroquinone","moa":"TYR","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Lutronic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Lutronic \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lutronic \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ATI-502","moa":"tyrosine kinase inhibitors: janus kinase inhibitors","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Dermatology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fenebrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Dermatology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Pfizer Inc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Duke University | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ Duke University | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Duke University | Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Zurich \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Zurich \/ Incyte Corporation"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Incyte Corporation"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Rochester \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"University of Rochester \/ Incyte Corporation"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Hershey Medical Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Hershey Medical Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Innovaderm","highestDevelopmentStatusID":"11","companyTruncated":"Incyte Corporation \/ Innovaderm"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"CMS","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ CMS","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ CMS"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Maruho","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Maruho"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Priovant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Priovant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Priovant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Priovant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"National Taiwan University Hospital \/ Eli Lilly"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Alabama at Birmingham \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Aclaris Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"15","companyTruncated":"Aclaris Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Incyte Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"||Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Upadacitinib","moa":"Tyrosine-protein kinase JAK3","graph1":"Dermatology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"TKL Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ TKL Research, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ TKL Research, Inc."},{"orgOrder":0,"company":"Medical University of Graz","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medical University of Graz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medical University of Graz \/ Almirall","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Graz \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Almirall"},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ PharmaEssentia"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Holdsworth House Medical Practice","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Dermatology","graph2":"Phase II","graph3":"Holdsworth House Medical Practice","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Holdsworth House Medical Practice \/ Rigel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Holdsworth House Medical Practice \/ Rigel Pharmaceuticals"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"GSK2646264","moa":"Tyrosine-protein kinase SYK (SYK)","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gusacitinib","moa":"Tyrosine-protein kinase SYK | Janus Kinase (JAK)","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Asana BioSciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Covance","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Covance"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PF-06826647","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"PF-06826647","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cerdulatinib","moa":"Tyrosine-protein kinase TYK2 | Tyrosine-protein kinase SYK | Tyrosine-protein kinase JAK3 | Tyrosine-protein kinase JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dermavant Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermavant Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Photonamic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PD P 506 A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Photonamic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Photonamic \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Photonamic \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"MEXICO","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"PRO-118","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Laboratorios Sophia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Laboratorios Sophia \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Steroid","year":"2010","type":"Inapplicable","leadProduct":"Memotasone","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Undisclosed"},{"orgOrder":0,"company":"BioFactura","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BFI-751","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"BioFactura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BioFactura \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"BioFactura \/ Avance Clinical"},{"orgOrder":0,"company":"Crown Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"146-9251","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Crown Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Crown Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Crown Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Genzada Pharmaceuticals","sponsor":"CTC Clinical Trial Consultants","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GZ21T","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Genzada Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Genzada Pharmaceuticals \/ CTC Clinical Trial Consultants","highestDevelopmentStatusID":"6","companyTruncated":"Genzada Pharmaceuticals \/ CTC Clinical Trial Consultants"},{"orgOrder":0,"company":"Kringle Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KP-100LI","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Kringle Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kringle Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kringle Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nanjing Immunophage Biotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IPG7236","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Nanjing Immunophage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Immunophage Biotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Nanjing Immunophage Biotech \/ Novotech"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SCT630","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sterna Biologicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SB011","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Sterna Biologicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Sterna Biologicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sterna Biologicals \/ Undisclosed"},{"orgOrder":0,"company":"Tego Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TPX-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Tego Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tego Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tego Science \/ Undisclosed"},{"orgOrder":0,"company":"Throne Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Throne Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Throne Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Throne Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"TotipotentRX Cell Therapy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous Prp","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"TotipotentRX Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TotipotentRX Cell Therapy \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TotipotentRX Cell Therapy \/ Undisclosed"},{"orgOrder":0,"company":"Xantho Biotechnology","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GM-XAN003","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Xantho Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xantho Biotechnology \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"8","companyTruncated":"Xantho Biotechnology \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Xantho Biotechnology","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"GM-XANTHO","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Xantho Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Xantho Biotechnology \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"8","companyTruncated":"Xantho Biotechnology \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Xantho Biotechnology","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GM-XANTHO","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Xantho Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xantho Biotechnology \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"7","companyTruncated":"Xantho Biotechnology \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"000-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"000-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"0416","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"0417","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"10156","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"122-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"122-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"122-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"122-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"122-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"14-C VC005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"188-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"188-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"188-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"188-0551","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"33525","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"608","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"608","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"608","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"611","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"A-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aclaris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Aclaris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovation Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Abacavir Glycolate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovation Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovation Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovation Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ABBV-553","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbCellera","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABCL575","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbCellera \/ Viking Global Investors","highestDevelopmentStatusID":"5","companyTruncated":"AbCellera \/ Viking Global Investors"},{"orgOrder":0,"company":"AbCellera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABCL575","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbCellera \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"AbCellera \/ Undisclosed"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AC-701","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"TWi Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TWi Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TWi Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Accuitis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ACCU-D1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Accuitis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Accuitis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Accuitis \/ Undisclosed"},{"orgOrder":0,"company":"Ace Cells Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Ace Csd","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Ace Cells Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ace Cells Lab \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ace Cells Lab \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ACH24","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Abyss Ingredients","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"ACT01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Abyss Ingredients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abyss Ingredients \/ Eurofins CDMO","highestDevelopmentStatusID":"1","companyTruncated":"Abyss Ingredients \/ Eurofins CDMO"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"ACT01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AD-208","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"AddPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD-2081","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"AddPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AddPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AddPharma \/ Undisclosed"},{"orgOrder":0,"company":"EHL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"EHL Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EHL Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EHL Bio \/ Undisclosed"},{"orgOrder":0,"company":"EHL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Adult Human Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"EHL Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EHL Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EHL Bio \/ Undisclosed"},{"orgOrder":0,"company":"Center for Clinical and Cosmetic Research","sponsor":"Afecta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"AFX5931","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Center for Clinical and Cosmetic Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Center for Clinical and Cosmetic Research \/ Afecta Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Center for Clinical and Cosmetic Research \/ Afecta Pharmaceuticals"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AGN-242428","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"AI-09","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Eirion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eirion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eirion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dolorgiet GmbH & Co. KG","sponsor":"CenTrial | d.s.h. statistical services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AK 3012","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dolorgiet GmbH & Co. KG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dolorgiet GmbH & Co. KG \/ CenTrial | d.s.h. statistical services","highestDevelopmentStatusID":"8","companyTruncated":"Dolorgiet GmbH & Co. KG \/ CenTrial | d.s.h. statistical services"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AK3280","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Pendulum Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Akkermansia Muciniphila","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical University of South Carolina \/ Pendulum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Medical University of South Carolina \/ Pendulum Therapeutics"},{"orgOrder":0,"company":"Laboratoires Pharmaceutiques Trenker","sponsor":"Complife Italia S.r.l | Universit\u00e0 degli Studi di Pavia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Alline Promen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Laboratoires Pharmaceutiques Trenker","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratoires Pharmaceutiques Trenker \/ Complife Italia S.r.l | Universit\u00e0 degli Studi di Pavia","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Pharmaceutiques Trenker \/ Complife Italia S.r.l | Universit\u00e0 degli Studi di Pavia"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALM223","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"},{"orgOrder":0,"company":"Arbor Life Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALRV5XR","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Arbor Life Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Life Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Arbor Life Labs \/ Undisclosed"},{"orgOrder":0,"company":"Arbor Life Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALRV5XR","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Arbor Life Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Life Labs \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Arbor Life Labs \/ Undisclosed"},{"orgOrder":0,"company":"AnaMar","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CAS 49715-04-0","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AnaMar","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnaMar \/ Covance","highestDevelopmentStatusID":"7","companyTruncated":"AnaMar \/ Covance"},{"orgOrder":0,"company":"IntegoGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMP-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"IntegoGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IntegoGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IntegoGen \/ Undisclosed"},{"orgOrder":0,"company":"Amplifica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Undisclosed"},{"orgOrder":0,"company":"Amplifica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AMP-303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Amplifica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplifica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Amplifica \/ Undisclosed"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMTX-100 CF","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amytrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amytrx Therapeutics \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amytrx Therapeutics \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amway (China) R&D Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Amway Herbal Drink","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Amway (China) R&D Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amway (China) R&D Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Amway (China) R&D Center \/ Undisclosed"},{"orgOrder":0,"company":"Anterios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ANT-1207","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Anterios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterios \/ Undisclosed"},{"orgOrder":0,"company":"Anterios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ANT-1207","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Anterios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anterios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anterios \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"ANT-1207","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liniment","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AP Collagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Apcp","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Apogee Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"APG990","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Apogee Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apogee Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogee Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Apo805K1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Arjil Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"AR100DP1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Arjil Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Arjil Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Arjil Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"M. Arkin 1999 Ltd.","sponsor":"VYNE Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ARK-E021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"M. Arkin 1999 Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M. Arkin 1999 Ltd. \/ VYNE Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"M. Arkin 1999 Ltd. \/ VYNE Therapeutics"},{"orgOrder":0,"company":"ARS Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ARS-1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"ARS Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARS Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ARS Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"INCE Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"ARTS-011","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Allorion Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Allorion Therapeutics \/ INCE Capital","highestDevelopmentStatusID":"5","companyTruncated":"Allorion Therapeutics \/ INCE Capital"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AS012","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"Azora Therapeutics Australia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AT193","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Azora Therapeutics Australia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azora Therapeutics Australia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azora Therapeutics Australia \/ Undisclosed"},{"orgOrder":0,"company":"Azora Therapeutics Australia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AT193","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Azora Therapeutics Australia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azora Therapeutics Australia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Azora Therapeutics Australia \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ATGC-100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ATGC-100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"ATGC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ATGC-110","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"ATGC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATGC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ATGC \/ Undisclosed"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Cromsource","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DUZALLO COMPONENT ALLOPURINOL","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AdvanCell \/ Cromsource","highestDevelopmentStatusID":"8","companyTruncated":"AdvanCell \/ Cromsource"},{"orgOrder":0,"company":"Azitra","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ATR04-484","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Azitra","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azitra \/ Prosoft Clinical","highestDevelopmentStatusID":"7","companyTruncated":"Azitra \/ Prosoft Clinical"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Timeless Chirurgia Plastyczna | Melitus | Polish Stem Cells Bank","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"POLAND","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Autologous Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medical University of Warsaw \/ Timeless Chirurgia Plastyczna | Melitus | Polish Stem Cells Bank","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of Warsaw \/ Timeless Chirurgia Plastyczna | Melitus | Polish Stem Cells Bank"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal And Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Aderans Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Cultured Dermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Aderans Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aderans Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aderans Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"S.Biomedics","sponsor":"Dt&Sanomedics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Autologous Dermal Fibroblasts","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"S.Biomedics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.Biomedics \/ Dt&Sanomedics","highestDevelopmentStatusID":"7","companyTruncated":"S.Biomedics \/ Dt&Sanomedics"},{"orgOrder":0,"company":"Kasiak Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Autologous Human Platelet Lysate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Kasiak Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kasiak Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kasiak Research \/ Undisclosed"},{"orgOrder":0,"company":"Kasiak Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Autologous Human Platelet Lysate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Kasiak Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kasiak Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kasiak Research \/ Undisclosed"},{"orgOrder":0,"company":"Kasiak Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Autologous Human Platelet Lysate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Kasiak Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kasiak Research \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Kasiak Research \/ Undisclosed"},{"orgOrder":0,"company":"Santiste Medical Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Autologous Platelet Rich Plasma","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Santiste Medical Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Santiste Medical Inc. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Santiste Medical Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Avalo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Avalo Therapeutics"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Avalo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"AVTX-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Avalo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Avalo Therapeutics \/ Avalo Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Amino Acid","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sanofi \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Perrigo Company plc"},{"orgOrder":0,"company":"Sanofi","sponsor":"Perrigo Company plc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Amino Acid","year":"2020","type":"Acquisition","leadProduct":"Azeloglycine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sanofi \/ Perrigo Company plc","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Perrigo Company plc"},{"orgOrder":0,"company":"Alimentary Health Ltd","sponsor":"Whately-Smith Ltd, King's Langley,UK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Probiotic","year":"2011","type":"Inapplicable","leadProduct":"B. Infantis 35624","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Alimentary Health Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Alimentary Health Ltd \/ Whately-Smith Ltd, King's Langley,UK","highestDevelopmentStatusID":"7","companyTruncated":"Alimentary Health Ltd \/ Whately-Smith Ltd, King's Langley,UK"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Balsam Peru","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Banana Flower Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BAY1003803","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BAY1003803","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BAY207543","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BBI-2000","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bright Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BC-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Bright Cell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bright Cell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Cell \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"BCT194","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BD9","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teva Pharmaceutical Industries \/ Biolojic Design","highestDevelopmentStatusID":"5","companyTruncated":"Teva Pharmaceutical Industries \/ Biolojic Design"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Beauty Drink","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Pharmanex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Undisclosed"},{"orgOrder":0,"company":"Pharmanex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Beauty Image","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pharmanex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmanex \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pharmanex \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemotrizinol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oil","sponsorNew":"Royal DSM \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BEN2293","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Accelovance | Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Benzyl Alcohol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Accelovance | Target Health Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Accelovance | Target Health Inc."},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Bepanthol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bluefin Biomedicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"BFB759","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Bluefin Biomedicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluefin Biomedicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bluefin Biomedicine \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BI765250","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Glac Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium Longum CCFM1029","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Glac Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glac Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Glac Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Derming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Bioscalin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Derming","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derming \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Derming \/ Undisclosed"},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BL3000","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biolab Sanus Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biolab Sanus Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BLI1100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"BLI1100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"BRAINTREE LABS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"BLI1100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BRAINTREE LABS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BRAINTREE LABS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BRAINTREE LABS \/ Undisclosed"},{"orgOrder":0,"company":"Philips","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Blue Light Photodynamic Therapy","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Philips","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philips \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Philips \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BMS-986166","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BMT101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Hugel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BMT101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hugel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hugel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hugel \/ Undisclosed"},{"orgOrder":0,"company":"Ancient + Brave","sponsor":"Princeton Consumer Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bovine Collagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ancient + Brave","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ancient + Brave \/ Princeton Consumer Research","highestDevelopmentStatusID":"1","companyTruncated":"Ancient + Brave \/ Princeton Consumer Research"},{"orgOrder":0,"company":"BioRay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BR201","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"BioRay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioRay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BioRay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Botanix Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BTX 1204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Botanix Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Botanix Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Botanix Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"BiomX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BX001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BiomX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BiomX \/ Undisclosed"},{"orgOrder":0,"company":"Brexogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BxC-I17e","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brexogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Brexogen \/ Undisclosed"},{"orgOrder":0,"company":"Brexogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BxC-I17e","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brexogen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Brexogen \/ Undisclosed"},{"orgOrder":0,"company":"Brexogen","sponsor":"BMI Korea","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"BxC-I17e","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Brexogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brexogen \/ BMI Korea","highestDevelopmentStatusID":"6","companyTruncated":"Brexogen \/ BMI Korea"},{"orgOrder":0,"company":"Organ, Tissue, Regeneration, Repair and Replacement","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CACIPLIQ20","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Organ, Tissue, Regeneration, Repair and Replacement","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organ, Tissue, Regeneration, Repair and Replacement \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Organ, Tissue, Regeneration, Repair and Replacement \/ Undisclosed"},{"orgOrder":0,"company":"University of the Philippines","sponsor":"Calmoseptine, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"PHILIPPINES","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Calmoseptine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of the Philippines","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"University of the Philippines \/ Calmoseptine, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"University of the Philippines \/ Calmoseptine, Inc."},{"orgOrder":0,"company":"University of the Philippines","sponsor":"Calmoseptine, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"PHILIPPINES","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Calmoseptine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"University of the Philippines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"University of the Philippines \/ Calmoseptine, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"University of the Philippines \/ Calmoseptine, Inc."},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CC-90005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CC-92252","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"CD0271","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CD0271","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"CD07223","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CD10367","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"CD1579","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CD2475\/101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CEE321","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Northwestern University \/ Bausch Health","highestDevelopmentStatusID":"1","companyTruncated":"Northwestern University \/ Bausch Health"},{"orgOrder":0,"company":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CG2001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Dayspring Pharmaceutical Technology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Dayspring Pharmaceutical Technology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"CG428","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Legacy Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Legacy Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CGB-400","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"CAGE Bio \/ ethica Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ ethica Clinical Research"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CGB-400","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"CAGE Bio \/ ethica Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ ethica Clinical Research"},{"orgOrder":0,"company":"CAGE Bio","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CGB-400","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CAGE Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"CAGE Bio \/ ethica Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CAGE Bio \/ ethica Clinical Research"},{"orgOrder":0,"company":"BioCis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cis-Urocanic Acid","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"BioCis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"BioCis Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioCis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Citryll","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citryll \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CKD-498","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CKD-843","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CKD-843","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CKD-843","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Clexio Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CLE-400","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Clexio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Clexio Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clexio Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"LOREAL USA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Hydrochloride","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hershey Medical Center \/ Loreal USA","highestDevelopmentStatusID":"1","companyTruncated":"Hershey Medical Center \/ Loreal USA"},{"orgOrder":0,"company":"Dream CIS","sponsor":"Curi Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Clostridium Botulinum Toxin Type A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dream CIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dream CIS \/ Curi Bio","highestDevelopmentStatusID":"15","companyTruncated":"Dream CIS \/ Curi Bio"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"CLS001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM512","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CM512","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Medical Entomology Centre","sponsor":"PN Lee Statistics and Computing | Riemann","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Coco Diethanolamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medical Entomology Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Medical Entomology Centre \/ PN Lee Statistics and Computing | Riemann","highestDevelopmentStatusID":"10","companyTruncated":"Medical Entomology Centre \/ PN Lee Statistics and Computing | Riemann"},{"orgOrder":0,"company":"Medical Entomology Centre","sponsor":"Riemann","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Coco Diethanolamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Medical Entomology Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Medical Entomology Centre \/ Riemann","highestDevelopmentStatusID":"9","companyTruncated":"Medical Entomology Centre \/ Riemann"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Coconut Oil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"SkinMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Caffeine","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SkinMedica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SkinMedica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SkinMedica \/ Undisclosed"},{"orgOrder":0,"company":"VIST","sponsor":"Tosla d.o.o. | Slovenian Research and Innovation Agency","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Colagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Tosla d.o.o. | Slovenian Research and Innovation Agency","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Tosla d.o.o. | Slovenian Research and Innovation Agency"},{"orgOrder":0,"company":"Guangdong HuaPeptides Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Collagen Tripeptide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Guangdong HuaPeptides Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangdong HuaPeptides Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Guangdong HuaPeptides Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Precision Health Food Technology Co. Ltd.,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Collagen Tripeptide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Shenzhen Precision Health Food Technology Co. Ltd.,","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed"},{"orgOrder":0,"company":"VIST","sponsor":"Tosla d.o.o. | Slovenian Research Agency","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CP5HA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Tosla d.o.o. | Slovenian Research Agency","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Tosla d.o.o. | Slovenian Research Agency"},{"orgOrder":0,"company":"Texas Tech University","sponsor":"Legion Athletics, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Creatine Monohydrate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Texas Tech University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University \/ Legion Athletics, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Texas Tech University \/ Legion Athletics, Inc"},{"orgOrder":0,"company":"GC Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CT303","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Cell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GC Cell \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CT-P55","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CU-10101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CU-20101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CU-40101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cutia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CU-40102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Cutia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cutia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cutia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Yorkville","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"CYPS317","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"FibroBiologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Yorkville","highestDevelopmentStatusID":"4","companyTruncated":"FibroBiologics \/ Yorkville"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"D-2570","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"InventisBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"D-2570","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"InventisBio \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International | Daniel Alain","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Applied Biology \/ Follea International | Daniel Alain","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International | Daniel Alain"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International | Daniel Alain","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DA-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Follea International | Daniel Alain","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International | Daniel Alain"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Daniel Alain | Follea International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DA-007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Daniel Alain | Follea International","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Daniel Alain | Follea International"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DA-4001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A ST Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DA-4001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Dong-A ST Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A ST Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Dong-A ST Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Let's Disco","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Daily Skin Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Let's Disco","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Let's Disco \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Let's Disco \/ Citruslabs"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Follea International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Daniel Alain Probiotic","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Follea International","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Follea International"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DA-OTC-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Natural Sciences and Engineering Council","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"DB-007-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DB-007-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DB-007-5","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Derm Research | Northsoundderm | Clear Dermatology","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DBI-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Derm Research | Northsoundderm | Clear Dermatology","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Derm Research | Northsoundderm | Clear Dermatology"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DBI-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DBI-102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"Fortuderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DD-25","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Fortuderm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Fortuderm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fortuderm \/ Undisclosed"},{"orgOrder":0,"company":"Equipmed USA LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Dermapen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Equipmed USA LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Equipmed USA LLC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Equipmed USA LLC \/ Undisclosed"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DFD06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"DFD06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DFD-06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Prosoft Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DFD-06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ Prosoft Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Primus Pharmaceutical \/ Prosoft Clinical"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"DFD07","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Promius Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DFD-07","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Promius Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Promius Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promius Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Dapsone","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Dignity Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dignity Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dignity Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dignity Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Primus Pharmaceutical","sponsor":"Northeastern University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Diosmiplex","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Primus Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primus Pharmaceutical \/ Northeastern University","highestDevelopmentStatusID":"1","companyTruncated":"Primus Pharmaceutical \/ Northeastern University"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Marc Edwards"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"DispersinB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Kane Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Delenex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLX105","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Delenex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Delenex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delenex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Delenex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"DLX105","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Delenex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Delenex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Delenex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DelArrivo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DLX105-DMP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"DelArrivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DelArrivo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"DelArrivo \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DMT210","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dermata Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"DMT210","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dermata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dermata Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dermata Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DNN.22.17.036","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ Undisclosed"},{"orgOrder":0,"company":"DermiPsor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DPS-102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DermiPsor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermiPsor \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermiPsor \/ Undisclosed"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DR-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Dren Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dren Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DS107E","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DS107E","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DS-2741a","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"DSXS1411","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DWP-708","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"DWP-712","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gateway Health Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dyglomera","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Gateway Health Alliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gateway Health Alliance \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Gateway Health Alliance \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"EDP1066","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"EDP1867","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"BMO Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ BMO Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ BMO Capital Markets"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Private Placement","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EDP2939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Elorac, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"Elimune","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Elorac, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elorac, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Elorac, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Azienda Ospedaliero Universitaria Maggiore della Carita","sponsor":"Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Enriched Nutrition Formula","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Azienda Ospedaliero Universitaria Maggiore della Carita","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azienda Ospedaliero Universitaria Maggiore della Carita \/ Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Azienda Ospedaliero Universitaria Maggiore della Carita \/ Nutricia Inc"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Concerto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Concerto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Concerto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Concerto Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Concerto Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Concerto Biosciences","sponsor":"Safar Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Series A Financing","leadProduct":"ENS-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Concerto Biosciences","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Concerto Biosciences \/ Safar Partners","highestDevelopmentStatusID":"2","companyTruncated":"Concerto Biosciences \/ Safar Partners"},{"orgOrder":0,"company":"Kari Nadeau, MD, PhD","sponsor":"National Jewish Health | University of Chicago | Children's Hospital Medical Center, Cincinnati | Harvard School of Public Health (HSPH) | Stanford University | National Institute of Allergy and Infectious Diseases | King's College London | Guy's and St T","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Epiceram","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Kari Nadeau, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Kari Nadeau, MD, PhD \/ National Jewish Health | University of Chicago | Children's Hospital Medical Center, Cincinnati | Harvard School of Public Health (HSPH) | Stanford University | National Institute of Allergy and Infectious Diseases | King's College London | Guy's and St T","highestDevelopmentStatusID":"8","companyTruncated":"Kari Nadeau, MD, PhD \/ National Jewish Health | University of Chicago | Children's Hospital Medical Center, Cincinnati | Harvard School of Public Health (HSPH) | Stanford University | National Institute of Allergy and Infectious Diseases | King's College London | Guy's and St T"},{"orgOrder":0,"company":"Sadick Research Group","sponsor":"Episciences, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Epionce","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Sadick Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sadick Research Group \/ Episciences, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Sadick Research Group \/ Episciences, Inc."},{"orgOrder":0,"company":"Escalier Biosciences BV","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ESR-114","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Escalier Biosciences BV","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Escalier Biosciences BV \/ Innovaderm","highestDevelopmentStatusID":"7","companyTruncated":"Escalier Biosciences BV \/ Innovaderm"},{"orgOrder":0,"company":"Longevity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ethoximod","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Longevity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Longevity \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Longevity \/ Undisclosed"},{"orgOrder":0,"company":"Allerderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Ethylene Diamine Dihydro Iodide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Allerderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Allerderm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Allerderm \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Clarteis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Exciplex","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Clarteis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarteis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clarteis \/ Undisclosed"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Extractum Cepae","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ablon Skin Institute Research Center","sponsor":"U.S. Nutraceuticals, Inc. dba Valensa International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Fatty Acid","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ablon Skin Institute Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ablon Skin Institute Research Center \/ U.S. Nutraceuticals, Inc. dba Valensa International","highestDevelopmentStatusID":"1","companyTruncated":"Ablon Skin Institute Research Center \/ U.S. Nutraceuticals, Inc. dba Valensa International"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FB102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Fountain Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Fountain Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fountain Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fountain Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.56999999999999995,"dosageForm":"Infusion","sponsorNew":"Oneness Biotech \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Leo Pharma"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"FB825","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oneness Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ Undisclosed"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"FCD105","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VYNE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VYNE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Medical University WanFang Hospital","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fespixon","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Taipei Medical University WanFang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taipei Medical University WanFang Hospital \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech","highestDevelopmentStatusID":"11","companyTruncated":"Taipei Medical University WanFang Hospital \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Oneness Biotech"},{"orgOrder":0,"company":"United Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JORDAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"United Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"United Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Follicum AB","sponsor":"proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FOL- 005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Follicum AB \/ proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ proDERM GmbH | Hair and Skin Institute, Charit\u00e9, Berlin, Germany | CentroDerm"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Follicum AB \/ Bioskin GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin GmbH"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Follicum AB \/ Bioskin","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Bioskin"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"FOL-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Follicum AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Follicum AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Follicum AB \/ Undisclosed"},{"orgOrder":0,"company":"Follicle Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FOL100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Follicle Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Follicle Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Follicle Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Finzelberg GmbH & Co. KG","sponsor":"Eurofins CDMO | Eurofins Dermscan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Finzelberg GmbH & Co. KG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Finzelberg GmbH & Co. KG \/ Eurofins CDMO | Eurofins Dermscan","highestDevelopmentStatusID":"1","companyTruncated":"Finzelberg GmbH & Co. KG \/ Eurofins CDMO | Eurofins Dermscan"},{"orgOrder":0,"company":"Kang Stem Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"Furestem-CD","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kang Stem Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kang Stem Biotech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kang Stem Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Guangzhou Fermion Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FZ007-119","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Guangzhou Fermion Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Fermion Technology \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Guangzhou Fermion Technology \/ Undisclosed"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GB-7624","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Generate Biomedicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generate Biomedicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Generate Biomedicines \/ Undisclosed"},{"orgOrder":0,"company":"Garnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GBT009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Garnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Garnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Garnet BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Balmoral Medical company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GDC 268","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Balmoral Medical company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Balmoral Medical company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Balmoral Medical company \/ Undisclosed"},{"orgOrder":0,"company":"Balmoral Medical company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"GDC 695","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Balmoral Medical company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Balmoral Medical company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Balmoral Medical company \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Guidon Pharmaceutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GD-iExo-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Guidon Pharmaceutics","highestDevelopmentStatusID":"6","companyTruncated":"Peking Union Medical College Hospital \/ Guidon Pharmaceutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GHZ339","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GI148512","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GK530G","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GK530G","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GM080","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"GenMont Biotech Incorporation","sponsor":"National Science and Technology Council, Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GMNL-133","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"GenMont Biotech Incorporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"GenMont Biotech Incorporation \/ National Science and Technology Council, Taiwan","highestDevelopmentStatusID":"1","companyTruncated":"GenMont Biotech Incorporation \/ National Science and Technology Council, Taiwan"},{"orgOrder":0,"company":"TC Erciyes University","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TURKEY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GN037","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"TC Erciyes University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"TC Erciyes University \/ Monitor CRO","highestDevelopmentStatusID":"6","companyTruncated":"TC Erciyes University \/ Monitor CRO"},{"orgOrder":0,"company":"Gen Pharmaceuticals and Health Products","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TURKEY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GN-037","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Gen Pharmaceuticals and Health Products","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gen Pharmaceuticals and Health Products \/ Monitor CRO","highestDevelopmentStatusID":"8","companyTruncated":"Gen Pharmaceuticals and Health Products \/ Monitor CRO"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GNR-068","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GR2002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GSK1358820","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK1940029","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK1940029","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK2585823","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"GSK2585823","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GSK2585823","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"GSK2800528","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"GW870086","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"GW870086","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GX-03","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Turn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hybrid Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"H-100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hybrid Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hybrid Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hybrid Medical \/ Undisclosed"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"HA Matrix","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Undisclosed"},{"orgOrder":0,"company":"BrandiZone","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hair Nutra Growth Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"BrandiZone","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrandiZone \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"BrandiZone \/ Citruslabs"},{"orgOrder":0,"company":"Histogen","sponsor":"Gleneagles CRC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Hair Stimulating Complex","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Gleneagles CRC","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Gleneagles CRC"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hair Stimulating Complex","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Haus Bioceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HAT01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Haus Bioceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haus Bioceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Haus Bioceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Haus Bioceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HAT01H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Haus Bioceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Haus Bioceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Haus Bioceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Huaota Biopharmaceutical Co., Ltd.","sponsor":"Dermatology Hospital affiliated to Shandong First Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HB0043","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Huaota Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Dermatology Hospital affiliated to Shandong First Medical University","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Huaota Biopharmaceutical Co., Ltd. \/ Dermatology Hospital affiliated to Shandong First Medical University"},{"orgOrder":0,"company":"Family Marketing","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Dietary Supplement","year":"2014","type":"Inapplicable","leadProduct":"HCap","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Family Marketing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Family Marketing \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Family Marketing \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Bio-Tech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Tianjin Hemay Bio-Tech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Bio-Tech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Tianjin Hemay Bio-Tech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Bio-Tech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Tianjin Hemay Bio-Tech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Hemay Bio-Tech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Hemay Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Hemay005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hemay Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemay Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hemay Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Hemay Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Hemay808","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Tianjin Hemay Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Hemay Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Vidya Herbs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Herbal Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Skin Science and Research \/ Vidya Herbs","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Vidya Herbs"},{"orgOrder":0,"company":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","sponsor":"Helsinki University Central Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FINLAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Hexylaminolaevulinate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Helsinki University Central Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Joint Authority for P\u00e4ij\u00e4t-H\u00e4me Social and Health Care \/ Helsinki University Central Hospital"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"HL-009","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Hanall Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hanall Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Hanlim Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"HL151","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hanlim Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanlim Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hanlim Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hope Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hope Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Hope Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hope Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hope Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hope Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Hope Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"HMI-115","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chime Biologics \/ Hope Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Chime Biologics \/ Hope Medicine"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"HP011-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HP-1050","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Noven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Arctic Bioscience","sponsor":"Smerud Medical Research International AS","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRO350","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Arctic Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arctic Bioscience \/ Smerud Medical Research International AS","highestDevelopmentStatusID":"8","companyTruncated":"Arctic Bioscience \/ Smerud Medical Research International AS"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20118","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20118","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-20137","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HSK21542","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Pharmaceuticals \/ Histogen"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"Histogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"HST-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Histogen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Histogen \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Histogen \/ Undisclosed"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Genoa Ventures"},{"orgOrder":0,"company":"Second Affiliated Hospital, Wannan Medical College","sponsor":"Guidon Pharmaceutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Human iPSC-derived Exosomes","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Second Affiliated Hospital, Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Second Affiliated Hospital, Wannan Medical College \/ Guidon Pharmaceutics","highestDevelopmentStatusID":"6","companyTruncated":"Second Affiliated Hospital, Wannan Medical College \/ Guidon Pharmaceutics"},{"orgOrder":0,"company":"Ennar Pharmaceuticals","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Human Recombinant Epidermal Growth Factor","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Ennar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ennar Pharmaceuticals \/ University of Zurich","highestDevelopmentStatusID":"6","companyTruncated":"Ennar Pharmaceuticals \/ University of Zurich"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"HY-209","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"Natals, Inc. dba Ritual","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hyacera","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Natals, Inc. dba Ritual","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natals, Inc. dba Ritual \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Natals, Inc. dba Ritual \/ Undisclosed"},{"orgOrder":0,"company":"Derming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Hyaluron","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Derming","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derming \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Derming \/ Undisclosed"},{"orgOrder":0,"company":"VIST","sponsor":"Slovenian Research and Innovation Agency | Tosla d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Hydrolyzed Fish Collagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Slovenian Research and Innovation Agency | Tosla d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Slovenian Research and Innovation Agency | Tosla d.o.o."},{"orgOrder":0,"company":"The First Affiliated Hospital of Soochow University","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IBI3002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"The First Affiliated Hospital of Soochow University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The First Affiliated Hospital of Soochow University \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"The First Affiliated Hospital of Soochow University \/ Innovent Biologics"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"IDP-107","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"IDP-121","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Infinimmune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"IFX-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Infinimmune","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Infinimmune"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"Imedeen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"IN-115314","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Dairy Goat Co-operative (N.Z.) Limited","sponsor":"Klinikum der Universit\u00e4t M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NEW ZEALAND","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Infant Formula","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Dairy Goat Co-operative (N.Z.) Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dairy Goat Co-operative (N.Z.) Limited \/ Klinikum der Universit\u00e4t M\u00fcnchen","highestDevelopmentStatusID":"1","companyTruncated":"Dairy Goat Co-operative (N.Z.) Limited \/ Klinikum der Universit\u00e4t M\u00fcnchen"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Ingenol Metabute","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Intact Cow\\'S Milk Protein Formula","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"INV-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Innovo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INV-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Innovo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Innovo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revolo Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"IRL201104","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Revolo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revolo Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Revolo Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Inventage Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"IVL3001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Inventage Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inventage Lab \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Inventage Lab \/ Undisclosed"},{"orgOrder":0,"company":"DermBiont","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"J. Lividum","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DermBiont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DermBiont \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DermBiont \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"JDP-205","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"JDP-205","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Algorithme Pharma Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"JDP-205","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TerSera Therapeutics \/ Algorithme Pharma Inc.","highestDevelopmentStatusID":"10","companyTruncated":"TerSera Therapeutics \/ Algorithme Pharma Inc."},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jiuweihuaban","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-39758979","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"JNJ-39758979","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JNJ-77242113","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JNJ-95475939","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"JOYO Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JYP0061","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"JOYO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JOYO Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JOYO Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"CAS 75885-58-4","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"K40a","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KB304","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Krystal Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Krystal Biotech \/ Undisclosed"},{"orgOrder":0,"company":"KoBioLabs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KBL697","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"KoBioLabs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KoBioLabs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KoBioLabs \/ Undisclosed"},{"orgOrder":0,"company":"KoBioLabs","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"KBL697","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"KoBioLabs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KoBioLabs \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"KoBioLabs \/ Novotech"},{"orgOrder":0,"company":"Nutracore","sponsor":"Novarex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Keranat","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutracore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutracore \/ Novarex","highestDevelopmentStatusID":"1","companyTruncated":"Nutracore \/ Novarex"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"KHK4323","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"KHK4577","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Kelun Pharmaceutical Research Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KL130008","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Sichuan Kelun Pharmaceutical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Kelun Pharmaceutical Research Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Kelun Pharmaceutical Research Institute \/ Undisclosed"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KM-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kamari Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Kamari Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kamari Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KM-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kamari Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Kamari Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kamari Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"KT-621","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Pill","sponsorNew":"Kymera Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"KX0826","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KX0826","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Kintor Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kintor Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kintor Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"UNITED LABORATORIES","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Lactezin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"UNITED LABORATORIES","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNITED LABORATORIES \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UNITED LABORATORIES \/ Undisclosed"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactic Acid Bacteria NTU 101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SunWay Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of New South Wales","sponsor":"Evolution Health Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei LPB27","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"University of New South Wales","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New South Wales \/ Evolution Health Pty Ltd","highestDevelopmentStatusID":"8","companyTruncated":"University of New South Wales \/ Evolution Health Pty Ltd"},{"orgOrder":0,"company":"L'Oreal","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Lactobacillus Paracasei NCC 2461","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"L'Oreal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"L'Oreal \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"L'Oreal \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"Moscow State University of Medicine and Dentistry | Moscow Dermatovenerologic Clinical Dispensary","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactofiltrum","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avva Rus JSC \/ Moscow State University of Medicine and Dentistry | Moscow Dermatovenerologic Clinical Dispensary","highestDevelopmentStatusID":"9","companyTruncated":"Avva Rus JSC \/ Moscow State University of Medicine and Dentistry | Moscow Dermatovenerologic Clinical Dispensary"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"LAS 41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LAS 41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Sciderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LAS41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Sciderm","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Sciderm"},{"orgOrder":0,"company":"Almirall","sponsor":"proDERM GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LAS41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ proDERM GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ proDERM GmbH"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LAS41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"proDERM GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LAS41004","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ proDERM GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ proDERM GmbH"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LAS41005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Young Pharmaceuticals","sponsor":"Lactobio A\/S","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Partnership","leadProduct":"LB356R","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Young Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Young Pharmaceuticals \/ Lactobio A\/S","highestDevelopmentStatusID":"15","companyTruncated":"Young Pharmaceuticals \/ Lactobio A\/S"},{"orgOrder":0,"company":"M\u00f8reforsking AS","sponsor":"Helse M\u00f8re og Romsdal HF | EPAX NORWAY AS | University of Manchester","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"LC-MUFA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"M\u00f8reforsking AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00f8reforsking AS \/ Helse M\u00f8re og Romsdal HF | EPAX NORWAY AS | University of Manchester","highestDevelopmentStatusID":"1","companyTruncated":"M\u00f8reforsking AS \/ Helse M\u00f8re og Romsdal HF | EPAX NORWAY AS | University of Manchester"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"LEM-S401","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Lemonex Bio \/ Undisclosed"},{"orgOrder":0,"company":"Lemonex Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"LEM-S401","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Lemonex Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lemonex Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lemonex Bio \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 130852A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LEO 134310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"LEO 22811","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LEO 27989","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LEO 29102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LEO 29102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LEO 29102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Leo 32731","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Leo 32731","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Leo 32731","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LEO 35299","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"LEO 39652","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LEO 39652","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"LEO 43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"CMIC Co, Ltd. Japan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LEO 80185","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ CMIC Co, Ltd. Japan","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ CMIC Co, Ltd. Japan"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LEO 80185","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 80185","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 80185","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"LEO 80185","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"LEO 90100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"LEO 90105","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"LEO32731","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"LEO32731","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"LEO43204","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"VICHY CANADA","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Liftactiv B3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ VICHY CANADA","highestDevelopmentStatusID":"8","companyTruncated":"University of Miami \/ VICHY CANADA"},{"orgOrder":0,"company":"Cosmetique Active International","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Lipikar Balm AP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Cosmetique Active International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cosmetique Active International \/ Innovaderm","highestDevelopmentStatusID":"1","companyTruncated":"Cosmetique Active International \/ Innovaderm"},{"orgOrder":0,"company":"GUERBET","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ethynodiol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"GUERBET","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"GUERBET \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"GUERBET \/ Undisclosed"},{"orgOrder":0,"company":"Scale Media Inc","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Live Conscious Beyond Collagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Scale Media Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scale Media Inc \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Scale Media Inc \/ Citruslabs"},{"orgOrder":0,"company":"Leadingtac Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LT-002-158","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Leadingtac Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadingtac Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leadingtac Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Leadingtac Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LT-002-158","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Leadingtac Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadingtac Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leadingtac Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Leadingtac Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LT-002-158","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Leadingtac Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Leadingtac Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Leadingtac Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lumosa Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LT5001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Lumosa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumosa Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Lumosa Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3041658","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"LY3041658","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"LY3316531","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LY3454738","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"LY3454738","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"LY3462817","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"LY3471851","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"LY3471851","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nektar Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LY3844583","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LY3872386","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY3972406","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LY4100511","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DICE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DICE Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DICE Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lycera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"LYC-30937-EC","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Lycera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lycera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lycera \/ Undisclosed"},{"orgOrder":0,"company":"LycoRed Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Lycoderm","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"LycoRed Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"LycoRed Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LycoRed Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lytera","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LZM012","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Medytox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MBA-P01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medytox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medytox \/ Undisclosed"},{"orgOrder":0,"company":"Medytox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MBA-P01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medytox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medytox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medytox \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MC2-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 CKD","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"MC2-25 VLS","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"MC2-32","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Zest Healthtech PLT","sponsor":"UCSI University","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Melicope Ptelefolia Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Zest Healthtech PLT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zest Healthtech PLT \/ UCSI University","highestDevelopmentStatusID":"1","companyTruncated":"Zest Healthtech PLT \/ UCSI University"},{"orgOrder":0,"company":"Cryopraxis","sponsor":"Hospital Federal de Bonsucesso","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Dermatology","graph2":"Phase I","graph3":"Cryopraxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cryopraxis \/ Hospital Federal de Bonsucesso","highestDevelopmentStatusID":"6","companyTruncated":"Cryopraxis \/ Hospital Federal de Bonsucesso"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Sonoma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2013","type":"Inapplicable","leadProduct":"Microcyn","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"University of Alabama at Birmingham \/ Sonoma Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Sonoma Pharmaceuticals"},{"orgOrder":0,"company":"Nazarbayev University Medical Center","sponsor":"Eurasia Invest | Ministry of Education and Science, Kazakhstan | Centre for Dermatology and Sexually Transmitted Diseases, Astana, Kazakhstan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"KAZAKHSTAN","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nazarbayev University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nazarbayev University Medical Center \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan | Centre for Dermatology and Sexually Transmitted Diseases, Astana, Kazakhstan","highestDevelopmentStatusID":"1","companyTruncated":"Nazarbayev University Medical Center \/ Eurasia Invest | Ministry of Education and Science, Kazakhstan | Centre for Dermatology and Sexually Transmitted Diseases, Astana, Kazakhstan"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-6194","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"MK-8226","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Botanee Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MLYAAT-1002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Botanee Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanee Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Botanee Group \/ Undisclosed"},{"orgOrder":0,"company":"Botanee Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MLYAAT-1002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Botanee Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanee Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Botanee Group \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Moisturizer","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"MOL4239","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Moleculin Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moleculin Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MSB0010841","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"UC San Diego","sponsor":"MatriSys Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MSB-3163","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UC San Diego \/ MatriSys Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ MatriSys Bioscience"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MT10109L","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MT10109L","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MT10109L","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MT10109L","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MT10109L","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MTX-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merakris Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Shenyang Sunshine Pharmaceutical Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Narfurine HCl","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Shenyang Sunshine Pharmaceutical Co Ltd","highestDevelopmentStatusID":"6","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Shenyang Sunshine Pharmaceutical Co Ltd"},{"orgOrder":0,"company":"Naked Biome","sponsor":"Dermatology Research Institute | QST Consultations, Ltd | Science 37","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NB01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Naked Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Pouch","sponsorNew":"Naked Biome \/ Dermatology Research Institute | QST Consultations, Ltd | Science 37","highestDevelopmentStatusID":"6","companyTruncated":"Naked Biome \/ Dermatology Research Institute | QST Consultations, Ltd | Science 37"},{"orgOrder":0,"company":"Naked Biome","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NB01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Naked Biome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Naked Biome \/ Therapeutics, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Naked Biome \/ Therapeutics, Inc."},{"orgOrder":0,"company":"Novacell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NCP112","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novacell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novacell \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novacell \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Luxbiotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Silicon Dioxide API","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Luxbiotech","highestDevelopmentStatusID":"11","companyTruncated":"EMS \/ Luxbiotech"},{"orgOrder":0,"company":"Next Science","sponsor":"Jacksonville Center For Clinical Research | St. Johns Center for Clinical Research | Fleming Island Center for Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Next Science Acne Gel","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Next Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Next Science \/ Jacksonville Center For Clinical Research | St. Johns Center for Clinical Research | Fleming Island Center for Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Next Science \/ Jacksonville Center For Clinical Research | St. Johns Center for Clinical Research | Fleming Island Center for Clinical Research"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hybrid Medical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Petros Pharmaceuticals \/ Hybrid Medical","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Hybrid Medical"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nicardipine Hydrochloride","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"NP000888","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Ablon Skin Institute Research Center","sponsor":"Nutraceutical Wellness Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Nutrafol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ablon Skin Institute Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablon Skin Institute Research Center \/ Nutraceutical Wellness Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Ablon Skin Institute Research Center \/ Nutraceutical Wellness Inc."},{"orgOrder":0,"company":"Ablon Skin Institute Research Center","sponsor":"Nutraceutical Wellness Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Nutrafol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ablon Skin Institute Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablon Skin Institute Research Center \/ Nutraceutical Wellness Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Ablon Skin Institute Research Center \/ Nutraceutical Wellness Inc."},{"orgOrder":0,"company":"Sadick Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Nutrafol","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sadick Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sadick Research Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sadick Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutrafol Men Hair Growth","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutrafol Vegan Women\\'S Hair Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Nutrafol Women\\'S Hair Growth Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Nutrafol Women\\'S Hair Growth Supplemnt","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Derming","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Nutrakos","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Derming","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derming \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Derming \/ Undisclosed"},{"orgOrder":0,"company":"Nextgen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NXC736","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Nextgen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nextgen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nextgen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Technological Centre of Nutrition and Health, Spain","sponsor":"Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili | Les Derives Resiniques et Terpeniques","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Oligopin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Technological Centre of Nutrition and Health, Spain","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili | Les Derives Resiniques et Terpeniques","highestDevelopmentStatusID":"1","companyTruncated":"Technological Centre of Nutrition and Health, Spain \/ Fundaci\u00f3 Eurecat | Hospital Universitari Sant Joan de Reus | University Rovira i Virgili | Les Derives Resiniques et Terpeniques"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLX104C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"OLX72021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliX Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"OliX Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"EMS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OMA102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Undisclosed"},{"orgOrder":0,"company":"Opsidio, LLC","sponsor":"Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OpSCF","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Opsidio, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opsidio, LLC \/ Innovaderm","highestDevelopmentStatusID":"8","companyTruncated":"Opsidio, LLC \/ Innovaderm"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"OQL025","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OQL036","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ornovi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"OR-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Ornovi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ornovi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ornovi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ORG101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"ORI-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Oruka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Merger","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Oruka Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Oruka Therapeutics \/ Oruka Therapeutics"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ORKA-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"P-3074","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polichem S.A. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polichem S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Patara Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PA101B","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Patara Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Patara Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Patara Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alastin Skincare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Alastin Skincare \/ Galderma"},{"orgOrder":0,"company":"Alastin Skincare","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Alastin Skincare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Alastin Skincare \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Alastin Skincare \/ Galderma"},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Pantovigar Vegan","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merz Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Merz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Palo Biofarma","sponsor":"Cl\u00ednica Universidad de Navarra","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PBF-1650","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Palo Biofarma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Palo Biofarma \/ Cl\u00ednica Universidad de Navarra","highestDevelopmentStatusID":"6","companyTruncated":"Palo Biofarma \/ Cl\u00ednica Universidad de Navarra"},{"orgOrder":0,"company":"Pyramid Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PBI-100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pyramid Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pyramid Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pyramid Bio \/ Undisclosed"},{"orgOrder":0,"company":"Hapten Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PDC-APB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hapten Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hapten Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hapten Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Hapten Sciences","sponsor":"Hershey Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PDC-APB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Hapten Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hapten Sciences \/ Hershey Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Hapten Sciences \/ Hershey Medical Center"},{"orgOrder":0,"company":"PDFE Pharma Innovations FZCO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PDFE-2304","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"PDFE Pharma Innovations FZCO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"PDFE Pharma Innovations FZCO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PDFE Pharma Innovations FZCO \/ Undisclosed"},{"orgOrder":0,"company":"Precision Dermatology, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PDI-192","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Precision Dermatology, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision Dermatology, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Precision Dermatology, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Precision Dermatology, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"PDI-320","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Precision Dermatology, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Precision Dermatology, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Precision Dermatology, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Ascension Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Petrolatum","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ascension Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascension Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ascension Health \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PF-07832837","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PF-07905428","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Prime Gene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PG-011","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Prime Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Prime Gene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Prime Gene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prime Gene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PG-033","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Prime Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Prime Gene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prime Gene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Photocil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"DEKA S.r.l.","sponsor":"Universitat Autonoma de Barcelona","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Platelets Rich Plasma","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"DEKA S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DEKA S.r.l. \/ Universitat Autonoma de Barcelona","highestDevelopmentStatusID":"1","companyTruncated":"DEKA S.r.l. \/ Universitat Autonoma de Barcelona"},{"orgOrder":0,"company":"Maxima Pharmaceuticals","sponsor":"Medisca","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Pluronic Lecithin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maxima Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Maxima Pharmaceuticals \/ Medisca","highestDevelopmentStatusID":"15","companyTruncated":"Maxima Pharmaceuticals \/ Medisca"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Industrial Farmac\u00e9utica Cantabria","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Polypodium Leucotomos Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Industrial Farmac\u00e9utica Cantabria","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern Medical Center \/ Industrial Farmac\u00e9utica Cantabria"},{"orgOrder":0,"company":"Fundaci\u00f3 Eurecat","sponsor":"Euromed, S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Pomanox","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Fundaci\u00f3 Eurecat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3 Eurecat \/ Euromed, S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Fundaci\u00f3 Eurecat \/ Euromed, S.A."},{"orgOrder":0,"company":"National University Hospital, Singapore","sponsor":"Mundipharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"National University Hospital, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"National University Hospital, Singapore \/ Mundipharma","highestDevelopmentStatusID":"8","companyTruncated":"National University Hospital, Singapore \/ Mundipharma"},{"orgOrder":0,"company":"Farmoquimica","sponsor":"Kosmoscience Ci\u00eancia e Tecnologia Cosm\u00e9tica Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Power Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Farmoquimica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Farmoquimica \/ Kosmoscience Ci\u00eancia e Tecnologia Cosm\u00e9tica Ltda","highestDevelopmentStatusID":"1","companyTruncated":"Farmoquimica \/ Kosmoscience Ci\u00eancia e Tecnologia Cosm\u00e9tica Ltda"},{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PP405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Pelage Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Pelage Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pelage Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pelage Pharmaceuticals","sponsor":"Main Street Advisors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"PP405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Pelage Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Pelage Pharmaceuticals \/ Main Street Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Pelage Pharmaceuticals \/ Main Street Advisors"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"PPC-06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Realm Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PR022","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Realm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Realm Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Realm Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PRCL Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PRCL-02","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"PRCL Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PRCL Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PRCL Research \/ Undisclosed"},{"orgOrder":0,"company":"PRCL Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PRCL-02","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"PRCL Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PRCL Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PRCL Research \/ Undisclosed"},{"orgOrder":0,"company":"Chang Gung Memorial Hospital","sponsor":"Glac Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic Lactobacillus Salivarius AP-32","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Chang Gung Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chang Gung Memorial Hospital \/ Glac Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Chang Gung Memorial Hospital \/ Glac Biotech Co., Ltd"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Methodex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Probiotic LRa05","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Methodex","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Methodex"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Product 0405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Product 0405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Product 0405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Fougera Pharmaceuticals Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Product 0405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Fougera Pharmaceuticals Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fougera Pharmaceuticals Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fougera Pharmaceuticals Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Topix Skin Health","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"ProteXidine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Topix Skin Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topix Skin Health \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Topix Skin Health \/ University of Minnesota"},{"orgOrder":0,"company":"Arctic Nutrition AS","sponsor":"University of Bergen | Haukeland University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NORWAY","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Psorax35","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Arctic Nutrition AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arctic Nutrition AS \/ University of Bergen | Haukeland University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Arctic Nutrition AS \/ University of Bergen | Haukeland University Hospital"},{"orgOrder":0,"company":"Phoenicis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PTM-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Phoenicis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenicis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Phoenicis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dream Plus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Pumpkin Seed Oil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Dream Plus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dream Plus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dream Plus \/ Undisclosed"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Unilever","sponsor":"Shanghai Skin Disease and Venereal Disease Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Q69","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Unilever","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Unilever \/ Shanghai Skin Disease and Venereal Disease Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Unilever \/ Shanghai Skin Disease and Venereal Disease Hospital"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QL2108","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QL2108","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"QLG2198","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLM3003","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLM3003","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QLM3003","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QLS12010","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"VIST","sponsor":"Valens Int. d.o.o., Slovenija | Nutrition Institute, Slovenia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Quvital","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Valens Int. d.o.o., Slovenija | Nutrition Institute, Slovenia","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Valens Int. d.o.o., Slovenija | Nutrition Institute, Slovenia"},{"orgOrder":0,"company":"E-nitiate Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QY101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"E-nitiate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"E-nitiate Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-nitiate Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"E-nitiate Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QY201","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"E-nitiate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"E-nitiate Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"E-nitiate Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"E-nitiate Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"QY211","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"E-nitiate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"E-nitiate Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"E-nitiate Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RepliCel","sponsor":"JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"RCS-01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"RepliCel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RepliCel \/ JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH","highestDevelopmentStatusID":"6","companyTruncated":"RepliCel \/ JensonR+ | PHARMALOG Institute | Syreon Corporation | Innovacell Biotechnologie | Datinf GmbH"},{"orgOrder":0,"company":"RDD Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"RDD1609","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"RDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RDD Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RDD Pharma \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Anti-G-Csf Receptor Monoclonal Antibody","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Anti-IL-17A Humanized Monoclonal Antibody","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Guojian Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Anti-IL-4R Alpha Monoclonal Antibody","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Sunshine Guojian Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Guojian Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sunshine Guojian Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"JHM BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Botulinum Toxin Type A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"JHM BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JHM BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"JHM BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"PT. Daewoong Infion","sponsor":"Equilab International","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Epidermal Growth Factor","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"PT. Daewoong Infion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"PT. Daewoong Infion \/ Equilab International","highestDevelopmentStatusID":"1","companyTruncated":"PT. Daewoong Infion \/ Equilab International"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Red Light","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Verdure Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Red Maple Leaf Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Integrative Skin Science and Research \/ Verdure Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Verdure Sciences"},{"orgOrder":0,"company":"Avita Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Regenerative Epidermal Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Avita Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avita Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avita Medical \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"REGN846","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene Pharmaceuticals \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Noos S.r.l.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Reuterin D3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Noos S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noos S.r.l. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Noos S.r.l. \/ Undisclosed"},{"orgOrder":0,"company":"CollPlant","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"rhCollagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"CollPlant","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"CollPlant \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"CollPlant \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"RHT-3201","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ildong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ildong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Heinz Italia SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Rice Flour","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Heinz Italia SpA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heinz Italia SpA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Heinz Italia SpA \/ Undisclosed"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rubedo Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Beiersdorf AG","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Beiersdorf AG","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Beiersdorf AG"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"RLS-1496","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Khosla Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Khosla Ventures"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RO7790121","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Botanee Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Rosa Roxburghii","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Botanee Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botanee Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Botanee Group \/ Undisclosed"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rose Bengal Disodium","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Provectus Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Provectus Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RSS0393","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RSS0393","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RSS0393","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RV5026B","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"ResVita Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"ResVita Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"ResVita Bio \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"ResVita Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S5G4T-1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S5G4T-1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S5G4T-1","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S6G5T-3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"S6G5T-3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Accelovance","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"S6G5T-3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Accelovance","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Accelovance"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"S6G5T-3","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sol-Gel Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Santa Ana Bio","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"SAB01","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Santa Ana Bio","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Santa Ana Bio \/ GV","highestDevelopmentStatusID":"5","companyTruncated":"Santa Ana Bio \/ GV"},{"orgOrder":0,"company":"Saie Beauty","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Saie Beauty\\'S Hydrabeam Sheer Brightening Under Eye Concealer","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Saie Beauty","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saie Beauty \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Saie Beauty \/ Undisclosed"},{"orgOrder":0,"company":"Santalis Pharmaceuticals","sponsor":"ClinDatrix | Texas Dermatology and Laser Specialists | Clinical Trials of Texas | Derm Research | Progressive Clinical Research | U.S. Dermatology Partners Bryan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SAN007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Santalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Santalis Pharmaceuticals \/ ClinDatrix | Texas Dermatology and Laser Specialists | Clinical Trials of Texas | Derm Research | Progressive Clinical Research | U.S. Dermatology Partners Bryan","highestDevelopmentStatusID":"8","companyTruncated":"Santalis Pharmaceuticals \/ ClinDatrix | Texas Dermatology and Laser Specialists | Clinical Trials of Texas | Derm Research | Progressive Clinical Research | U.S. Dermatology Partners Bryan"},{"orgOrder":0,"company":"Santalis Pharmaceuticals","sponsor":"ClinDatrix | Fremantle Dermatology","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SAN007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Santalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Santalis Pharmaceuticals \/ ClinDatrix | Fremantle Dermatology","highestDevelopmentStatusID":"8","companyTruncated":"Santalis Pharmaceuticals \/ ClinDatrix | Fremantle Dermatology"},{"orgOrder":0,"company":"Santalis Pharmaceuticals","sponsor":"Fremantle Dermatology | ClinDatrix","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SAN021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Santalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santalis Pharmaceuticals \/ Fremantle Dermatology | ClinDatrix","highestDevelopmentStatusID":"8","companyTruncated":"Santalis Pharmaceuticals \/ Fremantle Dermatology | ClinDatrix"},{"orgOrder":0,"company":"Santalis Pharmaceuticals","sponsor":"ClinDatrix | Clinical Trials of Texas | Dermatology Research Center of San Antonio | Derm Research | Progressive Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SAN021","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Santalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santalis Pharmaceuticals \/ ClinDatrix | Clinical Trials of Texas | Dermatology Research Center of San Antonio | Derm Research | Progressive Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Santalis Pharmaceuticals \/ ClinDatrix | Clinical Trials of Texas | Dermatology Research Center of San Antonio | Derm Research | Progressive Clinical Research"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"SAR447971","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"5","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"SWISS BIOPHARMA MED GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"sB24M","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SWISS BIOPHARMA MED GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SWISS BIOPHARMA MED GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SWISS BIOPHARMA MED GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Novella Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Sb414","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Novella Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Novan \/ Novella Clinical"},{"orgOrder":0,"company":"Novan","sponsor":"Novella Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Sb414","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Novella Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Novan \/ Novella Clinical"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SB705498","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sonoma Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SBT777101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sonoma Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonoma Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonoma Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SCM Lifescience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SCM-AGH","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"SCM Lifescience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SCM Lifescience \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SCM Lifescience \/ Undisclosed"},{"orgOrder":0,"company":"ScarX Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SCX-001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"ScarX Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"ScarX Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ScarX Corp \/ Undisclosed"},{"orgOrder":0,"company":"CKD Bio Corporation","sponsor":"Healis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Serotype A Botulinum Toxin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"CKD Bio Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CKD Bio Corporation \/ Healis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CKD Bio Corporation \/ Healis Therapeutics"},{"orgOrder":0,"company":"NovoBliss Research","sponsor":"Zywie Ventures Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Seszen-Bio","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"NovoBliss Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovoBliss Research \/ Zywie Ventures Private Limited","highestDevelopmentStatusID":"1","companyTruncated":"NovoBliss Research \/ Zywie Ventures Private Limited"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SFA002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SFA002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcium","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SFA-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SFA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SFA-002","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SFA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SFA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SFA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SHP-141C","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Atridia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SHR0410","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Atridia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atridia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atridia \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1139","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1139","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Atridia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1139","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Atridia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atridia \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Atridia \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR-1819","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Shanghai Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SIM0718","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aresus Pharma GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Sinecatechin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Aresus Pharma GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Aresus Pharma GmbH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aresus Pharma GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SK-1405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Undisclosed"},{"orgOrder":0,"company":"Sanwa Kagaku Kenkyusho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SK-1405","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanwa Kagaku Kenkyusho","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanwa Kagaku Kenkyusho \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanwa Kagaku Kenkyusho \/ Undisclosed"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"PolarityTE \/ Undisclosed"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"SkinTE","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Undisclosed"},{"orgOrder":0,"company":"Scarless Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SLI-F06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Scarless Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scarless Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Scarless Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Scarless Laboratories","sponsor":"ethica Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SLI-F06","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Scarless Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scarless Laboratories \/ ethica Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Scarless Laboratories \/ ethica Clinical Research"},{"orgOrder":0,"company":"SinoMab BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SM17","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SinoMab BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SinoMab BioScience \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SinoMab BioScience \/ Undisclosed"},{"orgOrder":0,"company":"Seanergy Dermatology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SNG100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Seanergy Dermatology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seanergy Dermatology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seanergy Dermatology \/ Undisclosed"},{"orgOrder":0,"company":"DFB Soria","sponsor":"Bioskin | US Biotest, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SOR007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"DFB Soria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"DFB Soria \/ Bioskin | US Biotest, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"DFB Soria \/ Bioskin | US Biotest, Inc."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Eurofins Dermscan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Soy Isoflavone","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ Eurofins Dermscan","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Eurofins Dermscan"},{"orgOrder":0,"company":"SIPO Biotechnology Co. Ltd.","sponsor":"Shanghai Ninth People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPOT-mRNA01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"SIPO Biotechnology Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SIPO Biotechnology Co. Ltd. \/ Shanghai Ninth People's Hospital","highestDevelopmentStatusID":"6","companyTruncated":"SIPO Biotechnology Co. Ltd. \/ Shanghai Ninth People's Hospital"},{"orgOrder":0,"company":"Circassia","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SPS4251","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Circassia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Circassia \/ Bioskin","highestDevelopmentStatusID":"6","companyTruncated":"Circassia \/ Bioskin"},{"orgOrder":0,"company":"G&E Herbal Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"SR-T100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"G&E Herbal Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"G&E Herbal Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G&E Herbal Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"G&E Herbal Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SR-T100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"G&E Herbal Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"G&E Herbal Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G&E Herbal Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"G&E Herbal Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SR-T100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"G&E Herbal Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"G&E Herbal Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G&E Herbal Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"G&E Herbal Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SR-T100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"G&E Herbal Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"G&E Herbal Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G&E Herbal Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"G&E Herbal Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SR-T100","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"G&E Herbal Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G&E Herbal Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"G&E Herbal Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Staphylococcus Epidermidis Strain","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ichnos Sciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.32000000000000001,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Astria Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Sciences \/ Astria Therapeutics"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"STAR-0310","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Astria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Astria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sukma Skin Treatment","sponsor":"Stem Cell and Cancer Institute, Kalbe Farma | Pharma Metric Labs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sukma Skin Treatment","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sukma Skin Treatment \/ Stem Cell and Cancer Institute, Kalbe Farma | Pharma Metric Labs","highestDevelopmentStatusID":"6","companyTruncated":"Sukma Skin Treatment \/ Stem Cell and Cancer Institute, Kalbe Farma | Pharma Metric Labs"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Funding","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"SymBiosis and Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Series C Financing","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ SymBiosis and Khosla Ventures"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"STMC-103H","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Siolta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Siolta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Siolta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Soterios Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"STS01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Soterios Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soterios Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Soterios Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sun Protection Foundation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Sun Protection Fabrics","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sun Protection Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Protection Foundation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sun Protection Foundation \/ Undisclosed"},{"orgOrder":0,"company":"Revision Skincare","sponsor":"Ablon Skin Institute Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Sunscreen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revision Skincare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Revision Skincare \/ Ablon Skin Institute Research Center","highestDevelopmentStatusID":"1","companyTruncated":"Revision Skincare \/ Ablon Skin Institute Research Center"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SYHX1901","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd."},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SYHX1901","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SYHX1901","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Chia Nan University of Pharmacy and Science","sponsor":"Glac Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tac","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Chia Nan University of Pharmacy and Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Nan University of Pharmacy and Science \/ Glac Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Chia Nan University of Pharmacy and Science \/ Glac Biotech Co., Ltd"},{"orgOrder":0,"company":"Mahidol University","sponsor":"HOE Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"THAILAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tapioca Starch Stimutex As","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Mahidol University \/ HOE Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Mahidol University \/ HOE Pharmaceuticals"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAVO-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tavotek Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tavotek Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Psoriasis Research Institute of Guangzhou","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"TC","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Psoriasis Research Institute of Guangzhou","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Psoriasis Research Institute of Guangzhou \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psoriasis Research Institute of Guangzhou \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"TCI66207","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"TCI999","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TD03","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Sao Thai Duong \/ Big Leap Research","highestDevelopmentStatusID":"10","companyTruncated":"Sao Thai Duong \/ Big Leap Research"},{"orgOrder":0,"company":"Teres Bio, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TER-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Teres Bio, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teres Bio, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teres Bio, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TEV-53408","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"WuXi AppTec \/ Sirona Biochem Corp","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTec \/ Sirona Biochem Corp"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TFC-1326","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TQH2722","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TQH2929","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TQH2929","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQH3906","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQH3906","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"TRexBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRB-061","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TRexBio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Undisclosed"},{"orgOrder":0,"company":"TRexBio","sponsor":"Delos Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TRB-061","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"TRexBio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"TRexBio \/ Delos Capital","highestDevelopmentStatusID":"6","companyTruncated":"TRexBio \/ Delos Capital"},{"orgOrder":0,"company":"TRexBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRB-061","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"TRexBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRexBio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"TRexBio \/ Undisclosed"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"TRIV-509","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Triveni Bio","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Triveni Bio \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"8","companyTruncated":"Triveni Bio \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series A Financing","leadProduct":"TRIV-509","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Triveni Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Triveni Bio \/ Atlas Venture","highestDevelopmentStatusID":"8","companyTruncated":"Triveni Bio \/ Atlas Venture"},{"orgOrder":0,"company":"CellinCells","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TRTP-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"CellinCells","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CellinCells \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CellinCells \/ Undisclosed"},{"orgOrder":0,"company":"Truology","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Truology A2","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Truology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Truology \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Truology \/ Citruslabs"},{"orgOrder":0,"company":"Thesan Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TSN2898","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Thesan Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thesan Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Thesan Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Dryox Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"TTB","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dryox Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dryox Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dryox Health \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"UCB1381","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"UCB9741","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UCB Pharma S.A \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"UCB Pharma S.A \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"UHE-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"UHE-103","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"UHE-105","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Ulthera, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Ulthera System","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ulthera, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ulthera, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ulthera, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Ever Union Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Tianjin Ever Union Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianjin Ever Union Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tianjin Ever Union Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PT Prodia StemCell Indonesia \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PT Prodia StemCell Indonesia \/ Undisclosed"},{"orgOrder":0,"company":"Gadjah Mada University","sponsor":"Topix Pharmaceuticals | Eclipse Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Universal Peel","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Gadjah Mada University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Gadjah Mada University \/ Topix Pharmaceuticals | Eclipse Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Gadjah Mada University \/ Topix Pharmaceuticals | Eclipse Aesthetics"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"V0034CR01B","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Alliance Pharmaceuticals","sponsor":"South Florida Family Health and Research Centers","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Vamousse Spray \\'N\\' Go","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Alliance Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Alliance Pharmaceuticals \/ South Florida Family Health and Research Centers","highestDevelopmentStatusID":"11","companyTruncated":"Alliance Pharmaceuticals \/ South Florida Family Health and Research Centers"},{"orgOrder":0,"company":"Innovaderm","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Varicella Zoster Vaccine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovaderm \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Innovaderm \/ Merck & Co"},{"orgOrder":0,"company":"Veloce BioPharma LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"VBP-926","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Veloce BioPharma LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Veloce BioPharma LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Veloce BioPharma LLC \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Veradermics","sponsor":"Suvretta Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Tablet, Extended Release","sponsorNew":"Veradermics \/ Suvretta Capital","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Suvretta Capital"},{"orgOrder":0,"company":"Veradermics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VDPHL01","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Veradermics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veradermics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veradermics \/ Undisclosed"},{"orgOrder":0,"company":"Scale Media Inc","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Vitamin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Scale Media Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scale Media Inc \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Scale Media Inc \/ Citruslabs"},{"orgOrder":0,"company":"Standard Process Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin C Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Standard Process Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standard Process Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Standard Process Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Irish Response t\/a Lifes2good","sponsor":"Stephens & Associates, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Viviscal Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Irish Response t\/a Lifes2good","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irish Response t\/a Lifes2good \/ Stephens & Associates, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Irish Response t\/a Lifes2good \/ Stephens & Associates, Inc."},{"orgOrder":0,"company":"Ablon Skin Institute Research Center","sponsor":"Irish Response t\/a Lifes2good","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Viviscal Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ablon Skin Institute Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablon Skin Institute Research Center \/ Irish Response t\/a Lifes2good","highestDevelopmentStatusID":"1","companyTruncated":"Ablon Skin Institute Research Center \/ Irish Response t\/a Lifes2good"},{"orgOrder":0,"company":"Ablon Skin Institute Research Center","sponsor":"Irish Response t\/a Lifes2good | DeNova Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Viviscal Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ablon Skin Institute Research Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ablon Skin Institute Research Center \/ Irish Response t\/a Lifes2good | DeNova Research","highestDevelopmentStatusID":"1","companyTruncated":"Ablon Skin Institute Research Center \/ Irish Response t\/a Lifes2good | DeNova Research"},{"orgOrder":0,"company":"Watson Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"WL8713","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Watson Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Watson Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Watson Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"DR. AUGUST WOLFF GMBH & CO. KG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"WO3970","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"DR. AUGUST WOLFF GMBH & CO. KG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DR. AUGUST WOLFF GMBH & CO. KG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DR. AUGUST WOLFF GMBH & CO. KG \/ Undisclosed"},{"orgOrder":0,"company":"DR. AUGUST WOLFF GMBH & CO. KG","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"WO3970","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"DR. AUGUST WOLFF GMBH & CO. KG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DR. AUGUST WOLFF GMBH & CO. KG \/ Therapeutics, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"DR. AUGUST WOLFF GMBH & CO. KG \/ Therapeutics, Inc."},{"orgOrder":0,"company":"DR. AUGUST WOLFF GMBH & CO. KG","sponsor":"Nuvisan GmbH | FGK Clinical Research | Charles River Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"WO3979","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"DR. AUGUST WOLFF GMBH & CO. KG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DR. AUGUST WOLFF GMBH & CO. KG \/ Nuvisan GmbH | FGK Clinical Research | Charles River Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"DR. AUGUST WOLFF GMBH & CO. KG \/ Nuvisan GmbH | FGK Clinical Research | Charles River Laboratories"},{"orgOrder":0,"company":"DR. AUGUST WOLFF GMBH & CO. KG","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"WOL071-007","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"DR. AUGUST WOLFF GMBH & CO. KG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"DR. AUGUST WOLFF GMBH & CO. KG \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"DR. AUGUST WOLFF GMBH & CO. KG \/ Parexel"},{"orgOrder":0,"company":"10xbio","sponsor":"Therapeutics, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XB-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"10xbio \/ Therapeutics, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Therapeutics, Inc."},{"orgOrder":0,"company":"Zhejiang Kanova Biopharmaceutical Co., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"XKH001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Zhejiang Kanova Biopharmaceutical Co., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhejiang Kanova Biopharmaceutical Co., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Kanova Biopharmaceutical Co., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Xencor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"XmAb27564","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"XENOPORT INC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"XP23829","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ XENOPORT INC","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Reddy\\'s Laboratories \/ XENOPORT INC"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"XPF-005","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Center for Clinical and Cosmetic Research","sponsor":"Restore Biologics Holdings, LLC | Xtress\u00e9 (TM)","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Xtress\u00e9 Supplement","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Center for Clinical and Cosmetic Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Center for Clinical and Cosmetic Research \/ Restore Biologics Holdings, LLC | Xtress\u00e9 (TM)","highestDevelopmentStatusID":"1","companyTruncated":"Center for Clinical and Cosmetic Research \/ Restore Biologics Holdings, LLC | Xtress\u00e9 (TM)"},{"orgOrder":0,"company":"Hangzhou Yirui Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"YR001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hangzhou Yirui Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Hangzhou Yirui Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Yirui Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Hangzhou Yirui Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"YR001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Hangzhou Yirui Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hangzhou Yirui Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Yirui Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Alphyn Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zabalafin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Alphyn Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alphyn Biologics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alphyn Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Fasa University of Medical Sciences","sponsor":"Herbmedx Co | ZAX company","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRAN","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"ZAX.1400.EC.02","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Fasa University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fasa University of Medical Sciences \/ Herbmedx Co | ZAX company","highestDevelopmentStatusID":"8","companyTruncated":"Fasa University of Medical Sciences \/ Herbmedx Co | ZAX company"},{"orgOrder":0,"company":"Fasa University of Medical Sciences","sponsor":"ZAX company | Herbmedx Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"ZAX.1400.P03","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Fasa University of Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fasa University of Medical Sciences \/ ZAX company | Herbmedx Co","highestDevelopmentStatusID":"8","companyTruncated":"Fasa University of Medical Sciences \/ ZAX company | Herbmedx Co"},{"orgOrder":0,"company":"Shulov Innovate for Science Ltd. 2012","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ZEP-3Na","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Shulov Innovate for Science Ltd. 2012","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shulov Innovate for Science Ltd. 2012 \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shulov Innovate for Science Ltd. 2012 \/ Undisclosed"},{"orgOrder":0,"company":"Xequel Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zifogaptide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Xequel Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xequel Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xequel Bio \/ Undisclosed"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Zinc Citrate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of New Mexico \/ AbbVie Inc"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Zinc Hyaluronate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ZL-1102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Zai Lab","highestDevelopmentStatusID":"8","companyTruncated":"Zai Lab \/ Zai Lab"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"ZL-1102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ZL-3101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Ziarco Pharma Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ZPL-5212372","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ziarco Pharma Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Ziarco Pharma Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ziarco Pharma Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Hydroxymethylquinoxalin Dioxide","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Shyla Cantor","sponsor":"Sytheon Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IDL RC-02-38","moa":"Unknown","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Shyla Cantor","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Shyla Cantor \/ Sytheon Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Shyla Cantor \/ Sytheon Ltd."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP 121","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"IDP-120","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"IDP-120","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"IDP-120","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP-120","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP-120","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"IDP-124","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IDP-124","moa":"Unknown","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IMP KM-001","moa":"Unknown","graph1":"Dermatology","graph2":"Phase I","graph3":"Kamari Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kamari Pharma \/ Bioskin","highestDevelopmentStatusID":"6","companyTruncated":"Kamari Pharma \/ Bioskin"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IN-A002","moa":"Unknown","graph1":"Dermatology","graph2":"Phase I","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Avobenzona","moa":"UV radiation","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Avobenzona","moa":"UV radiation","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Avobenzona","moa":"UV radiation","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Yardley Dermatology Associates","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Yardley Dermatology Associates","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yardley Dermatology Associates \/ Galderma","highestDevelopmentStatusID":"1","companyTruncated":"Yardley Dermatology Associates \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PAC-14028","moa":"Vanilloid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AIV001","moa":"Vascular endothelial growth factor receptor (VEGFR)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AIV001","moa":"Vascular endothelial growth factor receptor (VEGFR)","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"AiViva Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AIV001","moa":"Vascular endothelial growth factor receptor (VEGFR)","graph1":"Dermatology","graph2":"Phase I","graph3":"AiViva Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AiViva Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AiViva Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BFH772","moa":"Vascular endothelial growth factor receptor 2","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Changi General Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SINGAPORE","productType":"Amino Acid","year":"2010","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Vasopressin receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Changi General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changi General Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Changi General Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"Vidac Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tuvatexib","moa":"VDAC\/HK2 interaction","graph1":"Dermatology","graph2":"Phase II","graph3":"Vidac Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Vidac Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vidac Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Mabpharm Limitied","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CMAB015","moa":"VEGF","graph1":"Dermatology","graph2":"Phase III","graph3":"Mabpharm Limitied","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabpharm Limitied \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mabpharm Limitied \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Shiyu Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Shiyu Capital","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Shiyu Capital"},{"orgOrder":0,"company":"OnQuality Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"OQL011","moa":"VEGF receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"OnQuality Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"OnQuality Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"OnQuality Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polichem S.A. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polichem S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polichem S.A. \/ Almirall","highestDevelopmentStatusID":"10","companyTruncated":"Polichem S.A. \/ Almirall"},{"orgOrder":0,"company":"Tulane University","sponsor":"Mayne Pharma Do Brasil Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Tulane University \/ Mayne Pharma Do Brasil Ltda","highestDevelopmentStatusID":"6","companyTruncated":"Tulane University \/ Mayne Pharma Do Brasil Ltda"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly"},{"orgOrder":0,"company":"Wake Forest University","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Wake Forest University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University \/ Leo Pharma"},{"orgOrder":0,"company":"Tolmar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tolmar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tolmar \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor AB","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Lipidor AB"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor AB","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Lipidor AB"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Hyphens Pharma"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Almirall"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Endo Pharm"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Tigermed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Tigermed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Bioskin","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Bioskin"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Menarini"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Quintiles Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Quintiles Inc"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"University of Alabama at Birmingham \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Leo Pharma"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Calcitriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Calcitriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Calcitriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Emer, Jason, M.D.","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcitriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Emer, Jason, M.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Emer, Jason, M.D. \/ Galderma","highestDevelopmentStatusID":"11","companyTruncated":"Emer, Jason, M.D. \/ Galderma"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Maruho","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Maruho","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Maruho"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Maruho","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pefcalcitol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruho","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Maruho \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Maruho \/ Undisclosed"},{"orgOrder":0,"company":"Men's Health Boston","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Men's Health Boston","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Men's Health Boston \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Men's Health Boston \/ Undisclosed"},{"orgOrder":0,"company":"Ventrus Biosciences, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Diltiazem Hydrochloride","moa":"Voltage-gated L-type calcium channel","graph1":"Dermatology","graph2":"Phase I","graph3":"Ventrus Biosciences, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventrus Biosciences, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ventrus Biosciences, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Encube Ethicals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Encube Ethicals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Encube Ethicals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Encube Ethicals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Winicker Norimed GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ Winicker Norimed GmbH"},{"orgOrder":0,"company":"Saptalis pharm","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Saptalis pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Saptalis pharm \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Saptalis pharm \/ Biorasi"},{"orgOrder":0,"company":"Viatris","sponsor":"DPT Laboratories, Ltd | VYNE Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Viatris \/ DPT Laboratories, Ltd | VYNE Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Viatris \/ DPT Laboratories, Ltd | VYNE Therapeutics"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Permethrin","moa":"Voltage-sensitive sodium channel","graph1":"Dermatology","graph2":"Phase III","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ Biorasi"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SM04554","moa":"Wnt signaling pathway (Wnt pathway)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"SM04554","moa":"Wnt signaling pathway (Wnt pathway)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Biosplice","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SM04554","moa":"Wnt signaling pathway (Wnt pathway)","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biosplice \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biosplice \/ Undisclosed"},{"orgOrder":0,"company":"Kayuraeffect, LLP","sponsor":"COD Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Kayuraeffect, LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kayuraeffect, LLP \/ COD Research","highestDevelopmentStatusID":"8","companyTruncated":"Kayuraeffect, LLP \/ COD Research"},{"orgOrder":0,"company":"Shanghai Meifute Biotechnology Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Shanghai Meifute Biotechnology Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Meifute Biotechnology Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Meifute Biotechnology Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Universitas Padjadjaran","sponsor":"PT Prodia StemCell Indonesia | B-Crobes Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Universitas Padjadjaran","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Padjadjaran \/ PT Prodia StemCell Indonesia | B-Crobes Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"Universitas Padjadjaran \/ PT Prodia StemCell Indonesia | B-Crobes Laboratory"},{"orgOrder":0,"company":"Medy-Tox","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Medy-Tox","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medy-Tox \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Medy-Tox \/ Undisclosed"},{"orgOrder":0,"company":"GM Associates","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"GM Associates","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"GM Associates \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GM Associates \/ Undisclosed"},{"orgOrder":0,"company":"HiST Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"HiST Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"HiST Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HiST Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"University of Central Lancashire","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brinton Pharmaceuticals \/ University of Central Lancashire","highestDevelopmentStatusID":"4","companyTruncated":"Brinton Pharmaceuticals \/ University of Central Lancashire"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi Biologics \/ Almirall","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Almirall"},{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Almirall"},{"orgOrder":0,"company":"Max Planck","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Max Planck","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Planck \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Cosmetique Active International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Cosmetique Active International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Cosmetique Active International \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cosmetique Active International \/ Undisclosed"},{"orgOrder":0,"company":"Cosmetique Active International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Cosmetique Active International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Serum","sponsorNew":"Cosmetique Active International \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cosmetique Active International \/ Undisclosed"},{"orgOrder":0,"company":"Holostem","sponsor":"IRCCS San Raffaele | University of Modena and Reggio Emilia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Holostem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Holostem \/ IRCCS San Raffaele | University of Modena and Reggio Emilia","highestDevelopmentStatusID":"9","companyTruncated":"Holostem \/ IRCCS San Raffaele | University of Modena and Reggio Emilia"},{"orgOrder":0,"company":"Fondazione Policlinico Universitario Agostino Gemelli","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Fondazione Policlinico Universitario Agostino Gemelli","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fondazione Policlinico Universitario Agostino Gemelli \/ Leo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Fondazione Policlinico Universitario Agostino Gemelli \/ Leo Pharma"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"German Diabetes Center","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"German Diabetes Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"German Diabetes Center \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"10","companyTruncated":"German Diabetes Center \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Centre National de la Recherche Scientifique, France | INSERM","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Centre National de la Recherche Scientifique, France | INSERM","highestDevelopmentStatusID":"1","companyTruncated":"Pierre Fabre \/ Centre National de la Recherche Scientifique, France | INSERM"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.51000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Sanofi"},{"orgOrder":0,"company":"Almirall","sponsor":"University Of Dundee","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Almirall \/ University Of Dundee","highestDevelopmentStatusID":"2","companyTruncated":"Almirall \/ University Of Dundee"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma \/ Kubota Vision Inc"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":1.05,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie Inc"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Mallia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Mallia Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Mallia Therapeutics"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Micreos Human Health","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"LITHUANIA","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northway Biotechpharma \/ Micreos Human Health","highestDevelopmentStatusID":"4","companyTruncated":"Northway Biotechpharma \/ Micreos Human Health"},{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ingenza","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingenza \/ Amplifica","highestDevelopmentStatusID":"1","companyTruncated":"Ingenza \/ Amplifica"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kamari Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Kamari Pharma \/ GIBF2","highestDevelopmentStatusID":"4","companyTruncated":"Kamari Pharma \/ GIBF2"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Max Planck Institute for Multidisciplinary Sciences","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Max Planck Institute for Multidisciplinary Sciences"},{"orgOrder":0,"company":"Ulthera, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ulthera, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ulthera, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ulthera, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Allerderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Allerderm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Allerderm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allerderm \/ Undisclosed"},{"orgOrder":0,"company":"Allerderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Allerderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Allerderm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allerderm \/ Undisclosed"},{"orgOrder":0,"company":"Allerderm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Allerderm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Allerderm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allerderm \/ Undisclosed"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Goldman, Butterwick, Fitzpatrick and Groff","sponsor":"RoC Opco LLC","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Goldman, Butterwick, Fitzpatrick and Groff","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Goldman, Butterwick, Fitzpatrick and Groff \/ RoC Opco LLC","highestDevelopmentStatusID":"10","companyTruncated":"Goldman, Butterwick, Fitzpatrick and Groff \/ RoC Opco LLC"},{"orgOrder":0,"company":"Nutraceutical Wellness Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nutraceutical Wellness Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceutical Wellness Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceutical Wellness Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Seeding, Inc DBA Tiny Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Seeding, Inc DBA Tiny Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seeding, Inc DBA Tiny Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Seeding, Inc DBA Tiny Health \/ Undisclosed"},{"orgOrder":0,"company":"Cynosure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Cynosure","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cynosure \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cynosure \/ Undisclosed"},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Biosciences \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aldena Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aldena Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Aldena Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Orthopaedic Associates of Michigan, PC","sponsor":"Mercy Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Orthopaedic Associates of Michigan, PC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orthopaedic Associates of Michigan, PC \/ Mercy Health","highestDevelopmentStatusID":"11","companyTruncated":"Orthopaedic Associates of Michigan, PC \/ Mercy Health"},{"orgOrder":0,"company":"Henry Ford Health System","sponsor":"L'Oreal","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Henry Ford Health System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henry Ford Health System \/ L'Oreal","highestDevelopmentStatusID":"8","companyTruncated":"Henry Ford Health System \/ L'Oreal"},{"orgOrder":0,"company":"Procter & Gamble Beauty","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Procter & Gamble Beauty","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Procter & Gamble Beauty \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Procter & Gamble Beauty \/ Undisclosed"},{"orgOrder":0,"company":"Medical Life Care Planners, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Medical Life Care Planners, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Life Care Planners, LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medical Life Care Planners, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Austin Institute for Clinical Research","sponsor":"SkinCeuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Austin Institute for Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Austin Institute for Clinical Research \/ SkinCeuticals","highestDevelopmentStatusID":"1","companyTruncated":"Austin Institute for Clinical Research \/ SkinCeuticals"},{"orgOrder":0,"company":"PROCTER AND GAMBLE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"PROCTER AND GAMBLE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"PROCTER AND GAMBLE \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PROCTER AND GAMBLE \/ Undisclosed"},{"orgOrder":0,"company":"Next Science","sponsor":"Skin Laser & Surgery Specialists","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Next Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Next Science \/ Skin Laser & Surgery Specialists","highestDevelopmentStatusID":"6","companyTruncated":"Next Science \/ Skin Laser & Surgery Specialists"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AOBiome Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AOBiome Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharmaceuticals \/ Medicxi"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Follica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Follica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Follica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Follica \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Evommune"},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall"},{"orgOrder":0,"company":"Sequence Bio","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Sequence Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequence Bio \/ Leo Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Sequence Bio \/ Leo Pharma"},{"orgOrder":0,"company":"Nimbus Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Nimbus Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Nimbus Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Nimbus Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Turn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm-Biome Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbSci","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Almirall"},{"orgOrder":0,"company":"Evommune","sponsor":"Andera Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Evommune","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Andera Partners","highestDevelopmentStatusID":"2","companyTruncated":"Evommune \/ Andera Partners"},{"orgOrder":0,"company":"Revel Pharmaceuticals","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Revel Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Revel Pharmaceuticals \/ Kizoo Technology Capital","highestDevelopmentStatusID":"2","companyTruncated":"Revel Pharmaceuticals \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescita Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Crescita Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Queensland University of Technology","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Discovery","graph3":"Queensland University of Technology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queensland University of Technology \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Queensland University of Technology \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Secret of Youth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Secret of Youth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Secret of Youth \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Secret of Youth \/ Undisclosed"},{"orgOrder":0,"company":"Avra","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Avra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avra \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Avra \/ Springs Rejuvenation"},{"orgOrder":0,"company":"Integrative Skin Science and Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Integrative Skin Science and Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integrative Skin Science and Research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Integrative Skin Science and Research \/ Undisclosed"},{"orgOrder":0,"company":"Olistic Research Labs S.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Olistic Research Labs S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olistic Research Labs S.L. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Olistic Research Labs S.L. \/ Undisclosed"},{"orgOrder":0,"company":"Olistic Research Labs S.L.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Olistic Research Labs S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Olistic Research Labs S.L. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Olistic Research Labs S.L. \/ Undisclosed"},{"orgOrder":0,"company":"Good Molecules, LLC","sponsor":"Sequential Skin Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Good Molecules, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Good Molecules, LLC \/ Sequential Skin Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Good Molecules, LLC \/ Sequential Skin Inc."},{"orgOrder":0,"company":"Two Lines LLC","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Two Lines LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Two Lines LLC \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Two Lines LLC \/ Citruslabs"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Private Placement","leadProduct":"ORKA-002","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Oruka Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"6","companyTruncated":"Oruka Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Fibroblast Spheroids","moa":"Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"FibroBiologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"FibroBiologics \/ Undisclosed"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RLS-1496","moa":"GPX4","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Rubedo Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Zhaoke Ophthalmology","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lee\\'s Pharmaceutical \/ Zhaoke Ophthalmology","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ Zhaoke Ophthalmology"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"HONG KONG","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Adapalene","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Evommune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"EVO756","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Evommune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evommune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Evommune \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HSK44459","moa":"PDE4B","graph1":"Dermatology","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LAD191","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Reistone Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RSS0393","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Reistone Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Reistone Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reistone Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Haisco Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"HSK47388","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Haisco Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Haisco Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Haisco Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"TRIV-509","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Triveni Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Triveni Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Triveni Bio \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Brivekimig","moa":"OX40L | TNF-alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PF-08049820","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"JIANGSU VCARE PHARMATECH CO., LTD","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"VC005","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"JIANGSU VCARE PHARMATECH CO., LTD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"JIANGSU VCARE PHARMATECH CO., LTD \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4B","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SIM0278","moa":"IL-2R","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"E-nitiate Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"QY201","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"E-nitiate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"E-nitiate Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"E-nitiate Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MH004","moa":"JAK","graph1":"Dermatology","graph2":"Phase II","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HS-10374","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Granular Therapeutics Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"GTX-B001","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Granular Therapeutics Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Granular Therapeutics Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Granular Therapeutics Limited \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MH004","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Difamilast","moa":"PDE4B","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"MH004","moa":"JAK","graph1":"Dermatology","graph2":"Phase III","graph3":"Minghui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Minghui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Minghui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LW402","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Longwood Biopharmaceuticals Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Longwood Biopharmaceuticals Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PF-08049820","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZL-82","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Spesolimab","moa":"IL36 receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Leo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ Leo Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Ixekizumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase I","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Clarent Biopharma, Inc.","sponsor":"Elemental Traslational Research SAPI | Innovacion y Desarrollo de Estrategias en Salud | Elemental CRO","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"RAP-103","moa":"C-C chemokine receptor type 2 (CCR2)","graph1":"Dermatology","graph2":"Phase II","graph3":"Clarent Biopharma, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarent Biopharma, Inc. \/ Elemental Traslational Research SAPI | Innovacion y Desarrollo de Estrategias en Salud | Elemental CRO","highestDevelopmentStatusID":"8","companyTruncated":"Clarent Biopharma, Inc. \/ Elemental Traslational Research SAPI | Innovacion y Desarrollo de Estrategias en Salud | Elemental CRO"},{"orgOrder":0,"company":"Attovia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"ATTO-3712","moa":"SEMA3A","graph1":"Dermatology","graph2":"Phase I","graph3":"Attovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attovia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Attovia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FB102","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Forte Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forte Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Forte Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Merz Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase III","graph3":"Merz Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merz Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merz Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1905","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Roy G. Geronemus, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Roy G. Geronemus, M.D.","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Roy G. Geronemus, M.D."},{"orgOrder":0,"company":"Almirall","sponsor":"Daniel Kaplan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Phase I","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Almirall \/ Daniel Kaplan","highestDevelopmentStatusID":"6","companyTruncated":"Almirall \/ Daniel Kaplan"},{"orgOrder":0,"company":"The Emmes Company, LLC","sponsor":"Kanecia Obie Zimmerman","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Timolol Maleate","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"The Emmes Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"The Emmes Company, LLC \/ Kanecia Obie Zimmerman","highestDevelopmentStatusID":"8","companyTruncated":"The Emmes Company, LLC \/ Kanecia Obie Zimmerman"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Messoud Ashina","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Erenumab","moa":"Calcitonin gene-related peptide type 1 receptor||CGRP receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Messoud Ashina","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Messoud Ashina"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Albert Chiou","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NFX-179","moa":"ERK activator kinase (MEK)","graph1":"Dermatology","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"NFlection Therapeutics \/ Albert Chiou","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Albert Chiou"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Laura Tosi","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Dermatology","graph2":"Phase I","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Laura Tosi","highestDevelopmentStatusID":"6","companyTruncated":"Ultragenyx Pharmaceutical \/ Laura Tosi"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Jacob Thyssen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Betamethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Jacob Thyssen","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Jacob Thyssen"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Patel, Rita Vikram, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Patel, Rita Vikram, M.D.","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Patel, Rita Vikram, M.D."},{"orgOrder":0,"company":"DUSA Pharmaceuticals, Inc.","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"DUSA Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DUSA Pharmaceuticals, Inc. \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"1","companyTruncated":"DUSA Pharmaceuticals, Inc. \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"Suneva Medical","sponsor":"Gerald Pierone, Jr.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Polymethylmethacrylate","moa":"Homeostasis","graph1":"Dermatology","graph2":"Phase I","graph3":"Suneva Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suneva Medical \/ Gerald Pierone, Jr.","highestDevelopmentStatusID":"6","companyTruncated":"Suneva Medical \/ Gerald Pierone, Jr."},{"orgOrder":0,"company":"Merz Pharma","sponsor":"Kalpna Kay Durairaj","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"Hydroxylapatite","graph1":"Dermatology","graph2":"Phase I","graph3":"Merz Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merz Pharma \/ Kalpna Kay Durairaj","highestDevelopmentStatusID":"6","companyTruncated":"Merz Pharma \/ Kalpna Kay Durairaj"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"GWT-TUD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ GWT-TUD","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ GWT-TUD"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"James G. Krueger","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Secukinumab","moa":"Interleukin 17A","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ James G. Krueger","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ James G. Krueger"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Paul Steven Yamauchi, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Paul Steven Yamauchi, MD, PhD","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Paul Steven Yamauchi, MD, PhD"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Johann E Gudjonsson","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lebrikizumab","moa":"Interleukin-13","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Johann E Gudjonsson","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Johann E Gudjonsson"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jaehwan Kim","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Jaehwan Kim","highestDevelopmentStatusID":"15","companyTruncated":"AbbVie Inc \/ Jaehwan Kim"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Carlos Wambier","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tildrakizumab","moa":"Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Carlos Wambier","highestDevelopmentStatusID":"15","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Carlos Wambier"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Eric Simpson","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Eric Simpson","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Eric Simpson"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Emma Guttman","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Emma Guttman","highestDevelopmentStatusID":"8","companyTruncated":"Regeneron Pharmaceuticals \/ Emma Guttman"},{"orgOrder":0,"company":"Union Therapeutics","sponsor":"Gregor Jemec","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Orismilast","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Union Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Union Therapeutics \/ Gregor Jemec","highestDevelopmentStatusID":"8","companyTruncated":"Union Therapeutics \/ Gregor Jemec"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Professor Mikkel \u00d8stergaard","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase IV","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Celgene Corporation \/ Professor Mikkel \u00d8stergaard","highestDevelopmentStatusID":"11","companyTruncated":"Celgene Corporation \/ Professor Mikkel \u00d8stergaard"},{"orgOrder":0,"company":"Celgene Corporation","sponsor":"Julian M. Mackay-Wiggan","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Celgene Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celgene Corporation \/ Julian M. Mackay-Wiggan","highestDevelopmentStatusID":"8","companyTruncated":"Celgene Corporation \/ Julian M. Mackay-Wiggan"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"M.B.A. van Doorn","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2017","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ M.B.A. van Doorn","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ M.B.A. van Doorn"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Frank Behrens","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Apremilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Frank Behrens","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Frank Behrens"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ingenol Mebutate","moa":"Protein kinase C delta type; Protein kinase C alpha type","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Edward Lain","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VYNE Therapeutics \/ Edward Lain","highestDevelopmentStatusID":"11","companyTruncated":"VYNE Therapeutics \/ Edward Lain"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Bausch Health \/ Goldman, Butterwick, Fitzpatrick and Groff","highestDevelopmentStatusID":"11","companyTruncated":"Bausch Health \/ Goldman, Butterwick, Fitzpatrick and Groff"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Lisa E. Maier","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Lisa E. Maier","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Health \/ Lisa E. Maier"},{"orgOrder":0,"company":"GSK","sponsor":"Amylynne Frankel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Amylynne Frankel","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Amylynne Frankel"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Natalie Garcia Bartels","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Johnson & Johnson \/ Natalie Garcia Bartels","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Natalie Garcia Bartels"},{"orgOrder":0,"company":"PT KIMIA FARMA PERSERO TBK","sponsor":"Lili Legiawati","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minoxidil","moa":"Sulfonylurea receptor 2, Kir6.2","graph1":"Dermatology","graph2":"Undisclosed","graph3":"PT KIMIA FARMA PERSERO TBK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT KIMIA FARMA PERSERO TBK \/ Lili Legiawati","highestDevelopmentStatusID":"1","companyTruncated":"PT KIMIA FARMA PERSERO TBK \/ Lili Legiawati"},{"orgOrder":0,"company":"Evolus","sponsor":"Kalpna Kay Durairaj","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Prabotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase I","graph3":"Evolus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Evolus \/ Kalpna Kay Durairaj","highestDevelopmentStatusID":"6","companyTruncated":"Evolus \/ Kalpna Kay Durairaj"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Marco Alexandre Dias da Rocha","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Azelaic Acid","moa":"thioredoxin","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Marco Alexandre Dias da Rocha","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Marco Alexandre Dias da Rocha"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Jeffrey J Crowley MD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Dermatology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AbbVie Inc \/ Jeffrey J Crowley MD","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Jeffrey J Crowley MD"},{"orgOrder":0,"company":"Graceway Pharmaceuticals","sponsor":"Amylynne Frankel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Graceway Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Graceway Pharmaceuticals \/ Amylynne Frankel","highestDevelopmentStatusID":"11","companyTruncated":"Graceway Pharmaceuticals \/ Amylynne Frankel"},{"orgOrder":0,"company":"Menarini","sponsor":"Irma Bernadette","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Kojic Acid","moa":"Tyrosinase (TYR)","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Menarini \/ Irma Bernadette","highestDevelopmentStatusID":"1","companyTruncated":"Menarini \/ Irma Bernadette"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Emma Guttman","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brepocitinib","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Emma Guttman","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Emma Guttman"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Emma Guttman","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritlecitinib","moa":"Tyrosine-protein kinase JAK3 | TEC family kinase","graph1":"Dermatology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Emma Guttman","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Emma Guttman"},{"orgOrder":0,"company":"PT KIMIA FARMA PERSERO TBK","sponsor":"Lili Legiawati","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Adipose-Derived Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"PT KIMIA FARMA PERSERO TBK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"PT KIMIA FARMA PERSERO TBK \/ Lili Legiawati","highestDevelopmentStatusID":"10","companyTruncated":"PT KIMIA FARMA PERSERO TBK \/ Lili Legiawati"},{"orgOrder":0,"company":"Activ'inside","sponsor":"Complife Italia Srl","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Activ'inside","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Activ'inside \/ Complife Italia Srl","highestDevelopmentStatusID":"1","companyTruncated":"Activ'inside \/ Complife Italia Srl"},{"orgOrder":0,"company":"Stratpharma AG","sponsor":"Andrew T. Goldstein, MD","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"StrataMGT","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Stratpharma AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stratpharma AG \/ Andrew T. Goldstein, MD","highestDevelopmentStatusID":"6","companyTruncated":"Stratpharma AG \/ Andrew T. Goldstein, MD"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Mark Lebwohl","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TSO 2500","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coronado Biosciences \/ Mark Lebwohl","highestDevelopmentStatusID":"6","companyTruncated":"Coronado Biosciences \/ Mark Lebwohl"},{"orgOrder":0,"company":"GSK","sponsor":"Leon Kircik, M.D.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"GSK \/ Leon Kircik, M.D.","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Leon Kircik, M.D."}]

    Find Dermatology Clinical Drug Pipeline Developments & Deals

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Brivekimig

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

                            Details : Brivekimig is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Hidradenitis Suppurativa.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 12, 2025

                            Lead Product(s) : Brivekimig

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Upadacitinib Safety and Effectiveness In Japanese Adults/Adolescents with Alopecia Areata

                            Details : Upadacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Alopecia Areata.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2025

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGN-151586

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult...

                            Details : AGN-151586 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glabellar Lines.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 19, 2025

                            Lead Product(s) : AGN-151586

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onabotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Chan...

                            Details : Onabotulinumtoxin A is a Other Large Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Skin Aging.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 27, 2025

                            Lead Product(s) : Onabotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in...

                            Details : Lunsekimig is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Lunsekimig

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutikizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatm...

                            Details : Lutikizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 05, 2024

                            Lead Product(s) : Lutikizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Tha...

                            Details : Upadacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2024

                            Lead Product(s) : Upadacitinib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared ...

                            Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared ...

                            Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Dupilumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Allergan Aesthetics

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Onabotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allergan Launches BOTOX Cosmetic for Masseter Muscle Prominence in China

                            Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat Masseter Muscle Prominence in adults.

                            Product Name : Botox Cosmetic

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 11, 2024

                            Lead Product(s) : Onabotulinumtoxin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth